DEEP HEALTH AI INDIA LIMITED

CIN: L24100RJ1994PLC112895

32nd ANNUAL REPORT

2025-2026

INDEX

CORPORATE INFORMATION

Board of Directors:

1. **Mr. Narayan Singh Rathore**
   (Managing Director & Chairperson) - (DIN: 10900646) (Appointed w.e.f. 18/01/2025)

2. **Mrs. Laveena Pokharna**
   (Whole-Time Director & CFO) - (DIN: 10977709) (Appointed w.e.f. 10/03/2025)

3. **Mr. Kaushal Jain**
   (Non-Executive Director) - (DIN: 00848381) (Appointed w.e.f. 20/09/2023)

4. **Mr. Rajesh Nandkishore Pherwani**
   (Independent Director) - (DIN: 07576485) (Appointed w.e.f. 07/03/2025)

5. **Mrs. Shashi Kala Dhabriya**
   (Independent Director) - (DIN: 11611776) (Appointed w.e.f 20/03/2026)

6. **Kailash Chandra**
   (Independent Director) - (DIN: 10985611) (Ceased w.e.f. 03/04/2026)

Auditors:

1. **Statutory Auditor**
   M/s. V R S K & CO.

2. **Secretarial Auditor**
   M/s Ronak Jhuthawat & Co.

3. **Internal Auditor**
   M/s Valawat & Associates

Bankers: ICICI Bank

Offices:

Registered Office: 506-509 fifth floor, Apeksha, plot no. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001) Tel: 0294-3569097.

Registrar and Share Transfer Agent:

MUFG Intime India Private Limited C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai - 400083. Phone: +91 22 4918 6000 Website: www.in.mpms.mufg.com

Stock Exchange:

BSE Limited

NOTICE OF 32ND ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT THE 32ND ANNUAL GENERAL MEETING OF DEEP HEALTH AI INDIA LIMITED WILL BE HELD ON WEDNESDAY, SEPTEMBER 30, 2026, AT 11:30 A.M. (IST) THROUGH VIDEO CONFERENCE MODE ORGANIZED BY THE COMPANY, TO TRANSACT THE FOLLOWING BUSINESSES AND THE VENUE OF THE MEETING SHALL BE DEEMED TO BE THE REGISTERED OFFICE OF THE COMPANY.

ORDINARY BUSINESS:

To consider and if thought fit, to pass, with or without modification (s), the following resolution as an **Ordinary Resolution**:

1. To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2026, together with the Reports of the Board of Directors and the Auditors thereon.

2. To receive, consider and adopt the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, together with the Report of the Auditors thereon.

3. To re-appoint Mr. Narayan Singh Rathore (DIN: 10900646) as a Managing Director of the Company, who retires by rotation and being eligible, offers himself for re-appointment.

4. To Consider and Recommend the appointment of M/s Vimal C Surana & Co., Chartered Accountants as the Statutory Auditor of the Company for a term of five (5) consecutive years.

   "**RESOLVED THAT** pursuant to the provisions of Sections 139(1), 142 and all other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force, and pursuant to the recommendation of the Audit Committee and approval of the Board of Directors of the Company, M/s Vimal C Surana & Co., Chartered Accountants (FRN:015888C & Peer Review No.: 023318) , be and are hereby appointed as the Statutory Auditors of the Company to fill the vacancy caused due to the completion of tenure of M/s VRSK & Co. LLP Chartered Accountants, and to hold office for the consecutive term of five (5) years with effect from the date of the Annual General meeting held for the financial year 2026-2027 till the conclusion of the Annual General Meeting to be held for the financial year 2031-2032 at such remuneration, in addition to applicable taxes and reimbursement of out-of pocket expenses, as provided in the explanatory statement which would be mutually agreed upon between the Board of Directors of the Company and the Statutory Auditors.

   RESOLVED FURTHER THAT, Narayan Singh Rathore, Managing Director of the Company be and is hereby authorized to do all such acts, deeds, matters and things, and to take all such steps as may be deemed necessary, proper or expedient to give effect to this Resolution."

SPECIAL BUSINESS:

To consider and if thought fit, to pass, with or without modification (s), the following resolution as a **Special Resolution**:

5. To consider and approve appointment Mr. Virendra Choubisa: (DIN: 11923125) as a Non-executive Independent Director on the Board of Directors of Company.

   "RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152 and 160 and other applicable provisions of the Companies Act, 2013 (the "Act") and the rules made thereunder (including any statutory modifications or re-enactments), the Companies (Appointment and Qualification of Directors) Rules, 2014 read with Schedule IV, Regulations 16(1)(b), 17(1C), 25, and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), the Reserve Bank of India (Non-Banking Financial Companies – Governance) Directions, 2025, and the Articles of Association of the Company, and based on the recommendation of the Nomination and Remuneration Committee after evaluating his skills, experience, and expertise, Mr. Virendra Choubisa: (DIN: 11923125), who was appointed as an Additional Director, designated as Non-Executive Independent Director pursuant to Section 161(1) of the Act and Articles of Association of the Company with effect from September 03, 2026 and who meets the criteria of independence under Section 149(6) of the Act be and is hereby appointed as an Non-Executive Independent Director of the Company, not liable to retire by rotation, for a term of five (5) consecutive years from September 03, 2026 to September 02 , 2031.

   RESOLVED FURTHER THAT, Mr. Virendra Choubisa: (DIN: 11923125) may receive remuneration by way of sitting fees, reimbursement of expenses for participation in the meeting of the Board and/or Committees thereof and profit related commission, if any, within the limits prescribed under Section 197 of the Companies Act 2013 and as may be determined by the Board from time to time.

   RESOLVED FURTHER THAT Mr Narayan Singh Rathore, Managing Director of the Company be and is hereby authorised to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution."

6. To consider and approve the revision in remuneration of Mr. Narayan Singh Rathore (DIN: 10900646), Managing Director of the Company.

   "RESOLVED THAT pursuant to the provisions of Sections 197, 198 and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") read with the relevant rules made thereunder further read with Schedule V of the Act and SEBI (Listing Obligations &

Disclosure Requirements) Regulations, 2015; any statutory modification(s) or re-enactment thereof for the time being in force, and upon recommendation of the Nomination and Remuneration Committee and the Board of Directors, the approval of the members of the Company be and is hereby accorded for the revision in the remuneration payable to Mr. Narayan Singh Rathore (DIN: 10900646), Chairman and Managing Director of the Company, with effect from April 1, 2026, for a period of three years, i.e., up to March 31, 2029, as set out in Schedule V to the Companies Act, 2013 as stated below:

Remuneration: A sum not exceeding Rs.16,80,000/- (Sixteen Lakhs Eighty Thousand Only) per annum or by whatever name called paid on monthly basis Rs. 1,40,000/- p.m. within the aforesaid overall ceiling of remuneration excluding any other payment as may be received from any other agreement or arrangement.

RESOLVED FURTHER THAT, in the event of absence or inadequacy of profits in any financial year during the above-mentioned period, the aforesaid remuneration shall be treated as minimum remuneration and shall be payable to Mr. Narayan Singh Rathore in accordance with Part II of Schedule V of the Companies Act, 2013, and other applicable provisions, if any.

RESOLVED FURTHER THAT, Save and except for the aforesaid revision in salary payable to Mr. Narayan Singh Rathore, all other terms and conditions relating to his appointment, including other components of remuneration, as approved by the Members at the 31st Annual General Meeting shall remain unchanged and continue to be in full force and effect.

RESOLVED FURTHER THAT All or any of the Directors and Company Secretary of the Company be and are hereby authorised jointly or severally, to do all such acts, deeds, matters, and things as may be necessary or expedient to give effect to this resolution, including seeking necessary approvals and filing required e-forms with the Registrar of Companies.

For and on behalf of the
DEEP HEALTH AI INDIA LIMITED
(Formerly known as Deep Diamond India Limited)

SD/-
NARAYAN SINGH RATHORE
DIN: 10900646
ADDRESS: 506-509 fifth floor, Apeksha, plot no. 256, Main Road,
Hiran Magri, Sector 11, Udaipur, Rajasthan (313001)
DATE: September 7, 2026

REGISTERED OFFICE:
506-509 fifth floor, Apeksha, plot no. 256, Main Road, Hiran Magri,

Sector 11, Udaipur, Rajasthan (313001) Tel: 0294-3569097
CIN: L24100RJ1994PLC112895
E-mail: deephealthaiindia@gmail.com

Place: Udaipur
Date: September 7, 2026

Notes:

1. Pursuant to General Circulars No.14/2020 dated April 8, 2020; No.17/2020 dated April 13, 2020; No.20/2020 dated May 5, 2020; No. 02/2021 dated January 13, 2021; No. 21/2021 dated December 14, 2021; No. 2/2022 dated May 5, 2022; No. 10/2022 dated December 28, 2022; No.09/2023 dated September 25, 2023; and No. 09/2024 dated September 19, 2024; and No. 03/2025 dated September 22, 2025 issued by the Ministry of Corporate Affairs (collectively referred to as 'MCA Circulars'), the Company is convening the 32nd Annual General Meeting (AGM) through Video Conferencing (VC)/Other Audio Visual Means (OAVM), without the physical presence of the Members at a common venue.

   Further, the Securities and Exchange Board of India (SEBI), vide its Circular SEBI/HO/CFDICMD2/CIRIP/2022/62 dated May 13, 2022 followed by Circular No. SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated January 05, 2023, Circular No. SEBI/HO/CFD/CFDPoD-2/P/CIR/2023/167 dated October 07, 2023 and Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024 and June 05, 2025 (collectively referred to as "SEBI Circulars') and other applicable circulars issued in this regard, have provided relaxations from compliance with certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations). In compliance with the applicable provisions of the Companies Act, 2013 (the Act), the Listing Regulations and MCA Circulars, the 32nd AGM of the Company is being held through VC/OAVM on Wednesday, September 30, 2026**,** at 11:30 A.M. (IST).

2. For the purpose of the Companies Act, 2013 ("Act"), the proceedings of the meeting shall be deemed to take place at the registered office of the Company situated at 506-509 fifth floor, Apeksha, plot no. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001).

3. Details of the directors seeking re-appointment under item no.03 aforesaid pursuant to Regulation 36(3) of the Listing Regulations and Secretarial Standard - 2 on General Meetings ('SS-2'), issued by The Institute of Company Secretaries of India are annexed hereto.

4. The helpline number regarding any query/assistance for participation in the AGM through VC/OAVM is Tel: 0294-3569097

Pursuant to the provisions of the act, a member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote instead of himself and the proxy need not be a member of the company. Since this AGM is being held pursuant to the MCA circulars through VC/OAVM, the requirement of physical attendance of members has been dispensed with. Accordingly, the facility for appointment of proxies by members

will not be available for this AGM and hence, the proxy form, attendance slip, and route map of AGM are not annexed to this notice.

5. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.

6. Members can raise questions during the meeting if they have registered themselves as a speaker or in advance at deephealthaiindia@gmail.com. However, it is requested to raise the queries precisely and in short at the time of meeting to enable to answer the same.

7. Institutional / Corporate Shareholders (i.e., other than individuals / NRI, etc.) are required to send a scanned copy (PDF/JPG Format) of its Board or governing body resolution/authorization, etc., authorizing its representative to attend the AGM through VC / OAVM on its behalf and to vote through remote e-voting. The said resolution/authorization shall be sent to the Company by email through its registered email address to deephealthaiindia@gmail.com

8. In the case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote at the AGM.

9. Pursuant to the provisions of the act, a member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote instead of himself and the proxy need not be a member of the company. Since this AGM is being held pursuant to the MCA circulars through VC/OAVM, the requirement of physical attendance of members has been dispensed with. Accordingly, the facility for appointment of proxies by members will not be available for this AGM and hence, the proxy form, attendance slip, and route map of AGM are not annexed to this notice.

10. In terms of the MCA Circulars and the relevant SEBI Circulars, the Company is sending this AGM Notice along with the Integrated Annual Report for FY 2025-26 in electronic form only to those Members whose email IDs are registered with the Company/Depositories. The Company shall send the physical copy of the Integrated Annual Report for FY 2025-26 only to those Members who specifically request for the same at deephealthaiindia@gmail.com mentioning their Folio No/DP ID and Client ID. The Notice convening the AGM and the Annual Report for FY 2025-26 have been uploaded on the

website of the Company and may also be accessed from the relevant section on the websites of BSE Limited. The AGM Notice is also available on the website of NSDL at www.evoting.nsdl.com.

11. Members who have not registered their e-mail addresses are requested to register the same with the Company's Registrars and Transfer Agents / Depository Participant(s) for sending future communication(s) in electronic form. The email addresses can be registered with the Depository Participant ("DP") in case the shares are held in electronic form and with the Registrar and Transfer Agent of the Company ("RTA") in case the shares are held in physical form.

12. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in electronic form are, therefore, requested to submit their PAN to their Depository Participants with whom they are maintaining their Demat accounts. Members holding shares in physical form can submit their PAN to the Company / RTA.

13. In terms of Regulation 40(1) of the Listing Regulations, as amended, securities of listed companies can be transferred only in dematerialized form with effect from April 1, 2019. Members may please note that SEBI, vide its Circular No. SEBI/HO/MIRSD/MIRSD_ RTAMB/P/CIR/2022/8 dated January 25, 2022, has mandated Listed Companies to issue securities in demat form only while processing service requests viz. Issue of duplicate securities certificate; claim from Unclaimed Suspense Account; Renewal/Exchange of securities certificate; Endorsement; Sub-division/Splitting of securities certificate; Consolidation of securities certificates/folios; Transmission and Transposition.

    Accordingly, Members are requested to make service requests by submitting a duly filled and signed Form ISR–4, the format of which is available on the website of the Company's RTA. It may be noted that any service request can be processed only after the folio is KYC compliant. SEBI, vide its notification dated January 24, 2022, has mandated that all requests for transmission and transposition shall be processed only in dematerialized form.

    In view of the same and to eliminate all risks associated with physical shares and avail various benefits of dematerialization, Members are advised to dematerialize the shares held by them in physical form. Members can contact the Company or RTA for assistance in this regard.

Registration of Email Id:

a) In case, the shareholder's email ID is already registered with the Company/its Registrar & Share Transfer Agent / Depositories, login details for e-voting are being sent on the registered email address.

b) In case the shareholder has not registered his/her/their emails address with the Company/its RTA/Depositories and or has not updated the Bank Account mandate, the following instructions are to be followed:

i. Kindly login to the website of the RTA, namely, M/s Link Intime India Pvt Ltd, fill in the details and upload the required documents and submit. OR

ii. In the case of Shares held in Demat mode: The shareholder may please contact the Depository Participant ("DP") and register the email address and bank account details in the Demat account as per the process followed and advised by the DP.

Alternatively, Members may send an e-mail request to the email id: deephealthaiindia@gmail.com along with a scanned copy of the signed request letter providing the email address, mobile number, self-attested PAN copy, and Client Master copy in case of the electronic folio and copy of the share certificate in the case of the physical folio.

14. Members seeking any information with regard to any matter to be placed at the AGM are requested to write to the Company through an email on deephealthaiindia@gmail.com.

15. Those Members who have registered themselves as a speaker will only be allowed to express their views/ask questions during the AGM. The Company reserves the right to restrict the number of questions and several speakers depending upon the availability of time, for the smooth conduct of the AGM. The Company has also provided the facility to the Members to ask questions to the panellist via active chat board during the AGM and the same would be responded to by the Company appropriately.

16. To support the 'Green Initiative', the members who have not registered their email addresses are requested to register the same with RTA/ Depositories.

17. The business set out in the notice will be transacted through remote e-voting system and the instructions and other information relating to remote e-voting provided by M/s MUFG Intime India Private Limited are given herein below in this Notice. In case of any queries or grievances in connection with remote e-voting, the shareholders may write to the registered office address of the Company.

18. Members holding shares in physical form are requested to notify immediately changes, if any, in their address or bank mandate to the Company/Registrar & Share Transfer Agents (RTA) i.e., M/s MUFG Intime India Private Limited quoting their Folio Number and Bank Account Details along with self-attested documentary proofs. Members holding shares in

the Dematerialized (electronic) form may update such details with their respective Depository Participants. The Company or its Registrars cannot act on any request received directly from the shareholders holding shares in electronic form for any change of bank particulars or bank mandates. Such changes are to be advised only to the Depository Participant of the shareholders.

19. To prevent fraudulent transactions, Members are advised to exercise due diligence and notify the Company of any change in address or demise of any Member as soon as possible. Members are also advised to not leave their demat account(s) dormant for long. Periodic statement of holdings should be obtained from the concerned Depository Participant (DP), and holdings should be verified from time to time.

20. As per the provisions of Section 72 of the Act, the facility for making nomination is available to the Members in respect of the shares held by them. Members who have not yet registered their nomination, are requested to register the same by submitting Form No. SH-13. If a member desires to opt-out or cancel the earlier nomination and record a fresh nomination, the Member may submit the same in form ISR-3 or form SH-14, as the case may be. The said forms can be downloaded from the Company's RTAs website. Members are requested to submit the said form to their respective DPs in case the shares are held in electronic form, and to the RTA in case the shares are held in physical form.

21. Pursuant to MCA Circulars, a designated email address i.e., has been created by the company so that the Members can convey their vote when a poll is required to be taken during the meeting on any resolution at such designated email address through their email addresses which are registered with the RTA/DP.

22. In compliance with the provisions of Section 108 of the Companies Act, 2013 read with the Companies (Management and Administration) Amendment Rules, 2014 Company is pleased to provide the members to exercise their right to vote at the Annual General Meeting of the Company by electronic means through E-voting facility provided by NSDL.

23. **Mr. Ronak Jhuthawat of M/s. Ronak Jhuthawat & Co**, Practising Company Secretaries have been appointed as the **Scrutinizer to scrutinize the e-voting process** in a fair and transparent manner. The Scrutinizer shall immediately from the conclusion of the remote e-voting period unblock the votes in the presence of at least 2 witnesses, not in the employment of the Company and make a Scrutinizer's Report of the votes cast in favour or against, if any, and forward it to the Chairman of the Company.

24. The Results declared along with the Scrutinizer's Report shall be placed on the website of the Company at and on the website of the company www.deephealthaiindia.com immediately after the declaration of Result by the Chairman or any person authorized by him in writing and communicated to BSE.

25. **Norms for furnishing of PAN, KYC, Bank details and Nomination:**

Pursuant to SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023, as amended from time to time, and SEBI Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/81 dated June 10, 2024, SEBI has prescribed norms for furnishing PAN, KYC details and nomination by holders of physical securities.

The forms for updating of PAN, KYC, bank details and Nomination viz., Forms ISR-1, ISR-2, ISR-3, SH-13, SH-14 and the said SEBI circular are available on the website of the Company's RTA at https://liiplweb.linkintime.co.in/KYC-downloads.html

In view of the above, we urge Members holding shares in physical form to submit the requisite forms along with the supporting documents at the earliest. The Company has dispatched a letter to the Members holding shares in physical form in relation to the above-mentioned SEBI Circular. Members who hold shares in dematerialized form and wish to update their PAN, KYC, Bank details and Nomination are requested to contact their respective DPs.

26. **Voting through electronic means:**

In compliance with the provisions of Section 108 and other applicable provisions of the Act, read with Rule 20 of the Companies (Management and Administration) Rules, 2014 as amended, , and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and in terms of SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, the Company is providing the facility of remote e-Voting to its Members in respect of the businesses to be transacted at the AGM.The Company has engaged the services of NSDL for facilitating e-Voting to enable the Members to cast their votes electronically as well as for e-Voting during the AGM. Resolution(s) passed by Members through e-Voting is/are deemed to have been passed as if it/they have been passed at the AGM. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by NSDL.

The voting period begins **on Sunday, September 27, 2026, 09:00 A.M. (IST) and ends on Tuesday, September 29, 2026, 05:00 P.M. (IST)**. During this period shareholders of the Company, holding shares either in physical form or in Dematerialized form, as on the **cut-off date i.e., Wednesday, September 23, 2026**, may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.

1. Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.

Pursuant to Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with the applicable provisions of SEBI Master Circular No. **HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026**, listed entities are required to provide remote e-voting facility to their shareholders in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level. Currently, there are multiple e-voting service providers (ESPs) providing e-voting facilities to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders. In order to increase the efficiency of the voting process, pursuant to public consultation, it has been decided to enable e-voting to **all the Demat account holders**, **by way of a single login credential, through their Demat accounts/ websites of Depositories/ Depository Participants**. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-the voting process.

The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013.

2. **Pursuant to MCA General Circular No. 03/2025 dated September 22, 2025, read with the applicable circulars issued by the Ministry of Corporate Affairs in this regard, the facility to appoint a proxy to attend and cast votes for the Members is not available for this AGM being conducted through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM"). However, in pursuance of Sections 112 and 113 of the Companies Act, 2013, representatives of Members such as the President of India or the Governor of a State or body corporate can attend the AGM through VC/OAVM and cast their votes through e-voting.**

   The Notice calling the AGM has been uploaded on the website of the Company at www.deephealthaiindia.com. The Notice can also be accessed from the websites of the Stock Exchange i.e., BSE Limited at https://www.bseindia.com/. The AGM Notice is also disseminated on the website of NSDL (the agency for providing the Remote e-Voting facility and e-voting system during the AGM) i.e., www.evotingindia.com.

27. Members who have already cast their vote by remote e-Voting prior to the AGM, will also be eligible to participate at the AGM but shall not be entitled to cast their vote again on such resolution(s) for which the Member has already cast the vote through remote e-Voting.

28. Members of the Company holding shares either in physical form or electronic form, **as on the cut-off date of Wednesday September 23, 2026,** may cast their vote by remote e-Voting. The remote e-Voting period commences on Sunday **September 27, 2026, 09:00**

A.M. (IST) and ends on Tuesday **September 29, 2026, 05:00 P.M. (IST)**. The remote e-Voting module shall be disabled by NSDL for voting thereafter. Once the vote on a resolution is cast by the Member, the Member shall not be allowed to change it subsequently. The voting right of Members shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being **Wednesday September 23, 2026.**

29. **The instructions for shareholders for e-voting and joining virtual meetings are as under:**

The Members will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access the same by following the steps mentioned below for 'Log-in to NSDL e-Voting system'. The link for VC/OAVM will be available in 'Member login' where the 'EVEN' of the Company will be displayed. After successful login, the Members will be able to see the link of 'VC/OAVM link' placed under the tab 'Join Annual General Meeting' against the name of the Company. On clicking this link, the Members will be able to attend and participate in the proceedings of the AGM through a live webcast of the meeting and submit votes on announcement by the Chairman.

The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to at least 1000 members on a first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.

Members may join the AGM through laptops, smartphones, tablets and iPads for better experience. Further, Members will be required to use Internet with a good speed to avoid any disturbance during the Meeting. Members will need the latest version of Chrome, Safari, Internet Explorer 11, MS Edge or Firefox. Please note that participants connecting from mobile devices or tablets or through laptops connecting via mobile hotspot may experience Audio/Video loss due to fluctuation in their respective network. It is, therefore, recommended to use stable Wi-Fi or LAN connection to mitigate any glitches.

Members are encouraged to submit their questions in advance with regard to the financial statements or any other matters to be placed at the AGM, from their registered email ID, mentioning their name, DP ID and Client ID number /folio number and mobile number, to reach the Company's email ID at deephealthaiindia@gmail.com before 3:00 p.m. (IST) on ***Wednesday, September 23, 2026.***

Queries that remain unanswered at the AGM, will be appropriately responded by the Company at the earliest post the conclusion of the AGM.

Members who would like to express their ***views/ ask questions as a Speaker*** *at the AGM may preregister themselves* ***by sending a request*** *from their registered email ID mentioning their names, DP ID and Client ID/folio number, PAN and mobile number to deephealthaiindia@gmail.com* ***between Thursday, September 24, 2026(9:00 a.m. IST) and Tuesday, September 29, 2026(5:00 p.m. IST)****. Only those Members who have pre-registered themselves as Speakers will be allowed to express their views/ask questions during the AGM. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.*

Any person holding shares in physical form and nonindividual shareholders, who acquire shares and become Members of the Company after the Notice is sent through e-mail and holding shares as of the **cut-of date i.e., Wednesday September 23, 2026**, may obtain the login ID and password by sending a request at evoting@nsdl.co.in or Issuer/RTA.

However, if you are already registered with NSDL for remote e-voting, then you can use your existing user ID and password for casting your vote. If you forget your password, you can reset your password by using “Forgot User Details/Password” or “Physical User Reset Password” option available on http://www.evoting.nsdl.com or call on 022 - 4886 7000 and 022 - 2499 7000. In case of Individual Shareholders holding securities in demat mode who acquire shares of the Company and become Members of the Company after sending of the Notice and holding **shares as of the cut-off date i.e., Wednesday September 23, 2026***,* may follow steps mentioned in the Notice of the AGM under “Access to NSDL e-Voting system. Other methods for obtaining/ procuring user IDs and passwords for a-Voting are provided in the AGM Notice.

Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended, and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and the applicable circulars issued by the Ministry of Corporate Affairs in this regard, including General Circular Nos. 14/2020 dated April 08, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 05, 2020 and 03/2025 dated September 22, 2025, the Company is providing the facility of remote e-Voting to its Members in respect of the businesses to be transacted at the AGM.

For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as venue voting on the date of the EGM/AGM will be provided by NSDL.

AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular mentioned aforesaid.

THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING AND JOINING GENERAL MEETING ARE AS UNDER: -

The remote e-voting period begins on Sunday, September 27, 2026, 09:00 A.M. (IST) and ends on Tuesday, September 29, 2026, 05:00 P.M. (IST). The remote e-voting module shall be disabled by NSDL for voting thereafter. Members whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e., Wednesday, September 23, 2026, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being Wednesday, September 23, 2026.

How do I vote electronically using NSDL e-Voting system?

The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting and joining virtual meetings for Individual shareholders holding securities in demat mode

In terms of SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December09, 2020, on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	**Login Method**
Individual Shareholders holding securities in demat mode with NSDL.	1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting

		your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2. Existing **IDeAS** user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the "**Beneficial Owner**" icon under **"Login"** which is available under **'IDeAS'** section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on **"Access to e-Voting"** under e-Voting services and you will be able to see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select **"Register Online for IDeAS Portal"** or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen-digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or **e-Voting service provider i.e. NSDL** and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 5. Shareholders/Members can also download NSDL Mobile App "**NSDL Speede**" facility by scanning the QR code mentioned below for seamless voting experience.

	NSDL Mobile App is available on App Store Google Play
Individual Shareholders holding securities in demat mode with CDSL	1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi /Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my Easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the e-voting is in progress as per the information provided by company. On clicking the e-voting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the e-voting is in progress and also able to directly access the system of all e-Voting Service Providers.

Individual Shareholders (holding securities in demat mode) login through their depository participants	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	**Helpdesk details**
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.com or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) Login Method for e-Voting and joining virtual meetings for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

<u>How to Log-in to NSDL e-Voting website?</u>

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.
   Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at https://eservices.nsdl.com/ with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.
4. Your User ID details are given below :

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	**Your User ID is:**
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12****** then your user ID is IN300***12******.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12************** then your user ID is 12**************
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example, if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:
   a) If you are already registered for e-Voting, then you can user your existing password to login and cast your vote.

   b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.

   c) How to retrieve your 'initial password'?
   (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
   (ii) If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email IDs are not registered.

6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
   a) Click on "**Forgot User Details/Password**?"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
   b) **Physical User Reset Password**?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
   c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.co.in mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
   d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.

7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.

How to cast your vote electronically and join General Meeting on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.

2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join Meeting".

3. Now you are ready for e-Voting as the Voting page opens.

4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.

5. Upon confirmation, the message "Vote cast successfully" will be displayed.

6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.

7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to csronakjhuthawat@gmail.com with a copy marked to evoting@nsdl.co.in. Institutional shareholders (i.e., other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "Upload Board Resolution / Authority Letter" displayed under "e-Voting" tab in their login.

2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "Forgot User Details/Password?" or "Physical User Reset Password?" option available on www.evoting.nsdl.com to reset the password.

3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download

section of www.evoting.nsdl.com or call on.: 022 - 4886 7000 and 022 - 2499 7000 or send a request to Mr. Abhijeet Gunjal, Deputy Manager at evoting@nsdl.co.in

Process for those shareholders whose Email IDs are not registered with the depositories for procuring user id and password and registration of Email IDs for e-voting for the resolutions set out in this notice:

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) by email to deephealthaiindia@gmail.com
2. In case shares are held in demat mode, please provide DPID-CLID (16-digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self-attested scanned copy of PAN card), AADHAR (self-attested scanned copy of Aadhar Card) to deephealthaiindia@gmail.com. If you are an Individual shareholder holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A**) i.e. **Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode**.
3. Alternatively, shareholder/members may send a request to evoting@nsdl.co.in for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 09, 2020, on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE EGM/AGM ARE AS UNDER:

1. The procedure for e-Voting on the day of the EGM/AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the EGM/AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the EGM/AGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the EGM/AGM. However, they will not be eligible to vote at the EGM/AGM.

4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the EGM/AGM shall be the same person mentioned for Remote e-voting.

INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE EGM/AGM THROUGH VC/OAVM ARE AS UNDER:

1. Member will be provided with a facility to attend the EGM/AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of "VC/OAVM" placed under **"Join meeting"** menu against company name. You are requested to click on VC/OAVM link placed under Join Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.

2. Members are encouraged to join the Meeting through Laptops for better experience.

3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.

4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.

5. Shareholders who would like to express their views/have questions may send their questions in advance mentioning their name demat account number/folio number, email id, mobile number at deephealthaiindia@gmail.com. The same will be replied by the company suitably.

6. If any shareholder wishes to register himself / herself as the speaker in the AGM, he or she is requested to send an email to the Company at deephealthaiindia@gmail.com or to NSDL at https://www.evoting.nsdl.com/.

EXPLANATORY STATEMENT
[Pursuant to Section 102 of the Companies Act, 2013]

Item No.04:

To Consider and Recommend the appointment of M/s Vimal C Surana & Co., Chartered Accountants as the Statutory Auditor of the Company for a term of five (5) consecutive years.

M/s VRSK & Co. LLP, Chartered Accountants, Firm Registration No. 111426W, are the existing Statutory Auditors of the Company and were re-appointed for the further term of five consecutive years in the Annual General Meeting held for the Financial Year 2020-21 dated September 29, 2021, under the applicable provisions of the Companies Act, 2013. Their term of office in the Company will expire at the conclusion of the **32nd Annual General Meeting** of the Company.

Consequent to the completion of the tenure of the existing Statutory Auditors, the Company is required to appoint Statutory Auditors for the ensuing term in accordance with the provisions of Section 139 and other applicable provisions of the Companies Act, 2013 ("Act") read with the rules made thereunder subject to approval of the Members at an Annual General Meeting.

Accordingly, the Audit Committee, after considering the relevant factors and evaluating the suitability of the proposed auditor, recommended to the Board of Directors the appointment of **M/s Vimal C Surana & Co., Chartered Accountants (Firm Registration No. 015888C)** as the Statutory Auditors of the Company. The Audit Committee, inter alia, considered the professional expertise, experience, technical capabilities, resources and overall suitability of the firm for undertaking the statutory audit of the Company.

Based on the recommendation of the Audit Committee, the Board of Directors, at its meeting held on September 03, 2026, considered and approved the proposal for appointment of **M/s Vimal C Surana & Co., Chartered Accountants (Firm Registration No. 015888C)** as the Statutory Auditors of the Company, subject to the approval of the Members in this Annual General Meeting.

The Board of Directors recommends the appointment of M/s Vimal C Surana & Co Chartered Accountants, for a term of five (5) consecutive years, commencing from the Annual General meeting held for the financial year 2026-2027 till the conclusion of the Annual General Meeting to be held for the financial year 2031-2032 of the Company, at such remuneration as may be determined by the Board of Directors in consultation with the Statutory Auditors and based on the recommendation of the Audit Committee, in addition to applicable taxes and reimbursement of reasonable out-of-pocket expenses incurred in connection with the audit.

The proposed Statutory Auditors have also confirmed that they satisfy the eligibility criteria prescribed under **Section 141 of the Companies Act, 2013**, and that they are not disqualified from being appointed as the Statutory Auditors of the Company. They have further confirmed that their appointment, if approved by the Members, shall be within the limits prescribed under the applicable provisions of the Act and that they meet the applicable criteria relating to independence and eligibility for such appointment.

The terms of appointment include quarterly audit of standalone and consolidated financial results and annual audit of standalone and consolidated financial statements in accordance with the provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time along with the issuance of certificates in accordance with requirements of the Act and SEBI. M/s Vimal C Surana & Co., Chartered Accountants (Firm Registration No. 015888C) will be paid an annual fee of Rs. 1,80,000/- (Rupees One Lakh Eighty Thousand Only) plus outlays and taxes as applicable from time to time, for the purpose of audit of the Company's accounts. The power may be granted to the Board/ Audit Committee to alter and vary the terms and conditions of appointment, revision including upward revision of the remuneration during the tenure of appointment, in such manner and to such extent as may be mutually agreed with the Statutory Auditors. The remuneration paid to the Statutory Auditors will be disclosed in the Corporate Governance Report as well as the Annual Financial Statements of the Company on an annual basis.

Besides the audit services, the Company would also obtain certifications from the Statutory Auditors under various statutory regulations and certifications required by clients, banks, statutory authorities, audit related services and other permissible non-audit services as required from time to time, for which they will be remunerated separately on mutually agreed terms, as approved by the Board in consultation with the Audit Committee.

There has been an upward revision in the remuneration proposed to be paid to the proposed Auditors as compared to the fees paid to the outgoing Auditors. The revised fee structure has been determined after considering the enhanced scope of work, professional expertise required, and prevailing industry benchmarks, and is considered to be commensurate with the standards followed within the industry.

Accordingly, the consent of the shareholders is sought for the appointment of M/s Vimal C Surana & Co, Chartered Accountants (Firm Registration No. 015888C), as the Statutory Auditors of the Company for the aforesaid term and on such remuneration as may be determined in accordance with the provisions of the Act.

The Board of Directors, based on the recommendation of the Audit Committee, is of the opinion that the appointment of M/s Vimal C Surana & Co. Chartered Accountants, would be in the best interests of the Company and accordingly recommends the Ordinary Resolution set out at Item No. 04 of the accompanying Notice for approval of the Members.

Disclosure as required pursuant to terms of regulation 36(5) of SEBI Listing Regulations:

Particulars	**Details**
Terms of appointment of the Statutory Auditors	The terms and conditions of Vimal C Surana & Co., Chartered Accountants appointment include a tenure of five consecutive years, commencing from the Financial Year 2026-27 until the conclusion of the Annual General Meeting of the Company which will be held in the Financial Year 2031-32.
Proposed fees payable to the Statutory Auditors	The fixed remuneration and other permissible services set at Rs. 1,80,000 /- (Rupees One Lakh Forty thousand only), plus applicable taxes and other out-of-pocket costs incurred in connection with the audit. It is noteworthy that there is no material change in the proposed fee payable to M/s Vimal C Surana & Co., Chartered Accountants and hence the requirement for disclosure of rationale for change in proposed fee payable is not applicable. Further, the proposed fee is determined based on the scope of work, team size, industry experience, and the time and expertise required to conduct the audit effectively.
Basis of recommendation and auditor credentials	The recommendation for appointment of M/s Vimal C Surana & Co., Board of Directors and the Audit Committee, at their respective meetings held on September 03, 2026, have considered various parameters like capability to serve a widespread business landscape as that of the Company, audit experience across the industries, market standing of the firm, clientele served, technical knowledge, governance standards, etc., and found M/s Vimal C Surana & Co., Chartered Accountants suitable for this appointment and accordingly, recommended the same.

None of the Directors, Key Managerial Personnel of the Company or their respective relatives is concerned or interested, financially or otherwise, in the resolution set out at Item No. 04 of the Notice, except to the extent of their respective shareholding, if any, in the Company.

Item No.05:

To consider and approve appointment Mr. Virendra Choubisa: (DIN: 11923125) as an Additional Non-executive Independent Director on the Board of Directors of Company.

The Nomination and Remuneration Committee (NRC), after assessing the skills, experience, and expertise of Mr. Virendra Choubisa: (DIN: 11923125) and his potential contributions to the Board, and in accordance with the provisions of the Companies Act, 2013 ("Act") and the Articles of Association of the Company, recommended his appointment as a Non-Executive Independent Director of the Company. Based on the recommendation of NRC, the Board of Directors, at its meeting held on September 03, 2026, approved the appointment of Mr. Virendra Choubisa: (DIN: 11923125) as an Additional Director, designated as Non-Executive Independent Director not liable to retire by rotation. The Board of Directors also approved the term of office of Mr. Virendra Choubisa as Non-Executive Independent Director will be for a period of 5 (five) consecutive years from September 03, 2026, to September 02, 2031, subject to the approval of members of the Company. The Company has received the consent from Mr. Virendra Choubisa to act as a Director and has also received all requisite statutory disclosures and declarations from him, including confirmations that he meets the criteria for independence as prescribed under Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and that he is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India / Ministry of Corporate Affairs or any such statutory authority, and he is not disqualified from being appointed as a Director under Section 164 of the Act. Further he has complied with Rules 6(1) and 6(2) of the Companies (Appointment and Qualification of Directors) Rules, 2014, regarding registration with the data bank of Independent Directors maintained by the Indian Institute of Corporate Affairs. In the opinion of the NRC and Board Mr. Virendra Choubisa fulfils the conditions for appointment as an Independent Director as per the Act and the Listing Regulations and he is independent of management and possesses the necessary skills, experience, knowledge, and capabilities required for the role. Further Mr. Virendra Choubisa is a 'fit and proper person' to hold the said office. He shall be entitled to remuneration by way of sitting fees for attending Board and Committee meetings, reimbursement of expenses for participation in meetings, and profit-related commission, if any, within the limits prescribed under Section 197 of the Act and as may be determined by the Nomination and Remuneration Committee and the Board from time to time.

Brief Profile of Mr. Virendra Choubisa: He holds a Bachelor of Arts degree from Mohanlal Sukhadia University, Udaipur, with History and Sanskrit as his major subjects, awarded in 1998. He possesses professional expertise in Finance and has extensive experience in the field of Accounting. He has over 15 years of professional experience in the education sector, with his work involving teaching and academic responsibilities.

Mr. Choubisa was associated with Abhinav School as a Teacher from July 2009 to December 2023, where his area of work was primarily related to Accounting. Since July 2025, he has been associated with Happy Home School as a Teacher, where he is presently engaged in teaching History and Accounting. His academic background in History and Sanskrit, coupled with his professional experience in Finance, Accounting and teaching, provides him with a diverse understanding of financial and academic matters.

Disclosure Under Regulation 36 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standards on General Meetings 2015 and Secretarial Standards-2 for appointment / re-appointment of Directors is as below

Name of the Director	Mr. Virendra Choubisa
Age	53 Years
DIN	11923125
Date of Birth	05-05-1973
Date of Appointment	03-09-2026
Date of first appointment on the Board	03-09-2026
Date of appointment at current designation	03-09-2026
Category	Additional Non-executive Independent Director
Qualification	Bachelor of Arts (B.A.) from Mohanlal Sukhadia University, Udaipur (1998).
Nature of expertise in specific functional areas and Experience	1. Expertise in Finance and Accounting. 2. Extensive experience in Accounting and related financial functions. 3. Teaching experience in History and Accounting. 4. Associated with Abhinav School from July 2009 to December 2023 and Happy Home School since July 2025.
Terms and conditions of appointment/reappointment	Appointed for a period of five (5) consecutive years, with effect from September 03, 2026, to September 02, 2031, and shall not be liable to retire by rotation, subject to the applicable provisions of law and the Company's policies.
Number of shares held in the Company	Nil
Remuneration to be paid	NA
Directorship held in other Companies	None

Memberships/ Chairmanships of Committees of other Companies	None
Relationships between Directors inter-se	No Relation with Directors and other Key Managerial Personnel of the Company.
Last Drawn Remuneration and No. of Board Meetings attended during the year	1
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 National Stock Exchange of India Ltd. with ref. no. NSE/CML/2018/24 dated 20th June, 2018	

Item No.06

To consider and approve the revision in remuneration of Mr. Narayan Singh Rathore (DIN: 10900646), Managing Director of the Company.

The Members of the Company at its 31st Annual General Meeting held on September 23, 2025, had by way of special resolution, approved the re-appointment of Mr. Narayan Singh Rathore as Managing Director of the Company for a period of five consecutive years commencing from January 19, 2026 up to January 18, 2031 together with the remuneration payable to him.

Mr. Narayan Singh Rathore aged 47 years, is a Commerce Graduate and has significant experience in sales, marketing and administration. He has been associated with the Company since January 18, 2025. Over the last five decades, he has played a pivotal role in the Company's growth and success through his leadership, industry expertise, and strategic vision. He currently serves as the Chairman and Managing Director of the Company

Under his leadership, the Company has achieved significant growth, strengthened its market position He has extensive exposure to all aspects of the Company's business, and under his able leadership, the Company continues to strengthen its capabilities in the administration of the Company. Through a strong focus on innovation, operational excellence, and customer-centric services, the Company is consistently enhancing its value proposition in the industry. He has been instrumental in establishing and strengthening the Company's quality control systems and has significantly contributed to the development and marketing functions. His vast industry knowledge, longstanding experience, and understanding of the Company's operations have been invaluable in driving business expansion, strategic initiatives, and long-term value creation for stakeholders. He provides strategic leadership in the areas of sustainability and investor relations, strengthening the Company's commitment to responsible growth, transparency and long-term stakeholder value creation.

Considering Mr. Narayan Singh Rathore's significant contributions to the Company's growth the Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, considers it appropriate to increase the upper limit of remuneration payable to him, subject to the approval of the shareholders and such other approvals as may be required under applicable laws.

The Board believes that the proposed increase in the remuneration limit is commensurate with Mr. Narayan Singh Rathore's responsibilities, experience, contribution to the Company, and industry benchmarks, and is in the best interests of the Company and its shareholders.

Based on the recommendation of the Nomination and Remuneration Committee meeting and and the Board of Directors held on September 03, 2026, approved the revision in remuneration payable to Mr. Narayan Singh Rathore with effect from April 01, 2026, subject to the approval of the Members. The Board noted that the existing upper limit of the salary of Rs. 1,40,000/- per month, as approved by the Members, may not be adequate to accommodate the proposed increase in remuneration during the remaining tenure of Mr. Narayan Singh Rathore. Accordingly, approval of the Members is being sought for the enhancement of the maximum monthly salary from Rs. 65000 to Rs. 1,40,000/- with effect from April 01, 2026 for a period of three years, i.e., up to March 31, 2029, as set out in Schedule V to the Companies Act, 2013 as set out in Resolution No. 6 of this Notice.

Accordingly, approval of the Members is sought for revision in remuneration payable to Mr. Narayan Singh Rathore, Chairman and Managing Director of the Company, with effect from April 01, 2026 for a period of three years, i.e., up to March 31, 2029, as set out in Schedule V to the Companies Act, 2013.

Additional information pursuant to Regulation 36(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard-2 on General Meetings forms part of this Notice.

None of the Directors, Key Managerial Personnel, or their respective relatives are financially or otherwise interested in the Resolution under Item No. 06 of the Notice. The Board recommends the Special Resolution under Item No. 06 for approval by the Members.

Brief resume of Directors being appointed pursuant to Regulation 36(3)(a) of the Listing Regulations and Information pursuant to Clause 1.2.5 of the Secretarial Standard — II on General Meetings (SS-2) regarding Director seeking appointment / re-appointment:

Name of the Director	**Mr. Narayan Singh Rathore**

Director Identification Number ("DIN")	10900646
Category	Managing Director
Date of Birth	08/02/1979
Nationality	Indian
Date of First Appointment on the Board	18/01/2025
Relationship with Directors	None
Qualification	B. Com
Experience/ Expertise in specific functional area	Business field
Details of Board Meetings attended by the Director during the year	The Director has attended 11 meetings in the Financial Year 2025-2026.
Terms and Conditions of Appointment with remuneration	As per the Resolution and Explanatory Statement
Remuneration last drawn	65,000/-
List of Directorships held in other Companies	None
Membership/Chairmanship of Committees across other Companies.	The said Director is member of the Audit Committee of Deep Health AI India Limited.
Number of shares held in the Company including shareholdings beneficial owners	NIL
Skills and capabilities required for the role and the manner in which the proposed person meets such requirements	He has experience and knowledge of working in the field of business.
Justification for choosing the appointee for appointment as Independent Director	He has experience and knowledge of working in the field of business.
Rationale for the said agenda being taken in compliance of Regulation 17(11) of the Listing Regulations	As provided in the explanatory statement for item no. 06

Disclosures as required under sub clause (iv) of second proviso to clause (B) of section II of part-II of Schedule V:

1. **General Information**

   a. Nature of industry: The Company is engaged in the business of trading Diamond, Jewellery and Pharma products.

   b. Date or expected date of commencement of commercial production: Not Applicable as Company is not into manufacturing.

   c. In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus: Not Applicable

   d. Financial performance based on given indicators:

(in hundreds)

Particulars	2025-2026	2024-2025	2023-2024
Turnover	4,25,000.00	1,25,909.00	2,55,611.00
Other Income	4,24,023.00	74,630.00	1,09,109.60
Total Income	**8,49,023.00**	**2,00,538.00**	**3,64,720.60**
Profit Before Tax	1,76,242.00	1,09,860.00	57,686.17
Profit After Tax	1,29,911.00	86,073.00	41,883.79
Paid-up Equity Capital	14,41,500.00	4,80,500.00	4,80,500.00
Reserve & Surplus	37,12,326.96	17,53,898.00	15,61,615.38

   e. Foreign investments or collaborations, if any: Not Applicable as the Company has not made or entered into any foreign investments or collaborations.

2. **Information about the appointee:**

Narayan Singh Rathore	
Background details	He is a commerce graduate.
Past remuneration	Rs. 65,000/- per month.
Recognition or awards	-
Job profile and his suitability	Mr. Narayan Singh Rathore started his career as Sales Manager with Pyrotech Workspace Solutions Private. Ltd. and have gain more 12 years of experience in sales.

	He also has significant experience in the field of administration.
Remuneration proposed	As mentioned in the explanatory statement aforesaid
Comparative remuneration profile with respect to industry, size of the company, profile of the position and person (in case of expatriates the relevant details would be with respect to the country of his origin)	Taking into consideration the size of the Company, profile, knowledge the skills and responsibilities shouldered by Mr. Narayan Singh Rathore, the remuneration proposed to be paid is commensurate with the remuneration packages paid to him similar counterparts in other companies.
Pecuniary relationship directly or indirectly with the company, or relationship with the managerial personnel, if any	Apart from the remuneration paid to him as Managing Director as stated above, the Directors do not have any pecuniary relationship directly or indirectly with the Company and its managerial personnel.

3. **Other information:**

   a. Reasons of loss or inadequate profits: Currently Company has adequate profits. The Company is passing a special resolution pursuant to the proviso of the sub-section (1) of Section 17 of the Companies Act, 2013 and as a matter of abundant precaution, as the profitability of the Company may be adversely impacted in future due to business environment during the period for which remuneration is payable to Mr. Narayan Singh Rathore.

   b. Steps taken or proposed to be taken for improvement: Series of strategic and operational measures is expected to result in the improvement in the present position. The Company has further strategically planned to address various issues and enhance its profits and has put in place measures to reduce cost and improve the bottom-line.

   c. Expected increase in productivity and profits in measurable terms: The Company has been aggressively pursuing and implementing its strategies to improve its financial performance.

For and on behalf of the
DEEP HEALTH AI INDIA LIMITED
(Formerly known as Deep Diamond India Limited)

SD/-
NARAYAN SINGH RATHORE
DIN: 10900646
ADDRESS: 506-509 fifth floor, Apeksha, plot no. 256, Main Road,
Hiran Magri, Sector 11, Udaipur, Rajasthan (313001)
DATE: September 03, 2026

DIRECTORS REPORT

OF

DEEP HEALTH AI INDIA LIMITED

FOR THE FINANCIAL YEAR 2025-2026

NAMES OF PAST AND PRESENT DIRECTORS OF THE COMPANY WITH

DIRECTOR IDENTIFICATION NUMBERS (DIN)

- **Mr. Narayan Singh Rathore** -(DIN: 10900646) (Appointed w.e.f. 18/01/2025)
- **Mrs. Laveena Pokharna** - (DIN: 10977709) (Appointed w.e.f. 10/03/2025)
- **Mr. Kaushal Jain** - (DIN: 00848381) (Appointed w.e.f. 20/09/2023)
- **Mr. Rajesh Nandkishore Pherwani** - (DIN: 07576485) (Appointed w.e.f. 07/03/2025)
- **Mr. Narendra Kumar Shrimali** -(DIN: 09034181) (Ceased w.e.f. 24/11/2025)
- **Mrs. Shashi Kala Dhabriya** - (DIN: 11611776) (Appointed w.e.f 20/03/2026)
- **Mr. Kailash Chandra** - (DIN: 10985611) (Ceased w.e.f. 03/04/2026)

Note:
**Bhupesh Swami is appointed as Independent Director on the Board of the Company w.e.f. July 02, 2026*
**Virendra Choubisa is appointed as Additional Non-Executive Independent Director on the Board of the Company w.e.f. September 03, 2026.*

The above disclosure has been given in accordance with Section 158 of the Companies Act 2013, and reference of any of the above directors made in this document be read along with the above disclosure of their respective Director Identification Number.

DIRECTORS' REPORT

To
The Members,
Deep Health AI India Limited
Address: 506-509 fifth floor, Apeksha, plot no. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001) Tel: 0294-3569097

Your directors have the pleasure of presenting the 32nd Annual Report of the Company together with the Audited Statement of Accounts for the year ended March 31, 2026.

1. FINANCIAL SUMMARY & OPERATIONAL HIGHLIGHTS:

a) Financial Results

The Company's standalone performance during the year ended March 31, 2026, as compared to the previous financial year, is summarized below:

(Amount in Rupees)

Particulars	2025-2026	2024-2025
Total Income	8,49,02,285	2,00,53,900
Less: Expenses	94,93,636	90,67,800
Profit & (Loss) before extraordinary items & Tax	7,54,08,649	1,09,86100
Exception and Extraordinary items	(5,77,84,425)	-
Profit & (Loss) before Tax	**1,76,24,224**	**1,09,86100**
Less: Tax expense	(46,33,100)	(23,78,600)
Profit/Loss after tax	1,29,91,124	**86,07,323**
Other Comprehensive Income	(10,24,07,628)	1,06,20,967
Total Income	(8,94,16,504)	**1,92,28,290**

APPROPRIATION:

Interim Dividend	1,35,26,210	-
Final Dividend	-	-
Tax on distribution of dividend	8,88,790-	-
Transfer of General Reserve	-	-
Balance carried to Balance sheet	(10,38,31,500)	1,92,28,290

b) <u>Company's performance review:</u>

The Company continues to see marginal growth in its overall performance in the financial year 2025-2026. Driven by the performance of the segment in which the Company operates a quick summary of standalone results are given below:

During the Financial Year ended March 31, 2026, the Company's total Revenue from operations is **INR 4,25,00,000/- as against INR 1,25,90,900/-** in the corresponding previous Financial Year ended March 31, 2025.

The Profit after tax for the Financial Year ended March 31, 2026, is **INR 1,29,91,124 /-, as against Profit of INR 86,07,300/-** in the corresponding previous Financial Year ended March 31, 2025.

c) <u>Operations and Changes in nature of the business, if any:</u>

The Company continues to be engaged in activities pertaining to sale of gold and diamond studded jewellery and marketing of pharmaceutical goods also expanding it to AI based healthcare products in India during the year under review.

Further, there was no change in the nature of the business operations of the Company, which impacted on the financial position of the Company during the financial year under review.

d) <u>Transfer to Reserves</u>

The Company has not transferred any amount into the general reserve during the financial year under review.

e) <u>Dividend:</u>

The Board of Directors of the Company at its meeting held Friday, October 31, 2025 had inter-alia considered and declared the Interim Dividend at the rate of Rs. 0.10/- (10%) per Equity Share bearing Face Value of Rs. 1/- each for the Quarter ended September 30, 2025.

Further, the Company has not declared any dividend for the Financial Year 2025-2026

f) <u>Unpaid dividend & IEPF:</u>

Neither has the Company transferred any amount or shares, nor has the Company transferred any amount or shares to the Investor Education & Protection Fund (IEPF) and no amount is lying in Unpaid Dividend A/c of the Company.

g) <u>Disclosure with respect to demat suspense account / unclaimed suspense account:</u>

The Company maintains Demat Suspense Account in its name during the F.Y. 2025-2026 and hence the disclosure pertaining to the same in compliance with applicable provisions of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 by the Company for F.Y. 2025-2026.

h) <u>Report on the performance of Subsidiaries, Associates, and Joint venture companies:</u>

As on March 31, 2026, the Company has one Associate Company, namely Ferry Automotive Private Limited, in which the Company holds 33.33% of the equity share capital.

During the financial year 2025-26, Microcure Biotech Private Limited continued to be a subsidiary of the Company. However, during the said financial year, the Company initiated the process for striking off Microcure Biotech Private Limited in accordance with the applicable provisions of law. The process for striking off the said company was under process as at March 31, 2026.

Further, during the financial year 2025-26, the Company had a Joint Venture with Hemonc Pharma Private Limited. The Company disposed of its investment in the said Joint Venture on March 28, 2026, and consequently, Hemonc Pharma Private Limited ceased to be a Joint Venture of the Company with effect from March 28, 2026.

The details of the Associates Company is given below:

a) Ferry Automotive Private Limited:

M/s Ferry Automotive Private Limited CIN: U77100MH2023PTC401779 is a private company incorporated on April 27, 2023. The authorized Share Capital of the Company is INR 10,00,000/- divided into 1,00,000 equity shares of INR 10/- each and the Issued, Subscribed, and Paid-up Share Capital of the Company is INR 15000/- divided into 5,000 equity shares of INR 10/- each.

The Company has a 33.33% equity stake in M/s Ferry Automotive Private Limited and M/s Ferry Automotive Private Limited has thus become associate of the Company under Section 2(6) of the Companies Act, 2013.

Further, a statement containing salient features of the financial statements of the Company’s subsidiaries as required in Form AOC-1 is appended as **Annexure I** to this Report.

i) <u>Deposits:</u>

The Company has not accepted or renewed any amount falling within the purview of provisions of Section 73 of the Companies Act 2013 (“the Act”) read with the Companies (Acceptance of Deposit) Rules, 2014 during the year under review.

Hence, the requirement for furnishing details relating to deposits covered under Chapter V of the Act or the details of deposits that are not in compliance with Chapter V of the Act is not applicable.

j) **Loans From Directors:**

During the financial year under review, the Company has not borrowed any amount from the Director or its relatives.

However, the Company has an outstanding loan taken from Mr. Prakash Solanki, when he was a Director of the Company. Details of the same are as mentioned below:

- Repayment of loan during the year: INR. 25,88,770/-
- Interest Paid on the loan during the year: INR. 2,58,099/-
- Loan outstanding as on March 31, 2026: INR. 37,53,913/-

k) **Share Capital:**

As of March 31, 2026, the Authorized Share Capital of the Company is INR 50,00,00,000/- divided into 50,00,00,000 Equity Shares of Rs. 1/- each.

During the year under review, company has passed Ordinary Resolution through Postal Ballot in FY 2025-26 to Increase the Authorized Share Capital of the Company from INR 15,00,00,000/- divided into 10,00,00,000 equity shares of INR 1/- each to 50,00,00,000/- divided into 50,00,00,000 Equity Shares of Rs. 1/- each which was approved by the members of the Company.

As on March 31, 2026, the Issued and Paid-up Capital of the Company is INR 14,41,50,000/-, comprising 14,41,50,000 equity shares of INR 1/- each.

During the financial year 2025-26, the Company made a Rights Issue of 9,61,00,000 equity shares of face value of INR 1/- each at an issue price of INR 4.16/- per equity share (including a premium of INR 3.16/- per share), aggregating to INR 39,97,76,000/-, to the eligible equity shareholders of the Company on a rights basis in the ratio of 2 (Two) equity shares for every 1 (One) equity share held as on the Record Date, i.e. August 29, 2025. Pursuant to the allotment of the aforesaid equity shares on October 06, 2025, the Issued, Subscribed and Paid-up Share Capital of the Company increased to INR 14,41,50,000/-, comprising 14,41,50,000 equity shares of INR 1/- each.

l) **Particular of contracts or arrangements with Related parties:**

All the related party transactions/contracts/arrangements that were entered into by the Company with related party(ies) as defined under the provisions of Section 2(76) of the Companies Act, 2013 during the year under review were carried out in the Ordinary course of business of the Company and were on an arm's length basis along with being in compliance with the applicable provisions of the Act and the Listing Regulations. Hence no disclosure is required to be given in this regard in Form AOC-2.

There are no materially significant related party transactions entered into by the Company with its Promoters, Directors, KMP's, or Senior Management Personnel that may have a potential conflict with the interest of the Company at large.

All related party transactions as required under AS-18 are reported in the notes to the financial statement of the Company.

m) <u>Web address where annual return referred u/s 92(3) will be hosted.</u>

Pursuant to the provisions of Section 92(3) read along with Section 134(3)(a) of Companies Act, 2013, the **Annual Return** as on March 31, 2026, will be available on Company's website on www.deephealthaiindia.com

n) <u>Material changes and commitments affecting the financial position of the company and key developments:</u>

Except as disclosed elsewhere in this report there are no material changes and commitments affecting the financial position of the Company, subsequent to the close of the Financial Year 2025-2026 till the date of this Report.

o) <u>Particulars of loans, guarantees, securities or investments under section 186 of the Companies Act, 2013:</u>

The particulars of Loans, Guarantees, and Investments covered under section 186 of the Companies have been disclosed in Notes to the Financial Statement.

p) <u>Conservation of energy, technology absorption and foreign exchange earnings and outgo:</u>

The particulars as required under the provisions of Section 134(3) (m) of the Companies Act, 2013 read along with Rule 8 of the Companies (Accounts) Rules, 2014 in respect of conservation of energy, technology absorption, foreign exchange earnings and outgo etc. are as mentioned below:

A) Conservation of energy:

Steps taken or impact on conservation of energy	The operations of the Company do not involve high energy consumption. However, the Company has for many years now been laying great emphasis on the Conservation of Energy and has taken several measures

	including regular monitoring of consumption, implementation of viable energy saving proposals, improved maintenance of systems etc.
Steps taken by the company for utilizing alternate sources of energy	Though the activities undertaken by the Company are not energy-intensive, the Company shall explore alternative sources of energy, as and when the necessity arises.
Capital investment on energy conservation Equipment's	Nil

(B) Technology absorption:

Efforts made towards technology absorption	Nil
Benefits derived like product improvement, cost reduction, product development or import substitution	
In case of imported technology (imported during the last three years reckoned from the beginning of the financial year):	
• **Details of technology imported**	Nil
• **Year of import**	Not Applicable
• **Whether the technology has been fully absorbed**	Not Applicable
• **If not fully absorbed, areas where absorption has not taken place, and the reasons thereof**	Not Applicable
Expenditure incurred on Research and Development	Nil

(C) Foreign exchange earnings and Outgo:

	April 01, 2025, to March 31, 2026 [2025-2026]	**April 01, 2024, to March 31, 2025 [2024-2025]**
	Amount in Rs.	**Amount in Rs.**

Actual Foreign Exchange earnings	Nil	Nil
Actual Foreign Exchange outgo	Nil	Nil

q) Internal financial control systems and their adequacy:

The Company has its internal financial control systems commensurate with the size and complexity of its operations, to ensure proper recording of financials and monitoring of operational effectiveness and compliance of various regulatory and statutory requirements. The management regularly monitors the safeguarding of its assets, prevention and detection of frauds and errors, accuracy and completeness of the accounting records including timely preparation of reliable financial information.

The internal auditor consults and reviews the effectiveness and efficiency of the internal financial control systems and procedure to ensure that all the assets are protected against loss and that the financial and operational information is accurate and complete in all respects. Significant audit observations and corrective actions thereon are presented to the Audit Committee of the Company.

2. MATTERS RELATED TO DIRECTORS AND KEY MANAGERIAL PERSONNEL:

a) Board of Directors & Key Managerial Personnel:

There was a change in the Directorship of the Company during the year under review and accordingly the Board of the Company was re-constituted on various occasions throughout the financial year under review.

Below are the details regarding all the appointments done and resignations received for the period commencing from April 01, 2025, till the date of this report.

i. Appointment:

Mrs. Laveena Pokharna was appointed as CFO of the Company w.e.f. April 16, 2025.

Mr. Rakesh Vishnoi was appointed as Company Secretary and Compliance Officer of the Company w.e.f. August 13, 2025.

Mrs. Shashi Kala Dhabriya (DIN: 11611776) was appointed as Additional Non-Executive Independent Director w.e.f. March 20, 2026, and further the appointment was approved by the members in Extra-ordinary General Meeting on July 30, 2026, as Non-Executive Independent Director in the Board of the Company.

ii. **Details of the Directors and KMP's resigned during the year:**

Mr. Prashant Tali, resigned from the position of Company Secretary and Compliance Officer of the Company w.e.f. June 27, 2025.

Mr. Narendra Kumar Shrimali (DIN: 09034181) resigned from the position of Non-Executive Director of the Company w.e.f. November 24, 2025.

Mr. Kailash Chandra (DIN: 10985611) resigned from the position of Non-Executive Independent Director of the Company w.e.f. April 03, 2026.

The Directors and Key managerial personnel as on March 31, 2026, are as below:

Sr. No.	Name of Directors & KMP's	Designation	DIN/PAN
1.	**Mr. Narayan Singh Rathore**	Managing Director	10900646
2.	**Mrs. Laveena Pokharna**	Whole Time Director & Chief Financial Officer	10977709
3.	**Mr. Kaushal Jain**	Non-Executive Director	00848381
4.	**Mr. Rajesh Nandkishore Pherwani**	Independent Director	07576485
5.	**Mr. Kailash Chandra**	Independent Director	10985611
6.	**Mrs. Shashi Kala Dhabriya**	Independent Director	11611776
7.	**Mr. Rakesh Vishnoi**	Company Secretary & Compliance Officer	-

b) Retirement by Rotation

In accordance with the provisions of the Act, none of the Non-Executive Independent Directors are liable to retire by rotation.

As per the provisions of Section 152(6) of the Companies Act, 2013 read with the Companies (Appointment and Qualification of Directors) Rules, 2014, Mr. Narayan Singh Rathore (DIN:10900646) is liable to retire by rotation at the ensuing Annual General Meeting and being eligible, offer themselves for re-appointment.

Your directors recommend this for approval.

c) Declaration under section 149(6) of the Companies Act, 2013 and Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 from Independent Directors:

The Company has received the necessary declaration from each Independent Director under Section 149 (7) of the Companies Act, 2013 that they meet the criteria of independence laid down in Section 149 (6) of the Companies Act, 2013 read along with Schedule IV to the Companies Act, 2013 i.e., Code of Independent Directors and Regulation 16 (1) (b) and Regulation 25 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended).

All the Independent Director/s have submitted a declaration that he/she meets the criteria of independence and submits the declaration regarding the status of holding other directorship and membership as provided under law. The Board of Directors recorded their opinion that all the Independent Directors are independent of the management and have fulfilled all the conditions as specified under the governing provisions of the Companies Act, 2013 and the Listing Regulations.

The Independent Directors affirmed that none of them were aware of any circumstance or situation which could impair their ability to discharge their duties with an objective independent judgment and without any external influence.

Further, the Independent Directors have also confirmed that they have complied with the Company's code of conduct.

d) <u>Evaluation by Independent Director:</u>

In a separate meeting of Independent Directors, performance of non-independent directors, performance of the Board as a whole and performance of the Chairman was evaluated, considering the views of executive director.

e) <u>Disqualification of Directors:</u>

During the financial year 2025-2026 under review, the Company has received Form DIR-8 from all Directors as required under the provisions of Section 164(1) and 164(2) of the Companies Act, 2013 read with Companies (Appointment and Qualification of Directors) Rules, 2014.

The Board has taken the same on record.

f) <u>MD/WTD draws commission from co., and also draws Remuneration / Commission from holding / subsidiary Company:</u>

The provisions of Section 197(14) of the Companies Act, 2013 are not applicable to the Company for the financial year 2025-26. Accordingly, no disclosure is required to be made under the said provisions.

3. Disclosure related to Committees of the board:

As on March 31, 2026, the Board had Three (3) Committees viz; Audit Committee; Nomination & Remuneration Committee and Stakeholder Relationship Committee.

However, consequent to re-constitution of the Board during the financial year under review, the composition of the Board committees were also re-constituted accordingly.

i. Audit Committee:

The Audit Committee of Directors was constituted pursuant to the provisions of Section 177 of the Companies Act, 2013.

The composition of the Audit Committee was in conformity with the provisions of the said section as on March 31, 2026.

The Audit Committee comprises of as on date of this report:

Name of Members	Designation
Mr. Rajesh Nandkishore Pherwani	Chairperson
Mr. Kailash Chandra*	Member
Mr. Narayan Singh Rathore	Member
Mr. Bhupesh Swami**	Member

**Mr. Kailash Chandra resigned from the Board of Directors w.e.f. 03/04/2026.*
***Mr. Bhupesh Swami was appointed as member of Audit Committee w.e.f. 02/07/2026*

All members of the Audit Committee have the requisite qualification for appointment on the Committee and possess sound knowledge of finance, accounting practices and internal controls.

The Company Secretary of the Company acts as the Secretary of the Audit Committee.

The Audit Committee met 6 times during the financial year ended on March 31, 2026, at their meeting held on April 16, 2025, May 28, 2025, August 13, 2025, August 28, 2025, October 07, 2025, February 11, 2026.

During the year under review, the Board of Directors of the Company accepted all the recommendations of the Committee.

ii. **Nomination & Remuneration Committee:**

The Nomination and Remuneration Committee of Directors was constituted pursuant to the provisions of Section 178 of the Companies Act, 2013.

The composition of the Nomination and Remuneration Committee was in conformity with the provisions of the said section as on March 31, 2026.

The Nomination & Remuneration Committee comprises of as on the date of this report is as below:

Name of Members	Designation
Mr. Kaushal Jain#	Member
Mr. Narendra Kumar Shrimali****	Member
Mr. Kailash Chandra***	Member
Mr. Rajesh Nandkishore Pherwani*	Chairman
Mr. Bhupesh Swami**	Member

**Mr. Rajesh Nandkishore Pherwani was appointed as a Regular Chairperson of the Committee w.e.f. 24/02/2026.*
***** Mr. Narendra Kumar Shrimali resigned from the Company w.e.f. 24/11/2026.*
****Mr. Kailash Chandra resigned from the Board of Directors w.e.f. 03/04/2026.*
***Mr. Bhupesh Swami was appointed as member of Audit Committee w.e.f. 02/07/2026.*
#Mr. Kaushal Jain was the chairperson of the Company for two meetings i.e. 16/04/2025 and 13/08/2025.

The Board has in accordance with the provisions of sub-section (3) of Section 178 of the Companies Act, 2013, formulated the policy setting out the criteria for determining qualifications, positive attributes, independence of a Director, and policy relating to selection and remuneration for Directors, Key Managerial Personnel and Senior Management Employees.

Major criteria/gist defined in the policy framed for appointment of and payment of remuneration to the Directors of the Company, are as under:

- **Minimum Qualification**
- **Positive Attributes**
- **Independence**
- **Experience**

The Nomination & Remuneration Committee met 3 times during the financial year ended on March 31, 2026, at their meeting held on April 16, 2025, August 13, 2025, March 12, 2026.

iii. Stakeholder & Relationship Committee:

The Stakeholder & Relationship Committee of Directors was constituted pursuant to the provisions of Section 178(5) of the Companies Act, 2013.

The Stakeholder & Relationship Committee comprises of as on the date of this report of the below mentioned:

Name of Members	Designation
Mr. Kaushal Jain	Chairman
Mr. Kailash Chandra***	Member
Mrs. Shashi Kala Dhabriya*	Member
Mr. Narendra Kumar Shrimali****	Member
Mr. Bhupesh Swami**	Member

***** Mr. Narendra Kumar Shrimali resigned from the Company w.e.f. 24/11/2026.*
****Mr. Kailash Chandra resigned from the Board of Directors w.e.f. 03/04/2026.*
***Mr. Bhupesh Swami was appointed as member of Audit Committee w.e.f. 02/07/2026*
**Mrs. Shashi Kala Dhabriya was appointed in the Board of the Company w.e.f. 20/03/2026.*

The Company Secretary of the Company acts as the Secretary of the Stakeholders' Relationship Committee.

The Stakeholders' Relationship Committee met once during the financial year ended on March 31, 2026, at their meeting held on May 14, 2025.

SEBI Complaints Redress System (SCORES):

The investor complaints are processed in a centralized web-based complaints redress system. The salient features of this system are a centralized database of all complaints, online upload of Action Taken Reports (ATRs) by the concerned companies, and online viewing by investors of actions taken on the complaint and its current status.

Your Company has registered itself on SCORES and makes every effort to resolve all investor complaints received through SCORES or otherwise within the statutory time limit from the receipt of the complaint. The complaints received during the financial year 2025-2026 has been resolved by the company within 21 days as per statutory timeline.

4. Board & Committees Meetings:

i. Number of Board Meetings:

During the financial year under review, the Board of Directors met 11 times during the year in accordance with the provisions of the Companies Act, 2013 and rules made thereunder at their meeting held on April 16, 2025, May 28, 2025, August 13, 2025, August 28, 2025, October 07, 2025, October 17, 2025, October 31, 2025, November 13, 2025, December 16, 2025, February 11, 2026, February 24, 2026.

The Company has complied with the applicable Secretarial Standards in respect of all the above-Board meetings.

ii. Meeting of Independent Directors:

In compliance with Schedule IV to the Companies Act, 2013 and Regulation 25 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Independent Directors held their separate meeting on February 12,2026, without the attendance of non-independent directors and members of management, inter alia, to discuss the following:

- Review the performance of non-independent directors and the Board as a whole.
- Review the performance of the Chairperson of the Company, considering the views of executive directors and non-executive directors; and
- Assess the quality, quantity, and timeliness of flow of information between the Company Management and the Board that is necessary for the Board to perform their duties effectively and reasonably.

All independent directors were present at the meeting, deliberated on the above and expressed their satisfaction.

5. Policy(s) and Annual Evaluation:

(i) Vigil Mechanism Policy

The Board of Directors of the Company have, pursuant to the provisions of Section 177(9) of the Companies Act, 2013 read with Rule 7 of the Companies (Meetings of Board and its Powers) Rules, 2014, framed "Vigil Mechanism Policy" for Directors and employees of the Company to provide a mechanism which ensures adequate safeguards to employees and Directors from any victimization on raising of concerns of any violations of legal or regulatory requirements, incorrect or misrepresentation of any, financial statements and reports, etc.

The employees of the Company have the right/option to report their concern/grievance to the Chairman of the Board of Directors.

The Company is committed to adhering to the highest standards of ethical, moral, and legal conduct of business operations.

(ii) Policy on Nomination and Remuneration of Directors, KMPs and other Employees

In terms of sub-section 3 of Section 178 of the Companies Act, 2013; the Nomination and Remuneration Committee of the Company has laid down a policy on the selection and appointment of Directors and the Senior Management of the Company and their remuneration including criteria for determining qualifications, positive attributes, independence of a director and other matters.

The Remuneration Policy is available on Company's website and can be accessed in the link provided herein: https://deephealthaiindia.com/policies/

(iii) Risk management:

The Company has in place a mechanism to identify, assess, monitor, and mitigate various risks to key business objectives. Major risks identified by the businesses and functions are systematically addressed through mitigating actions on a continuing basis. These are discussed at the meetings of the Audit Committee and the Board of Directors of the Company.

(iv) Risk Management Policy:

The Board of Directors of the Company has designed Risk Management Policy and Guidelines to avoid events, situations or circumstances which may lead to negative consequences on the Company's businesses and define a structured approach to manage uncertainty and making use of these in their decision-making pertaining to all business divisions and corporate functions. Key business risks and their mitigation are considered in the annual/strategic business plans and in periodic management reviews.

(v) Criteria for making payments to non-Executive directors:

Pursuant to Regulation 46(2)(f) the Board has framed the policy containing the criteria for making the payments to non-executive directors**.**

The policy is available on the website at https://deephealthaiindia.com/policies/

(vi) Annual Evaluation of Directors, Committee and Board as a whole:

Pursuant to the provisions of Section 134(3)(p) of the Companies Act, 2013 the Board has carried out the formal annual performance evaluation of its own performance, the Directors individually as well as the evaluation of the working of its various Committees and the working of the Board as whole.

The evaluation exercise was carried out on various aspects of the Boards functioning such as composition of the Board & committees, experience & competencies, performance of the duties and obligations, governance issues, etc.

The manner in which the evaluation was carried out has been explained below:

- **Performance Evaluation criteria:**

Separate exercise was carried out to evaluate the performance of individual Directors including the Chairman by the Nomination and Remuneration committee as per the structured mechanism who were evaluated on following parameters / criteria:

- Participation and contribution by a director,
- Commitment (including guidance provided to senior management outside of Board/ Committee meetings),
- Effective deployment of knowledge and expertise,
- Effective management of relationships with stakeholders,
- Integrity and maintenance of confidentiality,
- Independence of behavior and judgment,
- Observance of Code of Conduct, and
- Impact and influence.

In the opinion of the Board, Independent Directors of the Company possess relevant expertise and experience (including proficiency)

6. Auditors and Reports:

The matters related to Auditors, and their Reports are as under:

(i) Statutory Auditor:

Pursuant to the provisions of Section 139 of the Companies Act, 2013 and the Companies (Audit and Auditors) Rules, 2014 M/s. V R S K & Co. LLP, Chartered Accountants (Registration No. 111426W), the Statutory Auditors of the Company have been appointed for a term of 5 years to hold office till the conclusion of the Annual General Meeting to be held for the F.Y. 2025-2026.

The Company proposes appointment of Vimal C. Surana & Co. Chartered Accountants in the ensuing Annual General Meeting for a term of 5 consecutive years commencing from the date of the Annual General meeting held for the financial year 2026-2027 till the conclusion of the Annual General Meeting to be held for the financial year 2031-2032.

The Company has received written consent and certificate of eligibility in accordance with Sections 139, 141 and other applicable provisions of the Companies Act, 2013 and Rules issued thereunder (including any statutory modification(s) or re-enactment(s) for the time being in force). Further, they have confirmed that they hold a valid certificate issued by the Peer Review Board of the Institute of Chartered Accountants of India (ICAI) as required under the Listing Regulations.

(ii) Observations of Statutory auditors on accounts for the year ended March 31, 2026:

The Statutory Auditors' Report for the financial year ended March 31, 2026, does not contain any observations, qualifications, reservations, disclaimers or adverse remarks. Accordingly, no further explanation or comments are required to be provided by the Board under Section 134(3) of the Companies Act, 2013.

(iii) Reporting fraud by statutory auditors under section 143(12):

There were no incidents of fraud reporting by Statutory Auditors of the Company under Section 143(12) of the Act read with Companies (Accounts) Rules, 2014.

(iv) Adequacy of Internal Controls with reference to Financial Statements:

In accordance with the opinion of the auditors, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026.

(v) Secretarial Auditor:

Pursuant to the provisions of Section 204 of the Act read with Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company had appointed M/s Ronak Jhuthawat & Co, Practicing Company Secretaries for the period of Five consecutive years commencing from F.Y. 2025-2026 till F.Y. 2029-2030,

The Secretarial Audit Report in the prescribed Form No. MR-3 for the financial year ended March 31, 2026 is annexed herewith with the report.

(vi) Secretarial Auditor Report for the financial year ended on March 31, 2026:

Secretarial Audit Report issued by M/s Ronak Jhuthawat & Co, Practicing Company Secretaries in Form MR-3 for the financial year 2025-2026 forms part of this report and attached as **Annexure- II**.

(vii) Cost auditor:

Pursuant to the provisions of Section 148 of the Companies Act, 2013 read with Notifications/Circulars issued by the Ministry of Corporate Affairs from time to time, the Company is not required to appoint Cost Auditor.

(viii) Maintenance of Cost records:

Pursuant to the provisions of Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Rules, 2014, as amended from time to time, the Company is not required to maintain Cost Records under said Rules.

(ix) Internal auditor:

In accordance with the provisions of Section 138 of the Companies Act, 2013 and Rules framed thereunder, the Board has appointed M/s. Valawat & Associates, Chartered Accountants to conduct the Internal Audit of the Company for the Financial Year 2025-26.

(x) Internal Auditor Report for the financial year ended on March 31, 2026:

M/s. Valawat & Associates, Chartered Accountants, who were appointed as Internal Auditors of the Company for the F.Y. 2025-2026 has issued their internal audit report and it contains no adverse remarks or observations.

7. Other Disclosures:

Other disclosures as per provisions of Section 134 of the Act read with Companies (Accounts) Rules, 2014 are furnished as under:

a) Details of significant and material orders passed by the Regulator or Court or Tribunal:

There were no significant and material orders issued against the Company by a regulating authority or court or tribunal that could affect the going concern status and company's operation in future.

b) Directors' Responsibility Statement:

In terms of Section 134(5) of the Companies Act, 2013, in relation to the audited financial statements of the Company for the year ended March 31, 2026, the Board of Directors hereby confirms that:

(i) in the preparation of the Annual Accounts for the year ended March 31, 2026, the applicable accounting standards had been followed along with proper explanation relating to material departures.

(ii) such accounting policies have been selected and applied consistently and the Directors made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31, 2026, and of the profit of the Company for the year ended as on that date.

(iii) proper and sufficient care was taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities.

(iv) the annual accounts of the Company have been prepared on a going concern basis.

(v) that the directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and operating effectively.

(vi) proper systems have been devised to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

c) <u>Disclosure regarding Internal Complaints Committee under the sexual harassment of women at workplace (Prevention, Prohibition and Redressal) Act, 2013:</u>

The Company has zero tolerance towards sexual harassment at the workplace and has adopted a policy on prevention, prohibition, and redressal of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules thereunder.

The Company had constituted a committee called as Internal Complain Committee for prevention and prohibition of Sexual Harassment of woman at workplace and complied with provisions relating to the constitution of Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 [14 of 2013.]

The following is the summary of Sexual Harassment complaints received and disposed of during the year 2025-2026.

Particulars	Number
Number of cases pending as on the beginning of the financial year	NIL

Number of complaints filed during the year	NIL
Number of cases pending as on the end of the financial year	NIL
Number of cases pending for a period exceeding 90 days	NIL

d) **<u>Disclosure under section 43(a)(ii) of the Companies Act, 2013:</u>**

The Company has not issued any shares with differential rights and hence no information as per provisions of Section 43(a)(ii) of the Act read with Rule 4(4) of the Companies (Share Capital and Debenture) Rules, 2014 is furnished.

e) **<u>Disclosure under section 54(1)(d) of the Companies Act, 2013:</u>**

The Company has not issued any sweat equity shares during the year under review and hence no information as per provisions of Section 54(1)(d) of the Act read with Rule 8(13) of the Companies (Share Capital and Debenture) Rules, 2014 is furnished.

f) **<u>Disclosure under section 62(1)(b) of the companies Act, 2013:</u>**

The Company has not issued any equity shares under the Employees Stock Option Scheme during the year under review and hence no information as per provisions of Section 62(1)(b) of the Act read with Rule 12(9) of the Companies (Share Capital and Debenture) Rules, 2014 is furnished.

g) **<u>Disclosure under section 67(3) of the companies Act, 2013:</u>**

During the year under review, there were no instances of non-exercising of voting rights in respect of shares purchased directly by employees under a scheme pursuant to Section 67(3) of the Act read with Rule 16(4) of Companies (Share Capital and Debentures) Rules, 2014 is furnished.

g) **<u>Details of utilization of funds raised through rights issue basis as specified under Regulation 32 of the Listing Regulations:</u>**

During the financial year 2025-26, the Company made a Rights Issue of 9,61,00,000 equity shares of face value of INR 1/- each at an issue price of INR 4.16/- per equity share (including a premium of INR 3.16/- per share), aggregating to INR 39,97,76,000/-, to the eligible equity shareholders of the Company on a rights basis in the ratio of 2 (Two) equity shares for every 1 (One) equity share held as on the Record Date, i.e. August 29, 2025. Pursuant to the allotment of the aforesaid equity shares on October 06, 2025, the Issued, Subscribed and Paid-up Share Capital of the Company increased to INR 14,41,50,000/-, comprising 14,41,50,000 equity shares of INR 1/- each.

There was a Deviation and Variation in the use of issue proceeds, and the requisite disclosure in this regard has been made under Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with detailed annexures.

h) Disclosure of proceedings pending, or application made under insolvency and bankruptcy code, 2016 (if applicable)

No application was filed for corporate insolvency resolution process, by a financial or operational creditor or by the company itself under the IBC before the NCLT.

i) Disclosure of reason for difference between valuation done at the time of taking loan from bank and at the time of one-time settlement:

There was no instance of a one-time settlement with any Bank or Financial Institution.

j) Human Resources:

Your Company treats its "Human Resources" as one of its most important assets. Your Company continuously invests in the attraction, retention, and development of talent on an ongoing basis. A number of programs that provide focused people's attention are currently underway. Your Company's thrust is on the promotion of talent internally through job rotation and job enlargement.

As on March 31, 2026, there were a total of 06 permanent employees The Company has all the required policies under the Indian laws for the time being in force and as required under the Companies Act, 2013 and SEBI LODR Regulations, 2015 to protect and safeguard the interest of the employees.

k) Particulars of Remuneration to Employees, etc.

The particulars of remuneration to directors and employees and other related information required to be disclosed under Section ESOP (12) and sub rule 1 of rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014the Companies Act, 2013 and the Rules made thereunder are given in **"Annexure III"** to this Report.

Further the Company has no employee who is in receipt of remuneration of Rs. 8,50,000 /- per month or INR 1,02,00,000/- per annum and hence the Company is not required to give information under sub rule 2 of rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. The details for the top ten employees of the Company are also mentioned in **Annexure III** to this report.

l) Management Discussion and Analysis:

Management Discussion and Analysis Report as required under Regulation 34 and Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is furnished as **"Annexure IV"**

m) Secretarial Standards of ICSI:

The Central Government has given approval on April 10, 2015, to the Secretarial Standards specified by the Institute of Company Secretary of India, the Secretarial Standards on Meetings of the Board of Directors (SS-1) and General Meetings (SS-2) came into effect from 1 July 2015.

The Company is in compliance with the same.

n) Corporate Governance:

Your Company is committed to maintaining the highest standards of corporate governance. We believe sound corporate governance is critical to enhance and retain investor trust. Our disclosures seek to attain the best practices in corporate governance. The Board considers itself as a trustee of its shareholders and acknowledges its responsibilities towards them for the creation and safeguarding of their wealth. In order to conduct business with these principles the company has created a corporate structure based on business needs and maintains a high degree of transparency through regular disclosures with a focus on adequate control systems.

As per provisions of Regulation 15 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Corporate Governance Report for the financial year 2025–2026 has become applicable to the Company, as its paid-up share capital has exceeded ₹10 crores . Accordingly, the requisite disclosure under Regulation 27 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been duly uploaded.

o) Code of Conduct:

The Board has laid down a specific code of Conduct for all Board Members and Senior Management of the Company. All the Board Members and Senior Management Personnel have affirmed compliance with the Code on an annual basis.

p) Insider Trading:

The Board has in consultation with the Stakeholder's Relationship Committee laid down the policy to regulate and monitor Insider Trading in the Company. The Committee regularly analyses the transactions and monitors them to prevent Insider Trading.

The Company has also adopted a Prohibition of Insider Trading Policy.

q) Means of Communication:

The Board believes that effective communication of information is an essential component of Corporate Governance. The Company regularly interacts with its shareholders through multiple channels of communication such as the Company's Website and stipulated communications to the Stock Exchange where the Company's shares are listed for the announcement of Financial Results, Annual Report, Notices, Outcome of Meetings, and Company's Policies etc.

r) Corporate Social Responsibility:

Pursuant to the provisions of Section 135 of the Companies Act, 2013 Corporate Social Responsibility is not applicable to the Company during the Financial Year 2024-2025 as the Company is not having net worth of Rs. 500 Crore or more, turnover of Rs. 1000 Crore or more or net profit of Rs. 5 Crore or more during the immediately preceding Financial Year 2025-2026.

s) Website:

The Company has a website addressed as www.deephealthaiindia.com

Website contains the basic information about the Company - details of its Business, Financial Information, Shareholding Pattern, Contact Information of the Designated Official of the Company who is responsible for assisting and handling investors grievances and such other details as may be required under sub regulation (2) of Regulation 46 of the Listing Regulations, 2015. The Company ensures that the contents of this website are periodically updated.

t) Indian accounting standards – IFRS converge standards:

The Ministry of Corporate Affairs vides its notification dated 16th February 2015 notified under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standards) Rules, 2015. In pursuance of the said notification, your Company has prepared the financial statements to comply in all material respects accordance with the applicability of Indian Accounting Standards.

u) Listing on stock exchange:

The Equity shares of the Company are listed on the main board of BSE Limited.

v) Depository System:

Your Company's equity shares are in Demat and Physical form. The Company has appointed National Depository Services India Limited (NDSL) as designated depositories to the Company.

w) **Annual listing fees to the stock exchanges:**

Deep Diamond India Limited has listed its equity shares on the Main Board of BSE Limited. The listing fees have been duly paid to the exchange and annual custodial fees have been paid to CDSL and NSDL for F.Y. 2025-2026 and F.Y. 2026-2027.

x) **Registrar and Share Transfer Agent ('RTA') of the Company:**

During the year under review, the RTA of the Company is M/s MUFG Intime India Private Limited.

y) **Statement on Compliance with Maternity Benefit Act, 1961:**

During the year under review the Company has complied with the applicable provisions of Maternity Benefit Act, 1961.

8. Acknowledgements and Appreciation:

Your directors take this opportunity to thank the customers, shareholders, suppliers, bankers, business partners/associates, financial institutions and Central and State Governments for their consistent support and encouragement to the Company.

For and on behalf of the Board
For and on behalf of Deep Health AI India Limited
(Formerly known as Deep Diamond India Limited)

SD/-	**SD/-**
Narayan Singh Rathore	**Laveena Pokharna**
Managing Director	**Whole Time Director & CFO**
DIN: 10900646	**DIN:** 10977709
Date: September 03,2026	**Date: September 03,2026**
Place: Udaipur	**Place:** Udaipur
Address: 506-509 fifth floor, Apeksha, plot no. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001)	**Address:** 506-509 fifth floor, Apeksha, plot no. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001)

ANNEXURE-I

Form AOC-I
(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries/ associate companies/ joint ventures

Part "A": Associates and Joint Ventures

(Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures)

Sr. No.	Particulars	
1	Name of Associates/Joint Ventures	**Ferry Automotive Private Limited (Associate)**
2	Latest audited Balance Sheet Date	March 31, 2026
3	Shares of Associate/Joint Ventures held by the company on the year end (in numbers)	5000
4	- Number -	5000
5	- Amount of Investment in Associates/ Joint Venture -	11625000
6	- Extent of Holding % -	33.33%
7	Description of how there is a significant influence	Through Shareholding
8	Reason why the associate/joint venture is not consolidated	NA

9	Net worth attributable to Shareholding as per the latest audited Balance Sheet	
10	Profit / Loss for the year	
11	Considered in Consolidation	
12	Not Considered in Consolidation	NIL

1. Names of associates / joint ventures which are yet to commence operations: NIL

2. Names of associates / joint ventures which have been liquidated or sold during the year: NA

For V R S K & CO. LLP, Chartered Accountants
Firm No.: 111426W
SD/-
Suresh Kothari
Partner
Membership No.: 047625
Place: Mumbai
Date: September 03, 2026

For Deep Diamond India Limited

SD/-
Narayan Singh Rathore
Managing Director
DIN: 10900646
Place: Udaipur
Date: September 03, 2026

SD/-
Laveena Pokharna
Whole Time Director & CFO
DIN: 10977709
Place: Udaipur
Date: September 03, 2026

SD/-
Rakesh Vishnoi
Company Secretary
PAN: AHZPV2608K
Place: Rajasthan
Date: September 03, 2026

ANNEXURE - II

Form No. MR-3
Secretarial Audit Report
(For the Financial Year ended on 31st March, 2026)
[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
DEEP HEALTH AI INDIA LIMITED
506-509, 5th Floor, Apeksha, Plot No. 256, Sec-11,
Udaipur, Girwa, Rajasthan,India, 313001

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **DEEP HEALTH AI INDIA LIMITED** (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, We hereby report that in our opinion, the Company has, during the audit period **1st April, 2025 to 31st March, 2026**, complied with the statutory provisions listed here under to this Report and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on **31st March, 2026** according to the provisions of;

1. The Companies Act, 2013 (the Act) and the rules made there under;

2. The Securities Contracts (Regulation) Act, 1956(SCRA) and the rules made there under;

3. The Depositories Act, 1996 and the Regulations and Bye-law framed hereunder;

4. Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;

5. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India, 1992 ('SEBI Act');

   a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**;**

b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015**;**

c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;

d) The Securities and Exchange Board of India Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2021**; Not Applicable during the Audit period;**

e) The Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021; **Not Applicable during the Audit period;**

f) Securities and Exchange Board of India (Registrars to an Issue and share transfer Agents) Regulations, 2025 regarding the Companies, Act and dealing with client; **Not applicable** as the Company is not registered as Registrar to Issue and Share Transfer Agent during the year under review;

g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021; **Not Applicable during the Audit period;**

h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **Not Applicable during the Audit period;**

i) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015;

6. We have also examined compliance with the applicable clauses of the following:

i. Secretarial Standards with respect to Meetings of Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India.

ii. The Listing Agreements entered into by the Company with BSE Limited.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above subject to the following observations:

1. The Company delayed compliance under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pertaining to submission of Annual Report for FY 2024-25, for which a fine of Rs. 7,080/- (including GST) was levied by the Stock Exchange.

We further report that

- The Board of Directors of the Company is duly constituted with a proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

- Adequate notices are given to all directors to schedule the Board Meetings and agenda were sent in advance, and a system exists for seeking and obtaining further information and clarification on the agenda items before the meeting and for meaningful participation at the meeting.
- All the decisions of the Board and Committees thereof were carried through with requisite majority/unanimously.

We further report that during the audit period the company has:

1. Made an allotment of 9,61,00,000 (Nine Crore Sixty-One Lakh) Equity Shares on Right issue basis on 06th October, 2025

2. By way of a special resolution passed at its Annual General Meeting held on 27th September 2024**,** altered the provisions of its Memorandum of Association to change the location of its Registered Office from the State of Maharashtra to the State of Rajasthan, thereby shifting jurisdiction from the Registrar of Companies (ROC), Mumbai to ROC, Jaipur**.**

   This alteration was subsequently confirmed by the Regional Director vide order dated 09th February 2026**.** The new Registered Office of the Company is now located at:

   "506-509, 5th Floor, Apeksha, Plot No. 256, Sec-11, Girwa, Udaipur- 313001, Rajasthan, India"

3. Changed its name from "DEEP DIAMOND INDIA LIMITED" to "DEEP HEALTH AI INDIA LIMITED" with effect from 09th February 2026.

We further report that there are adequate systems and processes commensurate with its size and operations of the Company to monitor and ensure compliance with all applicable laws, rules, regulations and guidelines.

For Ronak Jhuthawat & Co.
Practicing Company Secretaries

Dr. CS Ronak Jhuthawat
Partner
Membership No. F9738
C.P. No. 12094
Peer Review: 6592/2025
Unique Code: P2025RJ104300
UDIN: F009738H000534130

Place: Udaipur
Date: May 29, 2026

*Note: This report is to be read with our letter of even date which is annexed as **"ANNEXURE-I"** and forms an integral part if this report.*

"ANNEXURE-I"

To,
The Members,
DEEP HEALTH AI INDIA LIMITED
506-509, 5th Floor, Apeksha, Plot No. 256, Sec-11,
Udaipur, Girwa, Rajasthan,India, 313001

Our report of even date is to be read along with this letter.

A. Maintenance of Secretarial records is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.

B. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on the test basis to ensure that correct facts are reflected in Secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.

C. We have not verified the correctness and appropriateness of financial records and books of accounts of the Company.

D. Wherever required, we have obtained the Management representation about compliance of laws, rules and regulations and happenings of events etc.

E. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of the management. Our examination was limited to the verification of procedures on test basis.

F. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of efficacy or effectiveness with which the management has conducted the affairs of the Company.

For Ronak Jhuthawat & Co.
Practicing Company Secretaries

SD/-
Dr. CS Ronak Jhuthawat
Partner
Membership No. F9738
C.P. No. 12094
Peer Review: 6592/2025
Unique Code: P2025RJ104300
UDIN: F009738H000534130

Place: Udaipur
Date: May 29, 2026

Annexure – III

Remuneration Details

[Pursuant to Section 197(12) of the Companies Act, 2013 read with Rule 5 of the Companies (Appointmentand Remuneration of Managerial Personnel) Rules, 2014]

1. The ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year ending March 31, 2026:

(Rs. in Lakhs)

Sr. No.	Particulars	Director's Remuneration in Rs.	Median remuneration of Employees in Rs.	Ratio
1.	**Mr. Narayan Singh Rathore**	**7.83**	**1.61**	**4.86**
2.	**Mr. Narendra Kumar Shrimali**	**1.17**	**1.61**	**0.73**
3.	**Mrs. Shashi Kala Dhabriya ****		**1.61**	
4.	**Ms. Laveena Pokharna**	**2.24**	**1.61**	**1.39**
5.	**Mr. Rajesh Nandkishore Pherwani ****		**1.61**	
6.	**Mr. Kaushal Jain***		**1.61**	
7.	**Mr. Kailash Chandra ****		**1.61**	

Apart from the above, none of the other Directors are paid remuneration in any form.

**Being Non-Executive Director, No remuneration is paid to Mr. Kaushal Jain and was paid Profession Fees of Rs. 0 during the FY 2025-26.*

**Being Independent Directors of the Company, no remuneration was paid to them.

2. Percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year ending March 31, 2026:

Sr. No.	Particulars	% Increase
1.	**Mr. Narayan Singh Rathore**	-
2.	**Mr. Narendra Kumar Shrimali**	-

3.	**Ms. Laveena Pokharna**	-
4.	**Mr. Rajesh Nandkishore Pherwani** **	-
5.	**Mr. Kailash Chandra** **	NA
6.	**Mr. Kaushal Jain***	NA
7.	**Mr. Rakesh Vishnoi**	-

3. Percentage increase in the median remuneration of employees in the financial year 2025-2026:

Sr. No.	Name of the employee	% Increase in median remuneration
1	**Narayan Singh Rathore**	(3.01%)
2	**Laveena Pokharna**	(3.01%)
3	**Hetal Rathore**	NA
4	**Payal Meena**	NA
5	**Geetanjali Sonigara**	NA
6	**Atul Kumar**	NA
7	**Yuvraj Singh**	NA
8	**Rakesh Vishnoi**	NA

4. The number of permanent employees on the rolls of the Company

8 permanent employees as on March 31, 2026.

5. Average percentile increases already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increasein the managerial remuneration and justification thereof and point out if there are anyexceptional circumstances for increase in the managerial remuneration.

Sr. No.	Particulars	% Increase
1.	Average percentile increases in the salary of employees other than managerial personnel	NIL
2.	Average percentile increases in the salary of the managerial personnel	NIL

6. It is hereby affirmed that the Remuneration paid to the Director is as per the

Remuneration Policy of the Company.

7. **Statement pursuant to Rule 5(2) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014**

List of top 10 employees in terms of remuneration drawn:

Sr. No.	Name of the Employee	Designation	Remuneration (in Rupees)	Nature of Employment	Date of commencement of employment	Age of employee	Last employment held by such employee	Qualification	If the employee is a relative of Director or Manager
1.	**Narayan Singh Rathore**	Managing Director	7,82,500	Managing Director	18/01/2025	46	NA	B. Com	NIL
2.	**Laveena Pokharna**	Whole Time Director & CEO	2,24,130	Whole-time Director & CFO	10/03/2025	30	NA	M. Com	NIL

For and on behalf of the Board
For and on behalf of Deep Health AI India Limited
(Formerly Known as Deep Diamond India Limited)

SD/-

Narayan Singh Rathore
Managing Director
DIN: 10900646
Date: September 03, 2026
Place: Udaipur
Address: 506-509 fifth floor, Apeksha, plot no. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001)

SD/-

Laveena Pokharna
Whole Time Director & CFO
DIN: 10977709
Date: September 03, 2026
Place: Udaipur
Address: 506-509 fifth floor, Apeksha, plot no. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001)

Annexure IV

MANAGEMENT DISCUSSIONS & ANALYSIS REPORT

Your Directors are pleased to present the Management Discussion and Analysis Report for the year ended March 31, 2026.

The Management Discussion and Analysis have been included in consonance with the Code of Corporate Governance as approved by The Securities and Exchange Board of India (SEBI). Investors are cautioned thatthese discussions contain certain forward-looking statements that involve risk and uncertainties including those risks which are inherent in the Company's growth and strategy. The company undertakes no obligation to publicly update or revise any of the opinions or forward-looking statements expressed in this report consequent to new information or developments, events or otherwise.

The management of the company is presenting herein the overview, opportunities and threats, initiatives by the Company and overall strategy of the company and its outlook for the future. This outlook is based on management's own assessment, and it may vary due to future economic and other future developments in the country

Forward looking statement:

The Statements made in this report describe the Company's objectives and projections that may be forward looking statements which are based on certain assumptions and expectations of future events. The Company's actual results may differ materially from those projected in any such forward-looking statement depending on economic conditions, government policies and decisions which are beyond the control of the Company.

Segment-wise or product-wise performance:

The Company falls within two business segments viz. 'Diamond Jewellery' and 'Pharmaceuticals'. The sales are substantial in the domestic market and the said financial statements are reflective of the information required by Accounting Standard 17 "Segment Reporting", notified under the Companies (Accounting Standards) Rules, 2006.

The Company continues to be engaged in activities pertaining to sale of gold and diamond studded Jewellery.

Further the Company has also engaged itself in the new business segment pertaining to marketing of pharmaceutical goods in India during the year under review.

Internal Control Systems:

The Company has in place an adequate and effective internal audit and control systems which ensure efficiency in operations, and optimum use of resources. Internal Control weaknesses are reported regularly, and timely steps are taken as and when required. The effectiveness of the internal control systems is constantly monitored by the Audit Committee set up by the Board and the required changes are introduced as and when necessary.

Risk Management:

Your Company's risk management system comprises of prudential norms, timely reporting, and stringent controls.

Opportunities and Threats

Some of the key trends of the industry that are favorable to the company to exploit these emerging opportunities are:

- Clients are more comfortable with the uniform high quality and quick service and process across the enterprise.

- There are good prospects for expanding further activities in this direction.

Some of the key changes in the industry unfavorable to the company are:

- Heightened competition
- Increasing Compliances
- Attraction and retention of human capital.
- Regulatory changes.

Segment-wise/Product-wise Performance:

Your Company has two reporting segments. The revenue from operations from Diamond-Jewellery and Pharmaceutical segment for the year is Rs. NIL /- and Rs. 4,25,00,000/- respectively and the combined net profit after tax from both the segments is Rs. 1,29,91,124/- respectively.

Human resources:

Your company has been able to employ and retain qualified professionals by offering a challenging workenvironment and compensation. The Company provides in-house training to its employees.

- The Management believes in maintaining cordial relations with its employees. The management recognizes the importance of Human Resources and effective steps will be taken to strengthen the same depending on the requirements.
- The Company provided an excellent working environment so that the individual staff can reach his/her full potential.
- The Company is poised to take on the challenges and march towards accomplishing its mission with success.
- The Company maintained good Industrial/Business relations in the market which enhanced the Creditworthiness of the Company.

Insurance:

The Company has insured its assets and operations against all insurable risks including fire, earthquake, flood etc. as part of its overall risk management strategies

Key Financial Ratios:

In accordance with the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) (Amendment) Regulations, 2018, the Company is required to give details of significant changes (change of 25% or more as compared to the immediately previous financial year) in Key sector-specific financial ratios.

The Company has identified the following ratios as key financial ratios:

Particulars	**F.Y. 2025-26**	**F.Y. 2024-25**
Current Ratio[1]	19.34	3.04
Debt Equity Ratio	0.01	0.03
Return on Equity Ratio[2]	3.08	4.10
Trade Receivables Turnover Ratio[3]	2.48	1.28
Trade Payables Turnover Ratio[4]	0.00	0.23
Net Capital Turnover Ratio	32.54	38.51
Net Profit Ratio[5]	26.68	69.61
Return on Capital Employed[6]	3.34	4.18

[1]Increase in current ratio due Increase in current assets compared to current liabilities during the year.

[2]The Return on Equity Ratio has Increase in shareholders' equity was higher than the increase in net profit during the year.

[3]Trade Receivable Turnover Ratio is Increased due to Increase in credit sales and better recovery from debtors during the year.

[4]The Trade Payable Turnover Ratio is decreased as there is No significant credit purchases/payables during the current year.

[5] There is change in the Net Profit Ratio due to the Increase in operating and other expenses reduced the profit margin during the year

[6]The Return on Capital Employed Ratio is because there is The increase in capital employed during the year was not proportionately matched by growth in earnings before interest and taxes, resulting in a decline in the ratio.

Financial Performance

The Financial performance of the Company for the year ended March 31, 2026, is as follows:

Total revenue from operations at Rs. 4,25,00,000 for the year ended March 31, 2026 as against Rs.

1,25,90,863 for the corresponding previous period, Increase of 237.55 %. The reason of increase in the turnover being the company has also expanded its existing business segment pertaining to marketing of pharmaceutical goods in India during the year under review.

The EBIDTA (Earnings before Interest, Depreciation and tax) was Rs. (8,47,05,682/-) for the year ended March 31, 2026, as against Rs. 2,17,13,270/-for the corresponding previous period, a increase /decrease of (490.11%) mainly due to the lapse of advance bookings and failure in equity encashment.

EBIDTA margin for the year ended March 31, 2026 is (490.11%) as compared to 61.08% for the corresponding previous year ended March 31, 2025.

Net Profit was Rs. 1,29,91,124 in FY 2026 as against Net Profit of Rs. 86,07,323 in FY 2025.

Cautionary Statement:

The statement in the Management Discussion and Analysis describing the Company's objectives, exceptions or predictions may be forwards looking within the meaning of applicable securities, laws, and regulations. Actual results may differ materially from those expressed in the statement. Several factors could make a significant difference to the company's operation. These include climatic conditions and economic conditions affecting demand and supply, government regulations and taxation, natural calamities etc. over which the company does not have any control.

For and on behalf of the Board
For and on behalf of Deep Health AI India Limited
(Formerly known as Deep Diamond India Limited)

SD/-
Narayan Singh Rathore
Managing Director
DIN: 10900646
Date: September 03, 2026
Place: Udaipur
Address: 506-509 fifth floor, Apeksha, plot no. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001)

SD/-
Laveena Pokharna
Whole Time Director & CFO
DIN: 10977709
Date: September 03, 2026
Place: Udaipur
Address: 506-509 fifth floor, Apeksha, plot no. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001)

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34 (3) and Schedule V Para C clause (10) (i) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members
DEEP HEALTH AI INDIA LIMITED
506-509, 5th Floor, Apeksha, Plot No. 256, Sec-11, Udaipur,
Girwa, Rajasthan, India, 313001

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors (as enlisted in Table A) of **DEEP HEALTH AI INDIA LIMITED** having **CIN: L24100RJ1994PLC112895** and having registered office at **506-509, 5th Floor, Apeksha, Plot No. 256, Sec-11, Udaipur, Girwa, Rajasthan, India, 313001** (hereinafter referred to as '**the Company**') produced before us for the purpose of issuing this Certificate, in accordance with Regulation 34 (3) read with Schedule V Para C clause 10 (i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers, We hereby certify that none of the Directors on the Board of the Company as stated below for the financial year ended 31st March, 2026, have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, the Ministry of Corporate Affairs or any such other Statutory Authority.

Table A

Sr. No.	Name of the Directors	Category	Director Identification Number	Date of appointment in Company*
1.	Shashi Kala Dhabriya****	Additional Independent Director	11611776	20/03/2026
2.	Narayan Singh Rathore	Managing Director	10900646	11/04/2025
3.	Rajesh Nandkishore Pherwani	Independent Director	07576485	11/04/2025
4.	Laveena Pokharna	Whole-Time Director	10977709	11/04/2025
5.	Kaushal Jain	Non-Executive - Non Independent Director	00848381	20/09/2023
6.	Narendra Kumar Shrimali**	Non-Executive - Non Independent Director	09034181	02/06/2022
7.	Kailash Chandra***	Independent Director	10985611	07/03/2025

** the date of appointment is as per the MCA Portal.*

Notes:
***1. Mr. Narendra Kumar Shrimali resigned as a director of the Company w.e.f., 24/11/2025*
****2. Mr. Kailash Chandra resigned as a director of the Company w.e.f., 03/04/2026*
*****3.Appointment of Mrs. Shashi Kala Dhabriya as Non-Executive Independent Director of the Company w.e.f 30/07/2026 as approved by the members in the Extra-Ordinary General Meeting of the company held on 30/07/2026*

Ensuring the eligibility of the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these, based on my verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For Ronak Jhuthawat & Co.
Practicing Company Secretaries

SD/-
Dr. CS Ronak Jhuthawat
Partner
Membership No. F9738
C.P. No. 12094
Peer Review: 6592/2025
Unique Code : P2025RJ104300

Place: Udaipur
Date: 03.09.2026

CERTIFICATE ON CORPORATE GOVERNANCE
[Pursuant to Regulation 34(3) read with Schedule V Para E of SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015]

To,
The Members
DEEP HEALTH AI INDIA LIMITED
506-509, 5th Floor, Apeksha, Plot No. 256, Sec-11, Udaipur,
Girwa, Rajasthan, India, 313001

We have examined the compliance of conditions of Corporate Governance by DEEP HEALTH AI INDIA LIMITED ("the Company") for the financial year ended on 31st March, 2026, as stipulated under Regulations 17 to 27, clauses (b) to (i) and (t) of sub-regulation (2) of Regulation 46 and paragraphs C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") for the Financial Year ended on 31st March 2026.

The compliance of conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring compliance with the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the Financial Statements of the Company.

In our opinion and to the best of my information and according to the explanations given to me, and the representations made by the Management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in regulations 17 to 27 and clauses (b) to (i) and (t) of regulation 46(2) and paragraphs C, D and E of Schedule V of the Listing Regulations, as applicable.

We further state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

This certificate is issued solely for the purpose of complying with the aforesaid Regulations. This certificate should not be used for any other purpose.

For Ronak Jhuthawat & Co.
Practicing Company Secretaries

SD/-
Dr. CS Ronak Jhuthawat
Partner
Membership No. F9738
C.P. No. 12094
Peer Review: 6592/2025
Unique Code : P2025RJ104300
UDIN: F009738H001350891

Place: Udaipur
Date: 03.09.2026

REPORT ON CORPORATE GOVERNANCE
FINANCIAL YEAR 2025-2026

1. COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE:

Our Company's philosophy on good corporate governance envisages the attainment of the highest level of principles such as Accountability, Professionalism, transparency in dealings with our stakeholders, Emphasis on communication, and Transparent reporting that creates long term sustainable shareholder value.

The Company's philosophy on corporate governance is rooted in ethical business practices and a commitment to sustainable value creation through principled business decisions. Sound corporate governance strengthens stakeholder confidence, enhances shareholder value and enables the Company to fulfil its obligations to all stakeholders with integrity, transparency, fairness, accountability, and a commitment to timely and accurate disclosures. This governance approach extends to the Company's corporate structure and the manner in which it engages with various stakeholders. At Deep Health AI India Limited, corporate affairs are conducted in a fair, transparent and accountable manner, thereby fostering trust, confidence and credibility amongst all stakeholders. Accordingly, timely and accurate disclosure of information relating to the Company's financial position, performance, ownership, and governance forms an integral part of its corporate governance framework.

Deep Health AI India Limited is committed to adopting 'best practices' in corporate governance in line with applicable statutory and regulatory requirements and industry practices, with a view to ensuring financial discipline, ethical conduct, and compliance with all applicable legal and regulatory requirements. The Board lies at the core of the Company's governance framework and considers itself as the Trustee of the shareholders, acknowledging its responsibility to create and safeguard shareholders' value.

We have complied with the requirements of the applicable regulations, including SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, in respect of corporate governance including the constitution of the Board and Committees thereof. The corporate governance framework is based on an effective independent Board, the Board's supervisory role from the executive management team, and the constitution of the Board Committees, as required under law.

2. BOARD OF DIRECTORS:

Our Company has an experienced, diverse and well-informed Board. The Board of Directors is the apex body, constituted by the shareholders, for overseeing the Company's overall functioning.
The Board provides strategic direction, leadership and guidance to the Company Management as also monitors the performance of the Company with the objective of creating long-term value for the various stakeholders and the Company.

The Company's policy is to maintain an optimum combination of Executive and Non-Executive Directors, all of whom are eminent persons with considerable professional expertise and experience in business and industry, finance, management, and law.

During the Financial year 2025-26 under review the composition of the Board was in conformity with Regulation 17 of the SEBI Listing Regulations read with Sections 149 and 152 of the Companies Act, 2013 and rules framed thereunder. The strength of the Board of Directors as on

March 31, 2026, is Six (06); Two (02) being whole time Directors, out of which one is Managing Director and Four (04) being Non-Executive Directors, out of which Three (03) are Independent Directors.

Further as on date, the strength of the Board is Eight (08); Two (02) being whole time Directors, out of which one is Managing Director and Six (06) being Non-Executive Directors, out of which Five (05) are Independent Directors. The Company continues to ensure that the Board composition and its committees remain aligned with the applicable statutory and regulatory requirements.

None of the Directors are related to any other Directors on the Board. None of the Directors on the Board is a member of more than 10 (ten) Committees and Chairman of more than 5 (five) Committees, across Companies in which he/ she is a director. The necessary disclosures regarding committee positions have been made by all the Directors.

All Independent Directors have confirmed, in accordance with Regulation 25(8) of the SEBI Listing Regulations, that they meet the independence criteria as specified under Regulation 16(1)(b) of the SEBI Listing Regulations and Section 149 of the Companies Act, 2013 and the rules framed thereunder.

During the year under review the Board of Directors met Eleven (11) times at their meeting held on April 16, 2025, May 28, 2025, August 13, 2025, August 28, 2025, October 07, 2025, October 17, 2025, October 31, 2025, November 13, 2025, December 16, 2025, February 11, 2026, and February 24, 2026. The necessary quorum was present for all the meetings.

ROLE OF INDEPENDENT DIRECTORS:

Independent directors play a key role in the decision-making process of the Board as they approve the overall strategy of the Company and oversee the performance of the management. The Independent Directors are committed to acting in the best interest of the Company and its stakeholders. The Independent Directors are professionals, with expertise and experience in general corporate management, legal, public policy, finance, banking, and other allied fields. This wide knowledge of their fields of expertise, as well as the boardroom practices, helps foster varied, unbiased, independent, and experienced perspectives. The Company benefits immensely from its inputs in achieving its strategic direction.

A separate meeting of Independent Directors:

In accordance with the provisions of Section 149(8) read with Schedule IV of the Act and Regulation 25(3) and (4) of the Listing Regulations and Secretarial Standards, a separate meeting of the Independent Directors of the Company was held on February 05, 2026. All Independent Directors were present at the meeting with no presence of Non-Independent Directors and Members of the Management for transacting the following agenda:

i. Review the performance of Non-Independent Directors and the Board as a whole.
ii. Review the performance of the Chairperson of the Company, taking into account the views of Executive Directors and Non-Executive Directors.
iii. Assess the quality, quantity, and timeliness of the flow of information between the Company Management and the Board that is necessary for the Board to perform their duties effectively and reasonably.

The Independent Directors have further stated that they are unaware of any circumstance or situation, which exists or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgement and without any external influence.

Based on the declarations and disclosures received from all the Independent Directors and taken on record by the Board, the Board is of the opinion that all the Independent Directors of the Company meet the criteria of independence as prescribed under the provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as applicable. The Board further confirms that the Independent Directors are independent of the management of the Company and have fulfilled the conditions of independence as stipulated under the applicable laws and regulations.

During the financial year under review, Mrs. Shashi Kala Dhabriya (DIN: 11611776) was appointed as an Additional Non-Executive Independent Director of the Company. Subsequent to the closure of the financial year, Mr. Bhupesh Swami (DIN: 07999261) was appointed as a Additional Non-Executive Independent Director in the board of the Company and Appointment of Mrs. Shashi Kala Dhabriya and Mr. Bhupesh Swami as Independent Directors was approved by the members at the Extra-Ordinary General Meeting held on July 30, 2026.

Further, subsequent to the financial year-end, Mr. Virendra Choubisa (DIN: 11923125) was appointed as an Additional Non-Executive Independent Director of the Company by the Board at its meeting held on September 03, 2026.

During the financial year 2025-26, the time gap between any two Board Meetings did not exceed 120 (One Hundred and Twenty) days. None of the Directors on the Board hold the office of Director in more than 20 companies, including 10 public companies, as prescribed under Companies Act read with rules framed thereunder.

In accordance with the provisions of Section 150 of the Act read with the applicable Rules framed thereunder, the Independent Directors of the Company have registered themselves in the Independent Directors data bank maintained by the Indian Institute of Corporate Affairs ("IICA"). The Independent Directors, unless exempted, are required to pass an online proficiency self-assessment test conducted by IICA within one year from the date of their registration on the IICA databank.

None of the Independent Directors serve as Independent Directors in more than seven listed entities and none of the Whole-Time Directors/ Managing Director of the Company serve as Independent Directors in any listed entities. In accordance with Regulation 26 of the SEBI Listing Regulations, none of the Directors are members in more than 10 committees or act as chairperson of more than 5 committees (the committees being Audit Committee and Stakeholders' Relationship Committee) across all public limited companies in which he/ she is a director.

i. The summary of the composition of the Board of Directors during March 31, 2026, is given below:

Name of Directors	Category	Attendance Particulars		
		Board Meetings		Attendance at the last AGM held on September 23, 2025
		Held	Attended	
Narayan Singh Rathore	Promoter & Managing Director	11	10	Yes
Rajesh Nandkishore Pherwani	Non-Executive Independent Director	11	10	Yes
Shashi Kala Dhabriya	Non-Executive - Independent Director	11	0	NA *(Appointed w.e.f. March 20, 2026)*
Laveena Pokharna	Whole Time Director	11	9	Yes
Kaushal Jain	Non-Executive Non-Independent Director	11	10	Yes
Kailash Chandra	Non-Executive Independent Director	11	10	Yes
Narendra Kumar Shrimali	Non- Executive Director	11	7	Yes

ii. Details of the Board of Directors in terms of their directorships/memberships in committees of public companies are as under:

Sr. No.	Names of Directors	Category of Directorships	No. of Directorships*	No. of membership in Committees**		Name of the listed entities in which the person is director
				Member	Chairman	
1.	Narayan Singh Rathore	Promoter & Managing Director	1	1	0	• Deep Health AI India Limited
2.	Rajesh Nandkishore Pherwani	Non-Executive Independent Director	2	1	2	• Deep Health AI India Limited • Kshitij Polyline Limited

3.	Shashi Kala Dhabriya	Non-Executive Independent Director	1	1	0	• Deep Health AI India Limited
4.	Laveena Pokharna	Whole Time Director	1	0	0	• Deep Health AI India Limited
5.	Kaushal Jain	Non-Executive Non-Independent Director	1	1	0	• Deep Health AI India Limited
6.	Kailash Chandra	Non-Executive Independent Director	1	2	0	• Deep Health AI India Limited

*** Excluding Directorship on the Board of Private Limited Companies, Foreign Companies, Alternate Directorship, and Companies under Section 8 of the Companies Act, 2013.**

** **Includes only Audit Committees and Stakeholders Relationship Committees in all public limited companies including** Deep Health AI India Limited.

*** **Includes Directorships in deemed public companies (Subsidiary of Deep Health AI India Limited).**

Dates for the Board meetings are decided well in advance and communicated to the Directors. In case of exigencies or urgency of matters, resolutions are passed by circulation, for such matters as permitted by law. The Board takes note of the resolutions passed by circulation at its subsequent meeting.

iii. Disclosure of relationship between directors:

There is no inter-se relationship between the Board of Directors of the Company.

iv. Shares and convertible instruments held by non-executive director:

The Non-Executive Directors of the Company do not hold any equity shares or convertible instruments of the Company. Accordingly, the shareholding and convertible instruments held by the Non-Executive Directors as at the reporting date are **Nil**.

v. Familiarization programme:

The Independent Directors of the Company are apprised by the Company through formal and informal ways, from time to time and as and when a new Independent Director is appointed on the Board. Periodic presentations are being made to them at the Board and its various Committees meetings on the amendments in Company Law, Listing Regulations and SEBI Regulations, Corporate Governance Related Party Transactions, Internal Control over Financial Reporting, and Internal Audit Plans, Updates on Terms of Reference of Committees, Role of Audit Committee CSR, sustainability & Human Resource, etc. Besides that, the Independent Directors interact with the Company's senior management to get insight on business developments, competition in the market, regulatory changes etc.

Pursuant to Regulation 46 of the Listing Regulations, the details of the familiarization programme for the Directors held during F.Y. 2025-2026 are available on the Company's website at https://deephealthaiindia.com/familiarization-programme/

vi. Board effectiveness evaluation:

Pursuant to the provisions of the Act and the Listing Regulations, performance evaluation of the Board, its committees, and individual Directors, including the role of the Chairman of the Board was conducted during the year. For details pertaining to the same, kindly refer to the Board's Report.

a. Key Skills, Expertise, and Competencies of the Board:

The Board comprises of qualified Members who bring in the required skills, competence, and expertise that allow them to make effective contributions to the Board and its committees. These Directors are nominated based on well-defined selection criteria.

The Nomination and Remuneration Committee considers, inter alia, key skills, qualifications, expertise, and competencies, whilst recommending to the Board, the candidature for appointment of Director.

The Board of Directors have, based on the recommendations of the NRC, identified the following core key skills/expertise/ competencies of Directors as required in the context of the business of the Company and the sector in which the Company functions for its effective functioning which is currently possessed by the Board Members of the Company and mapped against each of the Directors:

Sr. No.	Particulars	Rajesh Nandkishore Pherwani	Shashi Kala Dhabriya	Kaushal Jain	Kailash Chandra
1.	Industry Knowledge / Expertise	✓	✓	✓	
2.	Operational Knowledge / Expertise	✓	✓		✓
3.	Leadership Attributes		✓	✓	✓
4.	Strategic Planning	✓	✓	✓	
5.	Risk Management	✓		✓	✓
6.	Financial		✓		✓
7.	Stakeholder Engagement	✓	✓	✓	
8.	Legal / regulatory Expertise				✓
9.	Human Resource	✓		✓	✓

Note: The absence of a mark against a Board Member's name does not necessarily mean the Director does not possess the corresponding skill, expertise, or competence.

vii. Confirmation that Independent Directors fulfil the conditions as specified in these regulations:

IDs are NEDs as defined under Regulation 16(1)(b) of the Listing Regulations read with Section 149(6) of the Act along with rules framed thereunder. In terms of Regulation 25(8) of the Listing Regulations, IDs have confirmed that they are not aware of any circumstance or situation which exists or may be reasonably anticipated that could impair or impact their ability to discharge their duties. Based on the declarations received from the IDs, the Board of Directors has confirmed that they meet the criteria of independence as mentioned under Regulation 16(1)(b) of the Listing Regulations and that they are independent of the management.

Further, in terms of Section 150 of the Act read with Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014, the IDs of the Company have included their names in the Independent Director's Database maintained with the Indian Institute of Corporate Affairs.

viii. Detailed reasons for resignation of Independent Directors:

During the Financial Year 2025-2026 there was no resignation of an Independent Director who have resigned before the expiry of his/her tenure.

3. BOARD COMMITTEES:

To enable better and more focused attention to the affairs of the Company, the Board delegates particular matters to committees of the Board set up for the purpose. These committees prepare the groundwork for decision-making and report the same to the Board at the subsequent meetings.

The following committees have been formed in compliance with the corporate governance norms:

A. Audit Committee
B. Nomination and Remuneration Committee
C. Stakeholder Relationships Committee

A. Audit Committee:

Audit Committee of the Company is constituted as per the provisions of Section 177 of the Companies Act, 2013 and Regulation 18 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

The terms of reference of the Audit Committee comply with the requirements of the Companies Act, 2013, and Securities Exchange and Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015.

The committee presently comprises of the following three (3) directors. The present composition of the Audit Committee and the attendance of each member at the Audit Committee meetings held during the financial year under review is as follows:

Composition of Audit Committee:

Name of the Director	Designation	Nature of Directorship	No. of Committees Meetings	
			Held	Attended
Mr. Rajesh Nandkishore Pherwani	Chairman	Non-Executive Independent Director	6	6
Mr. Narayan Singh Rathore	Member	Executive Director	6	6
Mr. Kailash Chandra*	Member	Non-Executive - Independent Director	6	6
Mr. Bhupesh Swami**	Member	Non-Executive - Independent Director	-	-

All the members of the Committee are financially literate and Mr. Rajesh Nandkishore Pherwani Chairman of the Audit Committee has adequate knowledge, experience, and expertise in accounts and finance. The Company Secretary is the Secretary to the Audit Committee.

**Mr. Kailash Chandra resigned from the Board of Directors w.e.f. 03/04/2026.*
***Mr. Bhupesh Swami was appointed as member of Audit Committee w.e.f. 02/07/2026*

Meetings of the Audit Committee:

The Audit Committee met Six times during the financial year ended on March 31, 2026, at their meeting held April 16, 2025, May 28, 2025, August 13, 2025, August 28, 2025, October 07, 2025 & February 11, 2026.

Role of the Audit Committee:

i. Overseeing the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statements are correct, sufficient, and credible.
ii. Recommending to the Board, the appointment, re-appointment and, if required, the replacement or removal of the statutory auditor and the fixation of audit fees.
iii. Approval of payment to statutory auditors for any other services rendered by the statutory auditors.
iv. Reviewing, with the management, the annual financial statements before submission to the board for approval, with reference to:
   a. Matters required being included in the Directors Responsibility Statement to be included in the Board's report in terms of clause (c) of sub-section 3 of Section 134 of the Companies Act, 2013.
   b. Changes, if any, in accounting policies and practices and reasons for the same.
   c. Major accounting entries involving estimates based on the exercise of judgment by management.
   d. Significant adjustments made in the financial statements arising out of audit findings.
   e. Compliance with listing and other legal requirements relating to financial statements.
   f. Disclosure of any related party transactions.
   g. Modified opinion(s) in the draft audit report.

v. Reviewing, with the management, the half-yearly and annual financial statements before submission to the board for approval.

vi. Reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document/ prospectus/notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the Board to take up steps in this matter.

vii. Reviewing and monitoring the auditor's independence and performance and effectiveness of the audit process.

viii. Approval of any transactions of the Company with Related Parties, including any subsequent modification thereof.

ix. Scrutiny of inter-corporate loans and investments.

x. Valuation of undertakings or assets of the Company, wherever it is necessary.

xi. Evaluation of internal financial controls and risk management systems.

xii. Reviewing, with the management, the performance of statutory and internal auditors, and the adequacy of the internal control systems.

xiii. Reviewing the adequacy of the internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure coverage, and frequency of internal audit.

xiv. Discussion with internal auditors on any significant findings and follow up thereon.

xv. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board.

xvi. Discussion with statutory auditors before the audit commences, about the nature and scope of the audit as well as post-audit discussion to ascertain any area of concern.

xvii. To look into the reasons for substantial defaults in the payment to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends), and creditors.

xviii. To review the functioning of the Whistle Blower mechanism, in case the same exists.

xix. Approval of appointment of CFO or any other person heading the finance function or discharging that function after assessing the qualifications, experience & background, etc. of the candidate.

xx. To overview the Vigil Mechanism of the Company and took appropriate actions in case of repeated frivolous complaints against any Director or Employee.

xxi. To implement Ind AS (Indian Accounting Standards).

Powers of the Audit Committee:

i. Investigating any activity within its terms of reference.
ii. Seeking information from any employee.
iii. Obtaining outside legal or other professional advice, and Securing attendance of outsiders with relevant expertise, if considers necessary.

The Audit Committee shall mandatorily review the following information:

i. Management Discussion and Analysis of financial condition and results of operations.
ii. Statement of significant related party transactions (as defined by the Audit Committee), submitted by management.
iii. Management letters/letters of internal control weaknesses issued by the statutory auditors.
iv. Internal audit reports relating to internal control weaknesses.
v. The appointment, removal, and terms of remuneration of the chief internal auditor shall be subject to review by the audit committee.
vi. Statement of deviations:
   a) Half-yearly statement of deviation(s) including the report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1).
   b) Annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7).

B. Nomination & Remuneration Committee:

Nomination and Remuneration Committee of the Board of Directors of the Company is constituted as per the provisions of Section 178 of the Companies Act, 2013 and Regulation 19 of Securities Exchange and Board of India (Listing Obligation and Disclosure Requirements) Regulations.

The committee presently comprises the following three (03) directors. The present composition of the Nomination and Remuneration Committee and the attendance of each member at the Nomination and Remuneration Committee meetings held during the year is as follows:

Name of the Director	Designation	Nature of Directorship	No. of Committees Meetings	
			Held	Attended
Mr. Kaushal Jain#	Member	Non-Executive Non- Independent Director	3	3
Mr. Narendra Kumar Shrimali****	Member	Non-Executive Independent Director	3	2
Mr. Rajesh Nandkishore Pherwani*	Chairman	Non-Executive Independent Director	3	3
Mrs. Kailash Chandra***	Member	Non-Executive Independent Director	3	3
Mr. Bhupesh Swami**	Member	Non-Executive Independent Director	-	-

**Mr. Rajesh Nandkishore Pherwani was appointed as a Regular Chairperson of the Committee w.e.f. 24/02/2026.*
***** Mr. Narendra Kumar Shrimali resigned from the Company w.e.f. 24/11/2026.*
****Mr. Kailash Chandra resigned from the Board of Directors w.e.f. 03/04/2026.*
***Mr. Bhupesh Swami was appointed as member of Audit Committee w.e.f. 02/07/2026*
#Mr. Kaushal Jain was the chairperson of the Company for two meetings i.e. 16/04/2025 and 13/08/2025.

Meetings of Nomination & Remuneration Committee:

The Nomination & Remuneration Committee met Three (3) times during the financial year ended on March 31, 2026, at their meeting held on April 16, 2025, August 13, 2025 & March 12, 2026. Mr. Rajesh Kumar Pherwani acted as the Chairman of the Committee for the meeting held on March 12, 2026.

Role of the Nomination & Remuneration Committee:

i. Formulation of the criteria for determining qualifications, positive attributes, and independence of a director and recommend to the Board of Directors a policy relating to, the remuneration of the directors, Key Managerial Personnel, and other employees.
ii. Formulation of criteria for evaluation of the performance of Independent Directors and the Board of Directors.
iii. Devising a policy on diversity of the Board of Directors.
iv. Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down and recommend to the Board of Directors their appointment and removal.
v. Whether to extend or continue the term of appointment of the Independent Director, on the basis of the report of performance evaluation of Independent Directors.
vi. Such other matters as may from time to time be required by any statutory, contractual, or other regulatory requirements to be attended to by such committee.

Performance evaluation criteria for Independent Directors:

As members of the Board, their performance as well as the performance of the entire Board and its Committees will be evaluated annually. Evaluation of each director shall be done by all the other directors. Your appointment and re-appointment on the Board shall be subject to the outcome of the yearly evaluation process. However, the actual evaluation process shall remain confidential and shall be a constructive mechanism to improve the effectiveness of the Board / Committee.

C. Stakeholder Relationship Committee:

The stakeholder relationships committee of the Board of Directors of the Company is constituted as per the provisions of Section 178(5) of the Companies Act, 2013 and Regulation 20 of Securities Exchange and Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015.

The committee presently comprises the following three (03) directors. The present composition of the Stakeholder Relationships Committee and the attendance of each member at the Stakeholder Relationships Committee meetings held during the year is as follows:

Name of the Director	Designation	Nature of Directorship	No. of Committees Meetings	
			Held	Attended
Mr. Kaushal Jain	Chairman	Non-Executive Non-Independent Director	1	1
Mr. Kailash Chandra***	Member	Non-Executive Independent Director	1	1
Mr. Narendra Kumar Shrimali****	Member	Non-Executive Independent Director	1	1
Mr. Bhupesh Swami**	Member	Non-Executive Independent Director	-	-
Mrs. Shashi Kala Dhabriya*	Member	Non-Executive Independent Director	-	-

***** Mr. Narendra Kumar Shrimali resigned from the Company w.e.f. 24/11/2026.*
****Mr. Kailash Chandra resigned from the Board of Directors w.e.f. 03/04/2026.*
***Mr. Bhupesh Swami was appointed as member of Audit Committee w.e.f. 02/07/2026*
**Mrs. Shashi Kala Dhabriya was appointed in the Board of the Company w.e.f. 20/03/2026.*

<u>Meetings of the Stakeholder Relationship Committee:</u>

The Stakeholders' Relationship Committee met 1 time during the financial year ended on March 31, 2026, at their meeting held on May 14, 2025.

<u>Role of the Stakeholder Relationship Committee</u>**:**

The Stakeholder Relationships Committee shall oversee all matters pertaining to investors of our Company. The terms of reference of the Investor Grievance Committee include the following:

i. Redressal of shareholders'/investors' complaints.
ii. Reviewing on a periodic basis the approval of the transfer or transmission of shares, debentures, or any other securities made by the Registrar and Share Transfer Agent.
iii. Issue of duplicate certificates and new certificates on split/consolidation/renewal.
iv. Non-receipt of declared dividends, balance sheets of the Company; and
v. Carrying out any other function as prescribed under the Securities Exchange and Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015.

<u>Investor grievance redressal:</u>

The investor complaints are processed in a centralized web-based complaints redress system. The salient features of this system are the centralized database of all complaints, online upload of Action Taken Reports (ATRs) by the concerned companies, and online viewing by investors of actions taken on the complaint and its current status. Your Company has been registered on SCORES and makes every effort to resolve all investor complaints received through SCORES or otherwise within the statutory time limit from the receipt of the complaint. The total number of complaints received and replied to the satisfaction of shareholders during the year under review is as under:

Quarter	Pending from earlier Quarter	Received during the year	Resolved during the year	Pending at the quarter end
April - June	0	0	0	0
July - September	0	0	0	0
October - December	0	1	1	0
January - March	0	0	0	0

The Secretarial Department of the Company and the Registrar and Share Transfer Agent (R & T Agent), MUFG Intime India Private Limited attends to all the grievances of the shareholders and investors received directly or through SEBI, Stock Exchanges, Ministry of Corporate Affairs, Registrar of Companies, etc.

The Company maintains continuous interaction with the said R & T Agent and takes proactive steps and actions for resolving complaints/queries of the shareholders/ investors and also takes initiatives for solving critical issues. Shareholders are requested to furnish their telephone numbers and email addresses to facilitate prompt action.

Name, designation, and address of the compliance officer:

Rakesh Vishnoi
Company Secretary & Compliance Officer
Address: 152, Guruji ki hotel ke peeche,
Jawahar nagar, Bhilwara, Rajasthan, India 311001
Tel: +91 9828613128
Email: deephealthaiindia@gmail.com

D. Risk Management Committee:

Formation of the Risk Management Committee was not applicable to the Company during the financial year ended March 31, 2026.

4. PARTICULARS OF SENIOR MANAGEMENT INCLUDING THE CHANGES, IF ANY:

Particulars of change in SMPs during the financial year 2025-2026:

There has been no change in SMP during the financial year 2025-2026.

List of SMPs as on March 31, 2026:

Sr No.	Name	Designation
1	Narayan Singh Rathore	Managing Director
2	Laveena Pokharna	Whole-time Director and Chief Financial Officer
3	Rakesh Vishnoi	Company Secretary
4	Hetal Rathore	Manager – Administration

5. REMUNERATION TO DIRECTORS AND KEY MANAGERIAL PERSONNEL:

i. Managing Director & Whole-Time Director:

The remuneration/compensation/commission etc. to the Managing Director, Whole time Director will be determined by the Committee and recommended to the Board for approval. The remuneration/compensation/ commission etc. to the Directors shall be subject to the prior/post approval of the shareholders of the Company and Central Government, wherever required.

The remuneration and commission to be paid to the Managing Director/Whole-time Director/Executive Director shall be in accordance with the Articles of Association of the Company and as per the provisions of the Companies Act, 2013, and Schedule V and other applicable rules made thereunder.

Revision to the existing remuneration/compensation structure may be recommended by the Committee to the Board subject to the approval of the Shareholder, when necessary, in the case of Managing Director/Whole-time Director/Executive Director and would be based on the individual's performance as well as the Company's overall performance.

If any Managing Director/Whole-time Director/Executive Director draws or receives, directly or indirectly by way of remuneration any such sums in excess of the limits prescribed under the Companies Act, 2013, he/ she shall refund such sums to the Company and until such sum is refunded, hold it in trust for the Company.

Where any insurance is taken by the Company on behalf of its Managing Director/Whole-time Director/ Executive Director, Chief Executive Officer, Chief Financial Officer, the Company Secretary, and any other employees for indemnifying them against any liability, the premium paid on such insurance shall not be treated as part of the remuneration payable to any such personnel. Provided that if such a person is proved to be guilty of negligence, default, misfeasance, breach of duty, or breach of trust, the premium paid on such insurance shall be treated as part of the remuneration.

Details of remuneration and perquisites paid to the Managing Director & Whole-Time Director (In lakhs):

Name	Salary & Allowances	Commission / performance incentives	Perquisites & Retirement Benefits	Contribution to provident Fund/pension funds	Total
Mr. Narayan Singh Rathore	7.83	-	-	-	7.83
Mrs. Laveena Pokharna	2.24	-	-	-	2.24

ii. Non-Executive Directors & Independent Directors:

The Non-Executive / Independent Director may receive sitting fees for attending meetings of the Board or Committee thereof. The Independent/Non-Executive Director shall be entitled to reimbursement of expenses for participation in the Board and other meeting.

None of the NEDs had any pecuniary relationship or transactions with the Company other than the Directors' sitting fees and Commission, as applicable, received by them. The Company reimburses the out-of-pocket expenses, if any, incurred by the Directors for attending meetings.

Criteria for making payments to NEDs is disseminated on the website of the Company at https://deephealthaiindia.com/policies/

An Independent Director shall not be entitled to any stock option of the Company.

Details of remuneration paid to Non-Executive Directors for the Financial Year 2025-2026.

(In Rupees)

Name of the Director	Remuneration	Sitting fees
Mr. Kaushal Jain	-	NIL
Mr. Rajesh Nandkishore Pherwani	-	25,000
Mrs. Shashi Kala Dhabriya	-	NIL
Mr. Kailash Chandra	-	25,000

For the financial year ended March 31, 2026, the remuneration payable to any single non-executive director of the Company did not exceed 50% of the total annual remuneration payable to all the Non-Executive Directors.

iii. **Key Managerial Personnel (KMP):**

The Key managerial personnel of the Company shall be paid remuneration as per the policies implemented by the Company from time to time.

Details of remuneration and perquisites paid to the Key Managerial Personnel:

Name of KMP	Designation	Salary & Allowances	Perquisites & Retirement Benefits	Contribution to provident fund / pension funds	Total
Rakesh Vishnoi	Company Secretary & Compliance officer	1,92,000	-	-	1,92,000
Laveena Pokharna	Whole-time Director & CFO	2,24,130	-	-	2,24,130
Narayan Singh Rathore	Managing Director	7,83,000	-	-	7,83,000

iv. **Disclosures with respect to Remuneration:**

a) **Service contract, notice period, severance fees:** Not Applicable

b) **Stock Option details:** Not Applicable

The Company has not issued any stock option to any of the directors of the Company.

6. GENERAL BODY MEETINGS:

i. Annual General Meetings:

Location, date, and time of the Annual General Meetings held during the preceding 3 (three) years and the Special Resolutions passed thereat are as follows:

Year	Date and Time	Location	Special Resolution passed
2024-2025	September 23, 2025, at 12:00 P.M.	309, 3rd Floor, V Star Plaza, Plot No. 16, Chandavarkar Road, Borivali West-400092, Maharashtra, India	1.To consider and approve the re-appointment of Mr. Narayan Singh Rathore (DIN: 10900646) as the Managing Director of the Company.
2023-2024	September 24, 2024, at 11:00 A.M.	309, 3rd Floor, V Star Plaza, Plot No. 16 Chandavarkar Road, Borivali West-400092, Maharashtra, India	1.To Shift the registered office from the State of Maharashtra (Mumbai) to the State of Rajasthan (Udaipur)
2022-2023	September 26, 2023, at 11:30 A.M.	408, CORPORATE AVENUE, WING-A, SONAWALA ROAD, GOREGAON EAST, NR. UDHYOG BHAVAN, MUMBAI 400063, MAHARASHTRA, INDIA	1.To approve increase in the borrowing limit of the Company and creation of charge 2.To increase the limits for giving Loans, giving Guarantees, providing Security in connection with any loan and / or acquire by way of subscription, purchase or otherwise the securities 3.To appoint Mr. Vinod Mandowara

			(DIN: 08436361) as a Director in the capacity of Non-Executive Independent Director of the Company

ii. **Special resolutions passed last year through postal ballot:**

(a) To consider and approve the proposal of change in name of the company and consequential alteration to MOA and AOA of the company.

Details of the scrutinizer who conducted the postal ballot: M/s. Ronak Jhuthawat & Co, (Certificate of Practice No. 12094), Practicing Company Secretary

iii. **Details of the special resolution proposed to be conducted through postal ballot:**

The Company does not have any special resolution proposed to be passed through postal Ballot as on the date of this report.

iv. **Procedure for postal ballot:** Not Applicable

7. **MEANS OF COMMUNICATION:**

The Company has promptly reported all material information as required under the Policy for determination of material events and archival of disclosures and Regulation 30 of the Listing Regulations to the Stock Exchanges. Such information and other material information which are relevant to the shareholders are also simultaneously hosted under a separate section of 'Investors' on the Company's website https://deephealthaiindia.com/

The Annual Report, Quarterly Results, Shareholding Pattern, Press Releases, Intimation/Outcome of the Board meetings, Schedule of analyst or institutional investor meet & presentations made to them, and other relevant information of the Company are submitted to the Stock Exchange through the **BSE Listing Centre** for investors' information, in compliance with the applicable Listing Regulations.

Calendar of the financial year ended March 31, 2026:

The Company follows April-March as the financial year. The meetings of the Board of Directors for approval of quarterly and annual financial results for the financial year ended March 31, 2026, were held on the following dates:

Particulars	Date
Quarter ended June 30, 2025	August, 13, 2025
Quarter/Half year ended September 30, 2025	October 10, 2025
Quarter/nine-months ended December 31, 2025	February 11, 2026
Quarter ended March 31, 2026	May 28, 2026

i. **Quarterly, Half-yearly and Annual Results:**

Quarterly, half-yearly and annual financial results of the Company are published in widely circulated national newspapers, as per the details given below:

Particulars	Name of the Newspaper	Language
Quarter ended June 30, 2025	1. Active Times 2. Mumbai Lakshadeep	English Marathi
Quarter/Half year ended September 30, 2025	1. Active Times 2. Mumbai Lakshadeep	English Marathi
Quarter/nine-months ended December 31, 2025	1. Active Times 2. Mumbai Lakshadeep	English Marathi
Quarter and year ended March 31, 2026	1. Active Times 2. Mumbai Lakshadeep	English Marathi

Post results, an Investor Conference call is held where members of the financial community are invited to participate in the Q&A session with the Company's management. The key highlights are discussed, and investor/analyst queries are resolved in this forum. The quarterly, half-yearly, annual financial results, audio call recordings of the analyst calls, and transcript are submitted with the Stock Exchange and are also uploaded on the Company's website at https://deephealthaiindia.com/about-us/#

ii. **News Releases, Presentations, etc.:**

Official news releases, detailed presentations made to media, analysts, institutional investors, etc. are displayed on the Company's website at https://deephealthaiindia.com/about-us/#

Official media releases, sent to the Stock Exchanges, are given directly to the press.

8. GENERAL SHAREHOLDER INFORMATION:

i. 32nd Annual General Meeting

Day & Date	Wednesday & September 30, 2026
Venue	The AGM will be held through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”). The deemed venue for the AGM Meeting will be the Registered Office of the Company situated at “506-509 Fifth Floor, Apeksha, Plot No. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001)
Time	Will be during the business hours.

ii. Financial Year and Calendar

The company’s accounting year comprises of 12 months from April 01 to March 31.

iii. Dividend Payment Date:

The Board has not recommended a final dividend for the Financial Year ended 2025-2026

iv. Listing on Stock Exchange

The Company's equity shares are listed and actively traded on the Main Board of BSE Limited (BSE). It is hereby confirmed that the listing fees payable to BSE for the financial year 2025-26 have been duly paid.

Bombay Stock Exchange Limited

Address: Floor 25, Phiroze Jeejeebhoy Tower, Dalal Street, Fort, Mumbai – 400001.
Website: https://www.bseindia.com/

v. Suspension from trading:

None of the Company's securities have been suspended from trading during the financial year 2025-2026 and as on date of this report.

vi. Registrar and Share Transfer Agent:

The Company has appointed M/s MUFG Intime India Private Limited (SEBI Registration number INR000004058) as its Registrar. As required under Regulation 7(3) of the SEBI Listing Regulations, the Company has filed a Certificate issued by the Registrar and the Compliance Officer of the Company certifying that all activities in relation to both physical and electronic share transfer facility are maintained by its RTA.

vii. Share Transfer Systems:

The Company's equity shares which are in dematerialized (Demat) form are transferable through the depository system. As per Regulation 40 of the Listing Regulations, as amended, securities of listed companies can be transferred only in dematerialized form w.e.f. April 01, 2019, except in case of request received for transmission or transposition of securities. However, Members are not barred from holding shares in physical form.

viii. Distribution of Shareholding:

Distribution of shareholding by size as on March 31, 2026:

Sr. No.	Shareholding of Nominal Value	No. of shareholders	% of shareholders	No. of shares hold	% of shareholding
1	1-500	68045	70.9083	8012485	5.56
2	501-1000	10269	10.7011	8532492	5.92
3	1001-2000	7178	7.4800	10934619	7.59
4	2001-3000	2884	3.0054	7409716	5.14
5	3001-4000	1419	1.4787	5079501	3.52
6	4001-5000	1421	1.4808	6732780	4.67
7	5001-10000	2579	2.6875	19124846	13.27
8	10001 & above	2167	2.2582	78323561	54.33
TOTAL		**95962**	**100.0000**	**144150000**	**100.00**

Distribution of Shareholding:

Statement showing shareholding pattern as on March 31, 2026:

Category of shareholders	No. of shares	% of share capital
Promoter & promoter group (A)	40330	0.03
Public category (B):		
Mutual Funds	0	0
Central Government/State Government	1000	0
Financial Institutions / Banks	0	0
Foreign Institutional Investors (including FPI)	500000	0.35
NBFC registered with RBI	0	0
Directors and their relatives (excluding independent directors and nominee directors)	0	
Individual shareholders holding nominal share capital up to Rs. 2 lakhs	124193205	86.16
Individual shareholder holding nominal share capital up in excess of Rs. 2 lakhs	12036201	8.35
Clearing Members	703901	0.49
Non-Resident Indians	964147	0.67
Foreign Companies	0	0
Body Corporate	3374484	2.34
HUF	2231353	1.55
Trusts	3834	0
Escrow Account	1276	0
Body Corp-Ltd Liability Partnership	100269	0.07
IEPF	0	0
Any Other (Foreign Portfolio Investor (Category - III)		
TOTAL (A+B)	**144150000**	**100.00**

ix. Dematerialization of Shares:

As on March 31, 2026, entire shareholding of the Company is in dematerialized form with CDSL and NSDL. The Company's equity shares are regularly traded on the main board of Bombay stock exchange Limited (BSE).

Particulars of shares as on March 31, 2026	Equity shares of Rs. 10 each	
	Number	% of Total
CDSL	112,281,266	77.89
NSDL	30,549,734	21.19
Total	**1319000**	**0.92**

x. Outstanding GDRS / ADRS / WARRANTS or any Convertible Instruments:

As on date of this report, Company has not issued GDRs / ADRs/ Warrants or any convertible instruments.

xi. Commodity price risk or Foreign Exchange risk and hedging activities:

The Company does not have any un-hedged exposure to commodity price risk and foreign exchange risk.

xii. Plant locations:

The Company is not in the business of manufacturing.

It operates from various offices in India and abroad for the purpose of business expansion with its registered and corporate office in Mumbai.

xiii. Address for Correspondence:

All shareholders' correspondence relating to share transfer/dematerialization of shares, payment of dividends, and any other queries about shares should be forwarded to M/s. MUFG Intime India Private Limited, the Registrar and Transfer Agent of the Company, or to the Corporate Secretarial Department at the Registered Office of the Company at the addresses mentioned below:

MUFG Intime India Private Limited C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai – 400083 **Tel:** +91 22 4918 6000 **Email:**investor.helpdesk@in.mpms.mufg.com **Website:** www.in.mpms.mufg.com	**Mr. Rakesh Vishnoi** **Company Secretary & Compliance Officer** 152, Guruji ki hotel ke peeche, Jawahar nagar, Bhilwara, Rajasthan, India 311001 **Tel**:+919828613128 **Email:** deephealthaiindia@gmail.com

xiv. List of credit ratings:

Credit rating disclosure is not applicable to the Company, as no credit rating was obtained during the year.

xv. Payment of Listing Fees/Annual Custody/Issuer Fee

The Company has paid the Annual Listing Fees to the Stock Exchange for the F.Y. 2024-2025, F.Y. 2025-2026 and F.Y. 2026-2027. The Company has also paid the Annual Custody/ Issuer fee for the F.Y. 2024-2025, F.Y. 2025-2026 and F.Y. 2026-2027 to Central Depository Services (India) Limited ("CDSL") and National Securities Depository Limited ("NSDL").

xvi. <u>Service of documents through email:</u>

Pursuant to the provisions of the Act service of documents to shareholders by a Company is allowed through electronic mode. Further, as per SEBI Listing Regulations, Listed Companies shall supply soft copies of entire annual reports to all those shareholders who have registered their e-mail addresses for the purpose. Accordingly, the Company proposes to send documents like shareholders meeting notices/other notices, Audited Financial Statements, Board's' Report, Auditor's Report, or any other document, to its shareholders in electronic form at the email address provided by them and/or made available to the Company by their depositories. This will definitely help in prompt receipt of the communication, reduce paper consumption, and save trees as well as avoid loss of documents in transit. Shareholders who have not yet registered their email id (including those who wish to change their already registered email id) may get the same registered/ updated either with their depositories or Company provided the facility to register their email id: investor.helpdesk@in.mpms.mufg.com Investor Registration.

xvii. <u>Loan to Senior management (other than the Managing director and Whole-time director) and other employees of the company:</u>

The loan may be given to the above concerned for the purposes such as Marriage, Education, Housing Loan, or such other purposes, in accordance with the policies implemented by the Company from time to time.

xviii. <u>Code of conduct:</u>

In terms of Regulation 46 (2) of Securities Exchange and Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Company has laid down and adopted a Code of Conduct for its Board of Directors and Senior Management Personnel, which is also disseminated on the Company's website: https://deephealthaiindia.com/policies/

The Company has received confirmation from all Directors as well as Senior Management Personnel regarding compliance with the Code of Conduct during the year under review.

9. <u>OTHER DISCLOSURES:</u>

<u>Details of compliance with mandatory requirements:</u>

All the mandatory requirements of Regulations 17 to 27 and clauses (b) to (i) of sub-regulation (2) of Regulation 46 of the Securities Exchange and Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 have been complied with by the Company and the Company has not adopted the discretionary / non-mandatory requirements as specified in Part E of Schedule II of the listing regulations.

i. <u>Policy on Subsidiary Companies:</u>

The Company has adopted the policy of subsidiary companies with specific reference to materially listed and unlisted subsidiary companies and the policy to be followed in such eventualities. The Policy for determining the material subsidiaries is available at the Website of the Company at https://deephealthaiindia.com/policies/

ii. Governance of subsidiaries:

All subsidiaries of the Company are managed by their Boards having rights and obligations in accordance with applicable laws. The Company nominates its representatives on the Boards of subsidiaries to monitor its operations and performance. Oversight on subsidiaries is also maintained inter alia through the following:

- Review of financial statements of subsidiaries and statement containing significant transactions and arrangements entered into by the subsidiaries.
- Review of minutes of Board Meetings of the subsidiaries on a quarterly basis.
- Extending necessary guarantees, letter of comfort and other support for their day-to-day operations from time-to-time.

iii. Related Party Transactions:

The Company has formulated a policy on the materiality of Related Party Transactions and also on dealing with Related Party Transactions, in accordance with relevant provisions of the Act and SEBI Listing Regulations. The said policy is also available on the website of the Company at https://deephealthaiindia.com/policies/

During the financial year under review, no transactions of material nature had been entered into by the Company that may have a potential conflict of interest of the Company at large and there was no material modification as well. All Related Party Transactions are approved by the Audit Committee prior to the transaction. The Audit Committee has, after obtaining approval of the Board of Directors, laid down the criteria for granting omnibus approval for such transactions which are of repetitive nature and are approved by the Audit Committee on an omnibus basis for one financial year at a time. Transactions with related parties are disclosed separately to the Standalone Financial Statements.

iv. Whistle Blower Policy/Vigil Mechanism:

The Company has established a Vigil mechanism / Whistle-blower policy under which the employees are free to report unethical behaviour, fraud, and violations of applicable laws and regulations and the Code of Conduct and also provides for adequate safeguards against victimization of persons who use such mechanism.

This mechanism has been appropriately communicated within the Company across all levels and has been displayed on the Company's website at https://deephealthaiindia.com/policies/

The Audit Committee periodically reviews the existence and functioning of the mechanism. On a quarterly basis, the reportable matters may be disclosed to the Vigilance and Ethics Officer which operates under the supervision of the Audit Committee. During the year under review, no personnel was denied access to the Audit Committee.

v. Reconciliation of Share Capital Audit:

M/s. Ronak Jhuthawat & Co, Practicing Company Secretaries, carry out the Reconciliation of Share Capital Audit as mandated by SEBI, and report on the reconciliation of total issued and listed Capital with that of total share capital admitted / held in dematerialized form with NSDL and CDSL and those held in physical form. This audit is carried out on a quarterly basis and the report thereof is submitted to the National Stock Exchange, where the Company`s shares are listed and is also placed before the Board for its noting.

vi. Compliance with mandatory requirements:

The Company has complied with all the applicable mandatory requirements of the SEBI Listing Regulations during the financial year ended, and as on, March 31, 2026.

vii. Details of non-compliance by the Company:

The Company has complied with all the requirements of regulatory authorities.

Further, no penalties and strictures were imposed on the Company by the Stock Exchange or SEBI or any other statutory authority on any matter related to the capital market during the last three years, other than those stated above.

viii. Code of Conduct for Prevention of Insider Trading:

The Code of Conduct prohibits the Designated Persons of the Company from dealing in the securities of the Company on the basis of any unpublished price-sensitive information, available to them by virtue of their position in the Company.

The Code of Conduct has been formulated to regulate, monitor, and ensure reporting of trading by the Designated Persons towards achieving compliance with the Regulations to prevent misuse of any unpublished price-sensitive information and prohibit any insider trading activity, in order to protect the interest of the shareholders at large.

The Code of Conduct is available on the website of the Company at https://deephealthaiindia.com/policies/

ix. Details of Utilization of funds raised through Preferential Allotment or Qualified Institutions Placement as Specified under Regulation 32(7A):

During the year under review the Company has not raised any funds through preferential allotment or Qualified Institution Placements.

x. Certificate for Non-Disqualification of Directors:

A certificate from M/s. Ronak Jhuthawat & Co. Company Secretaries in Practice, have been obtained certifying that none of the Directors on the Board of the Company have been debarred or disqualified from being appointed or continuing as directors of the Company by Securities and Exchange Board of India/Ministry of Corporate Affairs or any such statutory authority as on March 31, 2026, which is enclosed with this corporate governance report.

xi. Review of Prevention of Sexual Harassment:

The Company has complied with provisions relating to the constitution of the Internal Complaints Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition, and Redressal) Act, 2013 [14 of 2013]. The details of complaints received and redressed during the financial year 2025-2026 are as under:

a. number of complaints filed during the financial year: NIL

b. number of complaints disposed of during the financial year: NIL
c. number of complaints pending as on the end of the financial year: NIL

xii. Recommendation by the Committee of the Board:

During the financial year 2025-2026, the Board has accepted all the recommendations of all its committees (including the audit committee).

xiii. Statutory Audit Fees:

Total fees paid by the Company and its subsidiaries to the statutory auditors of their respective Company and all other entities forming part of the same network, during the financial year 2025-2026 is mentioned below:

- Deep Health AI India Limited: 1.75 Lakhs (in lakhs)
- Subsidiary Companies: Not Applicable, as the Company does not have any subsidiary company.

xiv. CEO/CFO Certification:

The 'Managing Director (MD)' & Chief Financial Officer ('CFO') have certified to the Board with regard to the compliance made by them in terms of Regulation 17(8) read with Part B of Schedule II of Securities Exchange and Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, and the said certificate forms part of this Report.

xv. Certificate on Corporate Governance:

Certificate from the Auditors, M/s. Ronak Jhuthawat & Co., Company Secretaries in Practice, confirming compliance with conditions of Corporate Governance as stipulated under Regulation 34 read with Schedule V of the SEBI Listing Regulations, and the said certificate forms part of this Report.

xvi. Shareholders' Rights:

As the quarterly and half-yearly, financial results are published in the newspapers and are also posted on the Company's website, the same are not being sent separately to the shareholders.

xvii. Separate posts of Chairperson and CEO:

The Company presently is having a separate post of the Chairperson and the Managing Director.

xviii. Reporting of Internal Auditor:

The Internal Auditors of the Company make a presentation to the Audit Committee on their reports as per the approved audit programmes by the Audit Committee at the beginning of the year on a quarterly basis.

xix. Outstanding ADRs/GDRs/Warrants or any Convertible instruments, conversion date, and likely impact on equity:

The Company has not issued any ADRs/GDRs/Warrants or any Convertible instruments. None of the securities are suspended from trading.

xx. Declaration signed by the Managing Director stating that the members of the board of directors and senior management personnel have affirmed compliance with the code of conduct of the board of directors and senior management.

The Company has adopted the Code of Conduct for directors and senior management personnel. The Code has been circulated to all the members of the Board and senior management personnel and the same has been posted on the Company's website. The Board and senior management personnel have affirmed their compliance with the Code and a declaration signed by the Managing Director of the Company is given below:

"It is hereby declared that the Company has obtained from all the Board and senior management personnel affirmation that they have complied with the Code of Conduct for the Directors and senior management of the Company for the year 2025-2026".

xxi. Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

The Company has zero tolerance for sexual harassment and has always believed in providing a safe and harassment- free workplace for every individual working in the Company. The Company has complied with the applicable provisions of the aforesaid Act, and the rules framed thereunder, including constitution of the Internal Committee. The Company has in place an Anti-Sexual Harassment Policy in line with the requirements of the aforesaid Act. All employees (permanent, contractual, temporary and trainees, etc.) are covered under this Policy. The Company took many initiatives for spreading awareness like Prevention of Sexual Harassment (POSH) posters, POSH films, caricature series, different competition regarding POSH, POSH stories in English and local languages. Going beyond, the Company arranged awareness and sensitisation programmes for regular employees, contract employees, trainees on regular basis. POSH awareness is made part of induction process for new joiners. Status of complaints as on March 31, 2026:

Sr. No.	Particulars	No. of Complaints
1.	No. of Complaints filed during the financial year	0
2.	No. of Complaints disposed of during the financial year	0
3.	No. of Complaints pending at the end of financial year	0

xxii. Disclosure on loans or advances by the listed entity or its Subsidiaries:

There have been loans or advances extended by the Company or its subsidiaries, which bear resemblance to loans, to any firms or companies where the Directors of the Company hold an interest.

Sr. No.	Name of the entity	Amount
1	Bhargav Kidney Foundation	20,00,000.00
2	Garnet Constructions Ltd	1,29,000.00
3	ABNCO Corporate Services Pvt Ltd	2,27,31,700.00
4	D41 World Trading LLP	19,05,966.00
5	Ferry Automotives Pvt. Ltd. (Loan)	1,68,92,606.98
6	Om Trading	15,00,000.00
7	Orhan Shipping Pvt Ltd	7,72,400.00
8	SP and Nisha Pvt Ltd	88,24,129.00

xxiii. Disclosure on material subsidiaries:

During the year under review, the Company did not have any **material subsidiary** as defined under Regulation 16 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Accordingly, the disclosure relating to material subsidiaries is **not applicable** to the Company.

xxiv. Non-compliance of any requirement of Corporate Governance:

There is no non-compliance with respect to any of the requirements of Corporate Governance as mentioned in Schedule V of the Securities Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.

xxv. Details regarding certain types of agreements binding the listed entities:

The Company has not disclosed any kind of agreements under clause 5A of paragraph A of Part A of Schedule III of the listing regulations during the financial year 2025-2026 and as on the date of this report.

DEEP HEALTH AI INDIA LIMITED

(Formerly known as **"Deep Diamond India Limited")** CIN: L24100RJ1994PLC112895
Regd. Office: 506-509 fifth floor, Apeksha, Plot No. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001) Tel: 0294-3569097.
E-mail: deephealthaiindia@gmail.com Website: www.deephealthaiindia.com

CEO/MD & CFO Certificate
under Regulation 17(8) read with Part B of schedule II and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors of
Deep Health AI India Limited
(Formerly known as Deep Diamond India Limited)

We, hereby certify that:

We, undersigned, in our respective capacities as Managing Director and Chief Financial Officer of Deep Health AI India Limited ("the Company"), to the best of our knowledge and belief, we state that:

A. I have reviewed the Financial Statements and the cash flow for the year ended on March 31, 2026, and that to the best of our knowledge and belief:

   1. These statements do not contain any materially untrue, misleading statement or figures or omit any material fact or contain statements that might be misleading;

   2. These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws, and regulations.

B. There are, to the best of our knowledge and belief no transactions entered into by the listed entity during the year ended on March 31, 2026, which are fraudulent, illegal, or violative of the Company's Code of Conduct.

C. We accept responsibility for establishing and maintaining internal controls for financial reporting and we have evaluated the effectiveness of internal control systems of the Company pertaining to Financial Reporting and they have disclosed to the Auditors and the Audit Committee, deficiencies in the design or operation of internal controls if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.

D. We have indicated to the Auditors and the Audit Committee:

   (i) that there are no significant changes in internal control over financial reporting during the year ended March 31, 2026.

   (ii) that there are no significant changes in accounting policies during the year; and that the same have been disclosed in the Notes to Financial Statement and

(iii) that there are no instances of significant fraud of which we became aware and the involvement therein if any, of the Management or an employee having a significant role in the company's internal control system over financial reporting.

For and on behalf of
Deep Health AI India Limited
(Formerly known as Deep Diamond India Limited)

Sd/-
Narayan Singh Rathore
Managing Director
DIN: 10900646
Date: September 03, 2026
Address: 506-509 fifth floor, Apeksha, plot no. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001)

Sd/-
Laveena Pokharna
Chief Financial officer
DIN: 10977709
Date: September 03, 2026
Address: 506-509 fifth floor, Apeksha, plot no. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan (313001)

INDEPENDENT AUDITORS' REPORT

TO THE MEMBERS OF
DEEP HEALTH AI INDIA LIMITED
(Formerly Known as Deep Diamond India Limited)

Report on the Audit of Standalone Financial Statements

Opinion

We have audited the Standalone Financial Statements of **DEEP HEALTH AI INDIA LIMITED** (hereinafter referred to as "the Company"), which comprise the Balance Sheet as at March 31, 2026, and the Statement of Profit and Loss including Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and notes to the Financial Statements, including a summary of significant accounting policies and other explanatory information (collectively referred to as 'Standalone Financial Statements').

In our opinion and to the best of our information and according to the explanations given to us, the Financial Statements give the information required by the Companies Act, 2013 (hereinafter referred to as "the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India, of the state of affairs (financial position) of the Company as at March 31, 2026, and its Profit, other comprehensive loss, the changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Standalone Financial Statements of the current period. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Sr. No.	Key Audit Matter	Auditor's response
1.	**Accounting implications arising from acquisition under Insolvency Resolution Process** The Company has proposed to acquire Oasis Ceramics Pvt. Ltd. pursuant to the Resolution Plan approved by the Hon'ble National Company Law Tribunal ("NCLT") under the Insolvency and Bankruptcy Code, 2016. As per the approved Resolution Plan, the Company was required to pay total acquisition consideration of ₹32 crore. The Company has paid ₹55 lakh as Earnest Money Deposit (EMD) and ₹2 crore towards the consideration; however, the balance amount could not be remitted within the stipulated timeline. Accordingly, the Company filed an application before the Hon'ble NCLT seeking extension of time for payment of the balance consideration and related reliefs, which remains pending as at the reporting date. Meanwhile, the Resolution Professional invoked the bank guarantee amounting to ₹3.21 crore. Further, members of the Committee of Creditors initiated proceedings consequent to non-compliance with the payment timelines prescribed under the approved Resolution Plan. In the minutes of the meeting of the Committee of Creditors, a resolution was also passed to consider initiation of the liquidation process. Based on management's assessment of the prevailing circumstances, the Company recognised the amount paid and the bank guarantee invoked as an exceptional loss in the standalone financial results. This matter was considered significant to our audit due to the materiality of the amounts involved, ongoing legal and contractual uncertainties, and the significant management judgement involved in determining the related accounting treatment and disclosures. Refer 25.ii to the Standalone Financial Statements	**Principal Audit Procedures Performed included the following:** • We obtained an understanding of the approved Resolution Plan and evaluated management's process for accounting of acquisition-related transactions and contingencies. • We inspected relevant documents including the NCLT order, application filed before the Hon'ble NCLT, correspondence with the Resolution Professional and Committee of Creditors, and other related records. • We evaluated management's assessment regarding the likelihood and financial implications of liquidation proceedings of Oasis Ceramics Pvt. Ltd. and pending legal matters. • We verified payments made towards acquisition consideration, invocation of the bank guarantee and related accounting entries using supporting bank documents and records. • We assessed the appropriateness of the accounting treatment adopted for recognition of exceptional loss in accordance with the applicable accounting standards. • We reviewed the disclosures made in the standalone financial results to assess whether they adequately describe the nature of the transaction, uncertainties involved and consequential financial impact.
2.	**Utilization of Proceeds from Right Issue and Deviation from Objects Stated in the Letter of Offer.**	**Principal Audit Procedures Performed included the following:**

	During the year, the Company raised an amount of Rs.39.97 crore through a Rights Issue. As disclosed in the Letter of Offer, the proceeds were proposed to be utilised, inter alia, towards acquisition of Oasis Ceramics Private Limited pursuant to the provisions of the Insolvency and Bankruptcy Code, 2016, for general corporate purposes and to meet the issue expense. Out of the total proceeds raised, the Company has utilised Rs.2.5 crore towards the objects stated in the Letter of Offer. The balance amount of Rs.37.47 crore was utilised for purposes other than those specified in the Letter of Offer, namely investment in securities through recognised stock exchange. The aforesaid deviation in utilisation of issue proceeds was subsequently ratified by the shareholders at the Extra-Ordinary General Meeting held on 22nd January 2026. Considering the significance of the amount involved, regulatory compliances relating to utilisation of issue proceeds and adequacy of related disclosures in the financial statements, the matter was considered to be a Key Audit Matter. Refer 25.iii to the Standalone Financial Statements	• Obtained and examined the Letter of Offer and related Board and shareholder resolutions pertaining to the Rights Issue; • Verified the utilisation of Rights Issue proceeds with supporting bank statements, books of account and underlying documents; • Examined the nature and purpose of utilisation of funds and assessed whether the same was in accordance with the objects stated in the Letter of Offer; • Verified the approval and ratification obtained from shareholders in the Extra-Ordinary General Meeting held on 22nd January 2026 in respect of the deviation in utilisation of proceeds; and • Assessed the adequacy and appropriateness of disclosures made in the financial statements in respect of utilisation and deviation of Rights Issue proceeds.

Other Information

The Company's Board of Directors are responsible for the other information. The other information comprises the information included in the annual report but does not include the Financial Statements and our auditor's report thereon.
Our opinion on the Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report the fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Financial Statements that give a true and fair view of the financial position, financial performance including Other Comprehensive

Income, Cash Flows and Changes in Equity of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities, selection and application of appropriate accounting policies;making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Financial Statements including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143 (11) of the Act, we give in "Annexure A" - a statement on the matters specified in paragraphs 3 and 4 of the Order.

2. As required by section 143(3) of the Act, we report that:

   a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;

   b) In our opinion, proper books of account as required by law have been kept by the Company, so far as appears from our examination of those books;

c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity dealt with by this report are in agreement with the books of account;

d) In our opinion the aforesaid Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014;

e) On the basis of written representations received from the directors as on March 31, 2026, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2026, from being appointed as a director in terms of Section 164 (2) of the Act.

f) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Companies Act, 2013, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to the directors is within the limits prescribed under the Act and is not in excess of the limit prescribed under Section 197 read with Schedule V to the Act."

g) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in Annexure-B.

h) With respect to the other matters to be included in the Auditor's Report in accordance with the Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us, we report that:

   i) The Company does not have any pending litigations which would impact its financial position other than those mentioned in notes to accounts;

   ii) The Company did not have any long term contracts including derivative contracts for which there were any material foreseeable losses;

   iii) There were no amounts which were required to be transferred to the Investors Education and Protection Fund by the Company;

   iv) (a) As per the information and explanation given to us by the management, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person or entity, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

   (b) As per the information and explanation given to us by the management, no funds have been received by the company from any person or entity, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

(c) On the basis of above representations, nothing has come to our notice that has caused us to believe that the above representations contained any material misstatement.

v) The Company has declared and paid dividend during the year in compliance with the provisions of Section 123 of the companies Act, 2013 to the extent applicable.

vi) Based on our examination, which included test checks, and other generally accepted audit procedures performed by us, we report that the company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit, we did not come across any instance of audit trail feature being tampered with and the audit trail has been preserved by the Company as per the statutory requirements for record retention.

For **V R S K & CO. LLP**
(Formerly known as V R S K & CO.)
Chartered Accountants
Firm Regn No. 111426W/W100988

SURESH G. KOTHARI
Partner
Membership No. 047625
UDIN: 26047625VVAWOL4406

Place : Mumbai
Dated : May 29, 2026

ANNEXURE-A TO INDEPENDENT AUDITOR'S REPORT

The Annexure referred to in paragraph 1 under the 'Report on Other Legal and Regulatory Requirements' our report to the members of **DEEP HEALTH AI INDIA LIMITED**, ('the Company') for the year ended on March 31, 2026. We report that: -

i. In respect of Property Plant and Equipment and Intangible Assets: -

(a) (A)The Company is maintaining proper records showing full particulars including quantitative details and situation of Property, Plant & Equipment;

(B) The Company does not have any intangible assets, hence Clause 3(i)(a)(B) is not applicable.

(b) The Company has a regular program of physical verification of PPE which is, in our opinion, reasonable having regard to the size of the Company and the nature of its assets. In accordance with this program, certain PPE have been physically verified by the management during the year and no material discrepancies have been noticed on such verification;

(c) As per the information and explanation given to us by the management and the records examined by us, the title deeds of immovable properties as disclosed in Note 3 on Investment in immovable property to the financial statements are held in the name of the company.

(d) As per the information and explanation given to us by the management of the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year and hence provisions of Clause 3(i)(d) of the Order are not applicable to the Company;

(e) As per the information and explanation given to us by the management, no proceedings have been initiated or are pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder and hence provisions of Clause 3(i)(e) of the Order are not applicable to the Company.

ii. In respect of its inventories:

(a) Physical verification of inventory has been conducted at reasonable intervals by the management and the coverage and procedure of such verification by the management is appropriate; No material discrepancies were noticed in the books of account;

(b) As per the information and explanation given to us by the management, the Company has not availed any working capital facility from any banks or financial institutions on the basis of security of current assets and hence provisions of Clause 3(ii)(b) of the Order are not applicable to the Company.

iii. According to the information and explanations given to us, the Company has made investment and also provided advances to companies, firms, Limited Liability Partnership and other parties details are as follows:

(Rs. in '00)

Aggregate amount during the year	Guarantees	Security	Loans & Advances in nature of loans
Subsidiaries	0	0	0
Holding	0	0	0

Joint Ventures	0	0	0
Associates	0	0	0
Common Directors	0	0	0
Others	0	0	15,000

(Rs. in '00)

Balance outstanding as at Balance sheet Date	Guarantees	Security	Loans & Advances in nature of loans
Subsidiaries	0	0	0
Holding	0	0	0
Joint Ventures	0	0	0
Associates	0	0	1,68,926.07
Common Directors	0	0	0
Others	0	0	3,78,631.95

(b) In our opinion and according to the information and explanations given to us, the terms and conditions of the grants of loans and advances in the nature of loans are, prima facie, not prejudicial to the interest of the Company, except in respect of a loan amounting to Rs. 2.27 Crore.

(c) According to information and explanations given to us and based on our audit procedures repayment of none of the loans is stipulated, all loans are repayable on demand.

(d) In absence of stipulated repayment schedule of principal, we are unable to comment as to whether there is any amount which is overdue for more than 90 days and the company has taken reasonable steps for recovery of the principal amount.

(e) None of the loan or advance in the nature of loan granted which has fallen due during the year, has been renewed or extended or fresh loans granted to settle the overdue of existing loans given to the same parties.

(f) The Company has granted a loan which is repayable on demand or without specifying any terms or period of repayment to promoters, related parties as defined in clause (76) of section 2 of the Companies Act, 2013.

iv. In our opinion and according to the information and explanation given to us, the Company has not granted any loans or provided any guarantee or security to the parties covered under Section 185 of the Act. Further, the Company has complied with provisions of Section 186 in respect of grant of loans and making investments as applicable.

v. In our opinion and according to the information and explanations given to us, the Company has not accepted deposits from the public within the meaning of Sections 73, 74, 75 and 76 of the Act and the Rules framed thereunder to the extent notified.

vi. According to the information and explanations given to us, the Company does not require maintaining cost records as prescribed by the Central Government under sub-section (1) of Section 148 of the Act.

vii. (a) According to the records of the Company, the Company is generally regular in depositing with appropriate authorities undisputed statutory dues including provident fund, employees' state insurance, income-tax, GST, duty of customs or cess and other statutory dues applicable to it. No undisputed amounts payable in respect of provident fund, employees' state insurance, income-tax, GST, duty of customs or cess and other statutory dues were outstanding, as at 31.03.2026, for a period of more than six months from the date they became payable.

(b) According to the records of the Company and information and explanations given to us no dues of income tax, GST, duty of customs or cess that have not been deposited on account of any disputes.

viii. According to the information and explanations given to us, there are no transactions that are not recorded in the books of accounts and have been surrendered of disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

ix. (a) Based on our audit procedures and according to the information and Explanations given to us by the management, we are of the opinion that the Company has not defaulted in repayment of dues to financial institutions and bank;

(b) According to the information and explanations given to us, the company has not been declared willful defaulter by any bank or financial institution or government or any government authority;

(c) According to the information and explanations given to us, the Company has not availed any term loan facility and hence provisions of Clause 3(ix)(c) of the aforesaid Order are not applicable to the Company;

(d) According to the information and explanations given to us, and the procedures performed by us, and on an overall examination of the financial statements of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the company;

(e) The Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures;

(f) The Company has not raised any loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies,

x. (a) Based on our audit procedures and according to the information and explanations given to us by the management, the Company has not raised any money by way of initial public offer or further public offer (including debt instruments) and hence provisions of Clause 3(x)(a) of the Order are not applicable to the Company;

(b) In our opinion and according to the information and explanation given to us, the company has utilized fund raised by way of Right issue of shares (at premium) for the purpose for which they were raised except for the following : (Rs. In '00)

Nature of Securities	Purpose for which funds were raised	Total Amount raised	Amount utilized for the other purpose	Unutilized balance as at the Balance sheet date	Remarks
Equity Shares	Acquisition of Oasis Ceramics Private Limited pursuant to Insolvency and Bankruptcy Code, 2016	30,00,000	30,00,000	0	Entire amount diverted to investment in Equity.
Equity Shares	To meet General corporate purposes	9,62,760	7,61,260	0	Partially utilised; balance diverted to investment in Equity and share issue expense.
Equity Shares	To meet the expenses of the Issue	35,000	0	0	Excess Utilization Rs 13.86 Lacs

xi. During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practices in India, and according to the information and explanations given to us, we have neither come across any instance of material fraud by the Company or on the Company noticed or reported during the year, nor have we been informed of any such case by the management. Clause 3(xi)(a) to (c) of the Order is, therefore, not applicable to the Company for the year under audit.

xii. The Company is not a Nidhi Company and the Nidhi Rules, 2014 are not applicable to the Company and hence provisions of Clause 3(xii) (a) to (c) of the Order are not applicable to the Company.

xiii. The Company has not entered into the transaction with the related parties in compliance with the provisions of the Section 177 and 188 of the Act. The details of such related party transactions have been disclosed in the financial statements as required under Accounting Standard (AS)18, Related Party Disclosures specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

xiv. (a)In our opinion and based on our examination, the company has an internal audit system commensurate with the size and nature of its business;

(b) We have considered internal audit reports of the company issued till date, for the year under audit.

xv. The Company has not entered into any non-cash transactions with its directors or the persons connected with him and hence provisions of Clause 3(xv) of the Order are not applicable to the Company.

xvi. The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934, hence reporting in clause 3(xvi) (a) to (d) is not required.

xvii. According to the information and explanations given to us, the company has not incurred any cash losses during the year under audit as well as in the immediately preceding financial year.

xviii. There has been no resignation of the statutory auditors during the year, and hence provisions of Clause 3(xix) of the Order are not applicable to the Company.

xix. According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

xx. According to the information and explanations given to us, the Company need not spend any amount as required in the Section 135 of the said Act. Accordingly, provisions of Clause 3(xxi) (a) and (b) of the Order are not applicable to the Company.

xxi. According to the information and explanations given to us, there were no qualifications or adverse remarks by the respective auditors in the Companies (Auditor's Report) Order (CARO) reports of the companies included in the consolidated financial statements.

For **V R S K & CO. LLP**
(Formerly known as V R S K & CO.)
Chartered Accountants
Firm Regn No. 111426W/W100988

SURESH G. KOTHARI
Partner
Membership No. 047625
UDIN: 26047625VVAWOL4406

Place : Mumbai
Dated : May 29, 2026

ANNEXURE-B TO INDEPENDENT AUDITOR'S REPORT

The Annexure referred to in paragraph 2(f) under the 'Report on Other Legal and Regulatory Requirements' our report to the members of **DEEP HEALTH AI INDIA LIMITED**, ('the Company') for the year ended on March 31, 2026.

Report on the Internal Financial Controls under Clause (i) of Sub-Section 3 of Section 143 of the Act

We have audited internal financial controls over financial reporting of **DEEP HEALTH AI INDIA LIMITED** ("the Company") as of March 31, 2026 in conjunction with our audit of the Financial Statements of the Company for the year then ended on that date.

Management's Responsibility for the Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of business, including adherence to Company's policies, the safeguarding of the assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting ('the Guidance Note') and the Standards on Auditing deemed to be prescribed under Section 143(10) of the Act to the extent applicable to an audit of internal financial controls, both applicable to an audit of internal financial controls and both issued by the ICAI. Those Standards and Guidance note require that we comply with ethical requirements and plan and perform audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedure to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal controls based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A Company's internal financial control over financial reporting is a process designed to provide a reasonable assurance regarding the reliability of financial reporting and preparation of Financial Statements for external purpose in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting includes those policies and procedures that:

1. Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
2. Provide reasonable assurance that the transactions are recorded as necessary to permit preparation of Financial Statements in accordance with the generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and
3. Provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the Financial Statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial control over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material aspects, an adequate internal financial control system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **V R S K & CO. LLP**
(Formerly known as V R S K & CO.)
Chartered Accountants
Firm Regn No. 111426W/W100988

SURESH G. KOTHARI
Partner
Membership No. 047625
UDIN: 26047625VVAWOL4406

Place : Mumbai
Dated : May 29, 2026

DEEP HEALTH AI INDIA LIMITED

CIN: - L24100RJ1994PLC112895

Notes to the Ind AS Financial Statements for the Year Ended 31st March, 2026

1. Corporate information

Deep Health AI India Limited (the Company) is domiciled in India and is incorporated under the provisions of the Companies Act, 1956 applicable in India. Its shares are listed on Bombay Stock Exchange in India. The Company was engaged in the business Rough & Polished Diamonds, sale, and trading of diamond studded jewellery & Gold Jewellery. From financial year 2022-23 the company has also started business of providing consultancy service to Pharmaceutical Industry.

During the year, the Company shifted its registered office from 309, 3rd Floor, V Star Plaza, Plot No. 16, Chandavarkar Road, Opp. Saraswat Bank, Borivali West, Opposite Raj Mahal Hotel, Mumbai, Maharashtra – 400092 to 506–509, Fifth Floor, Apeksha, Plot No. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan – 313001.

The Company has also changed its name from Deep Diamond India Limited to Deep Health AI Limited, in accordance with the applicable provisions of the Companies Act, 2013 and subject to the requisite approvals.

2. Basis of Preparation of Financial Statements

The financial statements of Deep Health AI Limited (the “Company”) have been prepared in accordance with the provisions of the Companies Act, 2013 and the Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) issued by Ministry of Corporate Affairs in exercise of the powers conferred by section 133 read with sub-section (1) of section 210A of the Companies Act, 2013. In addition, the guidance notes/announcements issued by the Institute of Chartered Accountants of India (ICAI) are also applied along with compliance with other statutory promulgations require a different treatment.

The Ind AS Financial Statements have been prepared on a going concern basis using historical cost convention and on an accrual method of accounting, except for certain financial assets and liabilities, which have been measured at fair value as described below:

Fair Value Measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

1) In the principal market for the asset or liability, or
2) In the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

Fair value for measurement and /or disclosure purpose in these financial statements is determined on such basis, except for share based payment transactions that are within the scope of Ind AS 102, leasing transactions that are within the scope of Ind AS 17, and measurements that have some similarities to fair value, such as net realisable value in Ind AS 2 or value in use in Ind AS 36.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

Management determines the policies and procedures for both recurring fair value measurement, such as derivative instruments and unquoted financial assets measured at fair value, and for non-recurring measurement, such as assets held for distribution in discontinued operations.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

Use of estimates and judgments:

The preparation of financial statements inconformity with Ind AS requires that the management of the Company estimates and assumptions that affect the reported amounts of income and expenses of the period, the reported balances of assets and liabilities and the disclosures relating to contingent liabilities as of the date of the financial statements. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates include expected credit loss on loan books, fair value measurement etc. Difference, if any, between the actual results and estimates is recognised in the period in which the results are known.

3. Significant Accounting Policies

(i) Property, Plant and Equipment

The initial cost of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, attributable borrowing cost and any other directly attributable costs of bringing an asset to working condition and location for its intended use. It also includes the present value of the expected cost for the decommissioning and removing of an asset and restoring the site after its use, if the recognition criteria for a provision are met.

Expenditure incurred after the property, plant and equipment have been put into operation, such as repairs and maintenance, are normally charged to the statements of profit and loss in the period in which the costs are incurred. Major inspection and overhaul expenditure is capitalized if the recognition criteria are met.

When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in the statement of profit and loss as incurred.

Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognized net within other income/other expenses in statement of profit and loss.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss, when the asset is derecognised.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

(ii) Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. The Company's income from operation is accounted for on accrual basis. Revenue from sales of Gold and Diamonds is recognized on delivery of the products, when all significant contractual obligations have been satisfied, the property in the goods is transferred for a price significant risks & rewards of ownership are transferred to the customers and no effective ownership is retained. Interest is recognized using the time-proportion method, based on rates implicit in the transaction. Dividend income is recognised when the Company right to receive dividend is established by the reporting date and no significant uncertainty as to collectability exists.

(iii) Taxation:

Current Tax

A provision for current income tax is made on the taxable income using the applicable tax rates and tax laws.

Deferred Tax

Deferred tax arising on account of timing differences and which are capable of reversal in one or more subsequent periods is recognized using the tax rates and tax laws that have been enacted or substantively enacted. Deferred tax assets are not recognized unless there is a virtual certainty with respect to the reversal of the same in future.

Deferred Tax on Comprehensive Income

Deferred tax arising on account of difference between fair value and cost of Financial Assets. which are capable of reversal in one or more subsequent periods is recognized using the tax rates and tax laws that have been enacted or substantively enacted. Deferred tax assets are not recognized unless there is a virtual certainty with respect to the reversal of the same in future.

(iv) Impairment of Assets

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating units (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or Company's assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered as impaired and is written down to its recoverable amount

Impairment losses are recognised in the statement of profit and loss.

(v) Provisions and Contingencies

The company creates a provision when there is present obligation as a result of a past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of obligation. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that probably will not require an outflow of resources or where a reliable estimate of the obligation cannot be made.

(vi) Employee Benefits

The retirement benefits, Gratuity and Leave encashment benefits will be debited as and when paid.

(vii) Segment information

The Company is engaged in following segment viz. Jewellery of Gold and Diamond Studded and in providing Consultancy related to Marketing of Pharmaceutical products. For reportable segments as per IND AS -108 refer note 28.

(viii) Borrowing Costs

Borrowing Costs that are attributable to the acquisition or construction of qualifying assets are capitalised as part of the cost of such assets. A qualifying asset is one that necessarily takes a substantial period of time to get ready for its intended use or sale. All other borrowing costs are charged to revenue. Borrowing costs consists of interest and other costs that an entity incurs in connection with the borrowing of funds.

(ix) Foreign Currency Transactions

a) Transactions in Foreign Currency are accounted at the exchange rate prevailing on the date of Transactions. Exchange fluctuations between the transaction date and the settlement date in respect of Revenue Transactions are recognized in Profit & Loss Account.

b) All export proceeds not realised at the yearend are restated at the rate prevailing at the year end. The exchange difference arising there from has been recognised as income / expenses in the Current Year's Profit & Loss A/c along with underlying transaction.

c) The premium or discount arising at the inception of forward exchange contract is amortised as expense or income over the life of the contract. Exchange differences on such contracts are recognised in the statement of profit and loss in the year in which the exchange rates change. Any profit or loss arising on cancellation or renewal of forward exchange contracts is recognised as income or as expense for the year. None of the forward exchange contracts are taken for trading or speculation purpose.

(x) Cash flow Statement

Cash flows are reported using the indirect method, whereby the net profit before tax is adjusted for the effects of transactions of a non-cash nature, any defects or accruals of past or future operating cash receipts and payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the company are segregated.

(xi) Cash and Cash Equivalent

Cash and Cash Equivalents for the purpose of cash flow statement comprise cash in hand and cash at bank including fixed deposit with original maturity period of three months and short term highly liquid investments with an original maturity of three months or less.

(xii) Inventories

Inventories are valued at the lower of cost and net realisable value except scrap and by products which are valued at net realisable value.

Costs incurred in bringing the inventory to its present location and condition are accounted for as follows:

- Raw materials: cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is determined on weighted average basis.
- Finished goods and work in progress: cost includes cost of direct materials and labour and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs. Cost is determined on weighted average basis.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

Obsolete inventories are identified and written down to net realisable value. Slow moving and defective inventories are identified and provided to net realisable value.

(xiii) Earnings Per Share(EPS)

Basic and diluted EPS is computed by dividing the net profit attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year.

DEEP HEALTH AI INDIA LIMITED

CIN:-L24100RJ1994PLC112895

Balance Sheet as at 31st March 2026

Rs. In Hundreds

Particulars	Note No.	As at 31st March, 2026	As at 31st March, 2025
(1) ASSETS			
(A) Non-current assets			
(i) Property Plant & Equipment	Note - 2	1,034	1,452
(ii) Financial Assets			
(a) Investments	Note - 3	32,99,160	10,02,615
(b) Loans & Advances	Note - 4	5,47,558	8,49,470
(c) Others	Note - 5	-	55,000
(B) Current assets			
(i) Inventories	Note - 6	51,457	51,457
(ii) Financial Assets			
(a) Trade Receivables	Note - 7	2,91,587	50,796
(b) Cash & Cash Equivalents	Note - 8	8,33,847	3,30,970
(c) Loans & Advances	Note - 9	86,350	52,749
(iii) Current Tax Assets (Net)	Note - 10	1,14,056	258
Total Assets		**52,25,050**	**23,94,765**
(2) EQUITY AND LIABILITIES			
(A) Equity			
(i) Equity Share capital	Note - 11	14,41,500	4,80,500
(ii) Other Equity	Note - 12	37,12,327	17,53,898
(B) LIABILITIES			
(i) Non-Current liabilities			
(ii) Current liabilities			
(a) Financial Liabilities			
i) Borrowings	Note - 13	37,281	60,846
ii) Trade Payables	Note - 14	33,502	66,618
(b) Other Current Liabilities	Note - 15	-	17,980
(c) Current Tax Liabilities (Net)	Note - 16	440	14,923
Total Equity and Liabilities		**52,25,050**	**23,94,765**

See accompanying notes to the financial statements

Significant Accounting Policies Note - 1

Other Notes on accounts from Nos. 24 to 35 are an integral part of the Financial Statements

This is the Balance Sheet referred to in our Report of even date.

For V R S K & CO. LLP
(Formerly known as V R S K & Co)
Chartered Accountants
Firm No.: 111426W/W100988

For DEEP HEALTH AI INDIA LIMITED
(Formerly known as Deep Diamond India)

Narayan Singh Rathore
Managing Director
(DIN - 10900646)

Laveena Pokharna
Whole Time Director
(DIN - 10977709)

Suresh G. Kothari
Partner
Membership No. 047625
UDIN: 26047625VVAWOL4406
Date : May 29,2026
Place : Mumbai

Rakesh Vishnoi
Company Secretary

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Statement of Profit and loss for the year ended 31st March , 2026

	Particulars	Note No.	For the year ended 31st March, 2026	For the year ended 31st March, 2025
			Rs. In Hundreds	Rs. In Hundreds
I.	Revenue from operations	Note - 17	4,25,000	1,25,909
II.	Other income	Note - 18	4,24,023	74,630
III.	**Total Income (I + II)**		**8,49,023**	**2,00,539**
IV.	Expenses:			
	1. Cost of material consumed		-	-
	2. Purchase of Stock -in-Trade		-	-
	3. Changes in inventories of finished goods work-in-progress and Stock -in-Trade	Note -19	-	14,506
	4. Employee benefits expense	Note - 20	18,806	16,735
	5. Finance costs	Note - 21	2,713	9,416
	6. Depreciation and Amortization	Note - 2	777	1,063
	7. Other expenses	Note - 22	72,640	48,958
	Total expenses (IV)		**94,936**	**90,678**
V.	**Profit/(loss) before exceptional items and Tax**		7,54,086	1,09,861
VI.	**Exceptional Items**			
	Loss on Business Acquisition/Undertaking		**5,77,844**	**0**
VII.	**Profit before tax (III-IV)**		1,76,242	1,09,861
VIII.	Tax expense: Provision for Taxation			
	1. Current tax			
	i. Current year		46,331	27,755
	ii. Earlier years			-3,969.00
	2. Deferred tax		-	-
	Profit (Loss) for the period /Profit After Tax (V - VI)		1,29,911	86,073
IX.	**Other Comprehensive Income**			
	1. Other Comprehensive Income not to be reclassified to profit and loss in subsequent periods		-	
	2. Net Gain/(Loss) on FVTOCI Investments		(10,24,076)	1,06,210
	3. Deferred Tax Asset on Comprehensive Income		-	-
X.	**Total Income for the period (VI - VII)**		**-8,94,165**	**1,92,283**
	(Profit/ loss + other comprehensive income)			
XI.	**Earnings per equity share :**			
	1. Basic (in Rupees)	Note 23	0.14	0.09
	2. Diluted (in Rupees)		0.14	0.09

See accompanying notes to the financial statements
Significant Accounting Policies Note - 1
Other Notes on accounts from Nos. 24 to 35 are an integral part of the Financial Statements

For V R S K & CO. LLP
(Formerly known as V R S K & Co)
Chartered Accountants
Firm No.: 111426W/W100988

For DEEP HEALTH AI INDIA LIMITED
(Formerly known as Deep Diamond India Limited)

Narayan Singh Rathore
Managing Director
(DIN - 10900646)

Laveena Pokharna
Whole Time Director
(DIN - 10977709)

Suresh G. Kothari
Partner
Membership No. 047625
UDIN: 26047625VVAWOL4406
Date : May 29,2026
Place : Mumbai

Rakesh Vishnoi
Company Secretary

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Cash Flow Statement for the year ended March 31, 2026

Rs. In Hundreds

	Particulars	As at 31st March, 2026	As at 31st March, 2025
A.	**Cash flow from operating activities:**		
	Profit/(loss) before tax	**1,76,242**	**1,09,860**
	Adjustments for:		
	Depreciation	777	1,063
	Finance Cost	2,713	9,416
	Profit on Sale of Gold	(3,29,467)	-
	Profit on sale of fixed assets(net)	-	48
	Interest Income	(71,171)	(74,059)
	Dividend Income	(62)	-
	Operating profit before working capital changes	**(2,20,967)**	**46,328**
	Adjustments for:		
	Trade and Other Receivables	(2,40,791)	94,712
	Inventories		14,506
	Loans and Advances	3,23,311	(6,431)
	Other Current Tax Liabilities	(13,644)	10,859
	Trade Payable & Provisions	(51,096)	(9,072)
	Cash (used in)/generated from operations	**(2,03,187)**	**1,50,902**
	Income Tax Paid/Refund (Net)	(1,60,969)	(16,749)
	Net cash (used in)/from operating activities	**(3,64,156)**	**1,34,153**
B.	**Cash flow from investing activities:**		
	Purchase of Fixed Asset	(360)	(98)
	Sale of Investment	12,44,037	-
	Purchase of Investment	(42,35,192)	(97,215)
	Interst Income	71,171	74,059
	Dividend Income	62	-
	Cash (used in)/from investing activities	**(29,20,282)**	**(23,254)**
C.	**Cash flow from financing activities:**		
	Proceeds from fresh issue of share capital	39,97,760	-
	Repayment of short term borrowings	(23,565)	(1,05,609)
	Right issue expense	(40,016)	-
	Dividend paid during the year	(1,44,150)	-
	Finance Cost	(2,713)	(9,416)
	Net cash (used in)/ from financing activities	**37,87,316**	**(1,15,025)**
	Net (decrease)/increase in cash and cash equivalents (A + B + C)	5,02,878	-4,126
	Cash and cash equivalents at beginning of the year	**3,30,970**	**3,35,095**
	Cash and cash equivalents at end of the year	**8,33,848**	**3,30,969**

Previous year's figures have beeen reworked, regrouped and rearranged wherever necessary.

As per our Report of even date

For V R S K & CO. LLP
(Formerly known as V R S K & Co)
Chartered Accountants
Firm No.: 111426W/W100988

SD/-
Suresh G. Kothari
Partner
Membership No. 047625
UDIN: 26047625VVAWOL4406
Date : May 29,2026
Place : Mumbai

For DEEP HEALTH AI INDIA LIMITED
(Formerly known as Deep Diamond India Limited)

SD/-
Narayan Singh Rathore
Managing Director
(DIN - 10900646)

SD/-
Laveena Pokharna
Whole Time Director
(DIN - 10977709)

SD/-
Rakesh Vishnoi
Company Secretary

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2026

a. Equity Share Capital
(i). Current reporting period **Rs. In Hundreds**

Balance at the beginning of the current reporting period	Changes in equity share capital during the current year	Balance at the end of the current reporting period
4,80,500.0	9,61,000.0	14,41,500.0

(ii). Previous reporting period **Rs. In Hundreds**

Balance at the beginning of the previous reporting period	Changes in equity share capital during the previous year	Balance at the end of the previous reporting period
4,80,500	-	4,80,500

b. Other Equity **Rs. In Hundreds**

Particular	Reserves and Surplus				Total
	Capital Reserve	Retained earnings	Securites Premium	Other Comprehensive Income	
Balance at the beginning of the previous reporting period	20,680	5,89,528	9,27,937	23,471	**15,61,616**
Profit /(Loss) for the year		86,073			**86,073**
Other comprehensive income				1,06,210	**1,06,210**
Total comprehensive income	-	86,073	-	1,06,210	**1,92,283**
Other adjustments	-		-		**-**
Balance at the beginning of the current reporting period	20,680	6,75,601	9,27,937	1,29,680	**17,53,898**
Profit /(Loss) for the year	-	1,29,911	30,36,760		**31,66,671**
Other comprehensive income	-			(10,24,076)	**(10,24,076)**
Total comprehensive income	-	1,29,911	30,36,760	(10,24,076)	**21,42,595**
Dividends		(1,44,150)			**(1,44,150)**
Right Issue Expense			(40,016)		**(40,016)**
Balance at the end of the current reporting period	**20,680**	**6,61,361**	**39,24,681**	**(8,94,396)**	**37,12,327**

As per our Report of even date
For V R S K & CO. LLP
(Formerly known as V R S K & Co)
Chartered Accountants
Firm No.: 111426W/W100988

SD/-

Suresh G. Kothari
Partner
Membership No. 047625
UDIN: 26047625VVAWOL4406
Date : May 29,2026
Place : Mumbai

For DEEP HEALTH AI INDIA LIMITED
(Formerly known as Deep Diamond India Limited)

SD/-
Narayan Singh Rathore
Managing Director
(DIN - 10900646)

SD/-
Laveena Pokharna
Whole Time Director
(DIN - 10977709)

SD/-
Rakesh Vishnoi
Company Secretary

DEEP HEALTH AI INDIA LIMITED

CIN: - L24100RJ1994PLC112895

Notes to the Ind AS Financial Statements for the Year Ended 31st March, 2026

1. Corporate information

Deep Health AI India Limited (the Company) is domiciled in India and is incorporated under the provisions of the Companies Act, 1956 applicable in India. Its shares are listed on Bombay Stock Exchange in India. The Company was engaged in the business Rough & Polished Diamonds, sale, and trading of diamond studded jewellery & Gold Jewellery. From financial year 2022-23 the company has also started business of providing consultancy service to Pharmaceutical Industry.

During the year, the Company shifted its registered office from 309, 3rd Floor, V Star Plaza, Plot No. 16, Chandavarkar Road, Opp. Saraswat Bank, Borivali West, Opposite Raj Mahal Hotel, Mumbai, Maharashtra – 400092 to 506–509, Fifth Floor, Apeksha, Plot No. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan – 313001.

The Company has also changed its name from Deep Diamond India Limited to Deep Health AI Limited, in accordance with the applicable provisions of the Companies Act, 2013 and subject to the requisite approvals.

2. Basis of Preparation of Financial Statements

The financial statements of Deep Health AI Limited (the "Company") have been prepared in accordance with the provisions of the Companies Act, 2013 and the Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) issued by Ministry of Corporate Affairs in exercise of the powers conferred by section 133 read with sub-section (1) of section 210A of the Companies Act, 2013. In addition, the guidance notes/announcements issued by the Institute of Chartered Accountants of India (ICAI) are also applied along with compliance with other statutory promulgations require a different treatment.

The Ind AS Financial Statements have been prepared on a going concern basis using historical cost convention and on an accrual method of accounting, except for certain financial assets and liabilities, which have been measured at fair value as described below:

Fair Value Measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

1) In the principal market for the asset or liability, or
2) In the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

Fair value for measurement and /or disclosure purpose in these financial statements is determined on such basis, except for share based payment transactions that are within the scope of Ind AS 102, leasing transactions that are within the scope of Ind AS 17, and measurements that have some similarities to fair value, such as net realisable value in Ind AS 2 or value in use in Ind AS 36.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

Management determines the policies and procedures for both recurring fair value measurement, such as derivative instruments and unquoted financial assets measured at fair value, and for non-recurring measurement, such as assets held for distribution in discontinued operations.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

Use of estimates and judgments:

The preparation of financial statements inconformity with Ind AS requires that the management of the Company estimates and assumptions that affect the reported amounts of income and expenses of the period, the reported balances of assets and liabilities and the disclosures relating to contingent liabilities as of the date of the financial statements. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates include expected credit loss on loan books, fair value measurement etc. Difference, if any, between the actual results and estimates is recognised in the period in which the results are known.

3. Significant Accounting Policies

(i) Property, Plant and Equipment

The initial cost of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, attributable borrowing cost and any other directly attributable costs of bringing an asset to working condition and location for its intended use. It also includes the present value of the expected cost for the decommissioning and removing of an asset and restoring the site after its use, if the recognition criteria for a provision are met.

Expenditure incurred after the property, plant and equipment have been put into operation, such as repairs and maintenance, are normally charged to the statements of profit and loss in the period in which the costs are incurred. Major inspection and overhaul expenditure is capitalized if the recognition criteria are met.

When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in the statement of profit and loss as incurred.

Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognized net within other income/other expenses in statement of profit and loss.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss, when the asset is derecognised.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

(ii) Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. The Company’s income from operation is accounted for on accrual basis. Revenue from sales of Gold and Diamonds is recognized on delivery of the products, when all significant contractual obligations have been satisfied, the property in the goods is transferred for a price significant risks & rewards of ownership are transferred to the customers and no effective ownership is retained. Interest is recognized using the time-proportion method, based on rates implicit in the transaction. Dividend income is recognised when the Company right to receive dividend is established by the reporting date and no significant uncertainty as to collectability exists.

(iii) Taxation:

Current Tax

A provision for current income tax is made on the taxable income using the applicable tax rates and tax laws.

Deferred Tax

Deferred tax arising on account of timing differences and which are capable of reversal in one or more subsequent periods is recognized using the tax rates and tax laws that have been enacted or substantively enacted. Deferred tax assets are not recognized unless there is a virtual certainty with respect to the reversal of the same in future.

Deferred Tax on Comprehensive Income

Deferred tax arising on account of difference between fair value and cost of Financial Assets. which are capable of reversal in one or more subsequent periods is recognized using the tax rates and tax laws that have been enacted or substantively enacted. Deferred tax assets are not recognized unless there is a virtual certainty with respect to the reversal of the same in future.

(iv) Impairment of Assets

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating units (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or Company's assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered as impaired and is written down to its recoverable amount

Impairment losses are recognised in the statement of profit and loss.

(v) Provisions and Contingencies

The company creates a provision when there is present obligation as a result of a past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of obligation. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that probably will not require an outflow of resources or where a reliable estimate of the obligation cannot be made.

(vi) Employee Benefits

The retirement benefits, Gratuity and Leave encashment benefits will be debited as and when paid.

(vii) Segment information

The Company is engaged in following segment viz. Jewellery of Gold and Diamond Studded and in providing Consultancy related to Marketing of Pharmaceutical products. For reportable segments as per IND AS -108 refer note 28.

(viii) Borrowing Costs

Borrowing Costs that are attributable to the acquisition or construction of qualifying assets are capitalised as part of the cost of such assets. A qualifying asset is one that necessarily takes a substantial period of time to get ready for its intended use or sale. All other borrowing costs are charged to revenue. Borrowing costs consists of interest and other costs that an entity incurs in connection with the borrowing of funds.

(ix) Foreign Currency Transactions

a) Transactions in Foreign Currency are accounted at the exchange rate prevailing on the date of Transactions. Exchange fluctuations between the transaction date and the settlement date in respect of Revenue Transactions are recognized in Profit & Loss Account.

b) All export proceeds not realised at the yearend are restated at the rate prevailing at the year end. The exchange difference arising there from has been recognised as income / expenses in the Current Year's Profit & Loss A/c along with underlying transaction.

c) The premium or discount arising at the inception of forward exchange contract is amortised as expense or income over the life of the contract. Exchange differences on such contracts are recognised in the statement of profit and loss in the year in which the exchange rates change. Any profit or loss arising on cancellation or renewal of forward exchange contracts is recognised as income or as expense for the year. None of the forward exchange contracts are taken for trading or speculation purpose.

(x) Cash flow Statement

Cash flows are reported using the indirect method, whereby the net profit before tax is adjusted for the effects of transactions of a non-cash nature, any defects or accruals of past or future operating cash receipts and payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the company are segregated.

(xi) Cash and Cash Equivalent

Cash and Cash Equivalents for the purpose of cash flow statement comprise cash in hand and cash at bank including fixed deposit with original maturity period of three months and short term highly liquid investments with an original maturity of three months or less.

(xii) Inventories

Inventories are valued at the lower of cost and net realisable value except scrap and by products which are valued at net realisable value.

Costs incurred in bringing the inventory to its present location and condition are accounted for as follows:

- Raw materials: cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is determined on weighted average basis.
- Finished goods and work in progress: cost includes cost of direct materials and labour and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs. Cost is determined on weighted average basis.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

Obsolete inventories are identified and written down to net realisable value. Slow moving and defective inventories are identified and provided to net realisable value.

(xiii) Earnings Per Share(EPS)

Basic and diluted EPS is computed by dividing the net profit attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year.

DEEP HEALTH AI INDIA LIMITED

CIN:-L24100RJ1994PLC112895

Financial Year 2025-26

Note - 2 : Property Plant & Equipment

Rs. In Hundreds

Fixed Assets	Gross Block				Accumulated Depreciation				Net Block	
	Balance as at 31st March 2025	Additions	Disposals/Retirement	Balance as at 31st March 2026	Balance as at 31st March 2025	Depreciation charge for the year	Accumulated Depreciation on assets sold/retired	Balance as at 31st March 2026	Balance as at 31st March 2026	Balance as at 31st March 2025
Tangible Assets										
Air conditioner	1,031			1,031	1,031		-	1,031	-	-
Furniture & Fittings	1,769		-	1,769	895	336	-	1,231	538	874
Computers	2,208	106	-	2,314	2,041	152	-	2,193	121	167
Office equipment	4,310	254		4,564	4,208	63	-	4,271	292	102
Laptops	1,662	-		1,662	1,353	226		1,579	83	309
Total	10,980	360	-	11,340	9,528	777	-	10,305	1,034	1,452
Previous Year	10,929	13,304	8,315	10,97,919	8,464	1,06,335	-	9,52,751	1,45,168	2,465

DEEP HEALTH AI INDIA LIMITED

CIN:-L24100RJ1994PLC112895

Financial Year - 2025-26

Note 3 : INVESTMENTS — **Rs. In Hundreds**

Particulars	Face Value	Number	As at 31st March 2026	Number	As at 31st March 2025
Non Current Investments					
A) Investment in Immovable Properties					
Investment in Flats / Bunglow			4,43,258		4,43,258
			4,43,258		**4,43,258**
B) Unquoted Equiy shares					
I) Investment in Associates					
Ferry Automotives Pvt. Ltd.	10	5,000	1,16,250	5,000	1,16,250
@ Rs 2325/- each fully paid up					
			1,16,250		**1,16,250**
II) Investment in Subsidiary					
Microcure Biotech Pvt. Ltd.	10	20,000	-	20,000	1,834
@ Rs 9.17 each fully paid up					
			-		**1,834**
III) Investment in Joint Venture					
Hemonc Pharma Pvt. Ltd.	10	50,000	-	50,000	5,000
@ Rs 10/- each fully paid up					
			-		**5,000**
III) Investment in Listed Equity Shares					
Equity Shares			36,34,090		-
Aggregate value of quoted investments			**36,34,090**		**-**
Aggregate value of unquoted investments			**5,59,508**		**5,66,342**
Fair Market Value of Quoted Shares			27,39,652		**-**
Other Investment					
Investment in Gold			-		4,36,273
			-		**4,36,273**
Total Investment.			**32,99,160**		**10,02,615**

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Financial Year - 2025-26

Note - 4 : Loans & Advances - Non Current Asset

Rs. In Hundreds

Loans and advances	As at 31st March, 2026	As at 31st March,2025
Other Loans and Advances	21,290	21,296
Unsecured, considered good		
- Inter corporate Loans *	5,26,268	8,28,174
Total	**5,47,558**	**8,49,470**

(* Intercorporate Loans given are refundable on demad, are interest bearing, are not discounted, therefore valued at their transaction value)

Note - 5 : Other - Non-Current Assets

Rs. In Hundreds

Other Non-Current Assets	As at 31st March, 2026	As at 31st March,2025
Earnest Money Deposit	-	55,000
Total	**-**	**55,000**

*The deposits being refundable, however the refundable time period not being defined hence there is no need for discounting.

Note - 6 : Inventories

Rs. In Hundreds

Inventories	As at 31st March, 2026	As at 31st March,2025
a. Raw Materials	**1,844**	**1,844**
b. Stock in Process	-	-
c. Finished Goods	49,613	49,613
Total	**51,457**	**51,457**

Note - 7 : Trade Receivables

Rs. In Hundreds

Trade Receivables	As at 31st March, 2026	As at 31st March,2025
Unsecured, considered good		
Over Six Months *	-	-
Others *	2,91,587	50,796
Total	**2,91,587**	**50,796**

***1. No lien/charge against trade receivables**
***2. No trade receivables are due from directors or other officers of the Company either severally or jointly with any other person. Nor any trade receivables are due from firms or private companies respectively in which any director is a partner, a director or a member.**

Trade receivables ageing Schedule - for the year 2025-26

	Particulars	*Outstanding for following periods from due date of payment*					
		Less than 6 months	*6 months -1 year*	*1-2 Years*	*2-3 years*	*More than 3 years*	*Total*
(i)	Undisputed Trade receivables – considered good	1,86,087	1,05,500				2,91,587
(ii)	Undisputed Trade Receivables – which have significant increase in credit risk						
(iii)	Undisputed Trade Receivables – credit impaired						
(iv)	Disputed Trade Receivables–considered good						
(v)	Disputed Trade Receivables – which have significant increase in credit risk						
(vi)	Disputed Trade Receivables – credit impaired						
	TOTAL	1,86,087	1,05,500				2,91,587

Trade receivables ageing Schedule - for the year 2024-25

	Particulars	*Outstanding for following periods from due date of payment*					
		Less than 6 months	*6 months -1 year*	*1-2 Years*	*2-3 years*	*More than 3 years*	*Total*
(i)	Undisputed Trade receivables – considered good	50,796	-				50,796
(ii)	Undisputed Trade Receivables – which have significant increase in credit risk						
(iii)	Undisputed Trade Receivables – credit impaired						
(iv)	Disputed Trade Receivables–considered good						
(v)	Disputed Trade Receivables – which have significant increase in credit risk						
(vi)	Disputed Trade Receivables – credit impaired						
	TOTAL	50,796	-				50,796

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Financial Year - 2025-26

Note - 8 : Cash & Cash Equivalents

Rs. In Hundreds

Cash and cash equivalents	As at 31st March, 2026	As at 31st March, 2025
a. Balances with banks*		
In Current Accounts		
ICICI Bank Ltd.641505000331	8,30,983	1,926
Fixed Deposit with ICICI Bank Ltd.	-	3,25,000
b. Cash on Hand	2,865	4,044
(As per Books & Certified)		
	8,33,847	3,30,970

Note - 9 : Loans & Advances - Current Asset

Rs. In Hundreds

Short-term loans and advances	As at 31st March, 2026	As at 31st March, 2025
Unsecured, considered good		
Advances recoverable in cash or in kind or for value to be received	85,000	25,000
Security Deposits - Rental Deposit	1,350	2,550
Interest Accured on FDR	-	25,199
CIRP Expenses	-	-
Total	**86,350**	**52,749**

(* Intercorporate Loans given are for short term, refundable on demad, are interest bearing, are not discounted, therefore valued at their transaction value)

Note - 10 : Current Tax Assets (Net)

Rs. In Hundreds

Current Tax Assets (Net)	As at 31st March, 2026	As at 31st March, 2025
Income tax Refundable	55,897	-
GST	5,451	-
TDS Receivables Net	52,450	
Deferred Tax Asset	258	258
	1,14,056	**258**

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Financial Year - 2025-26

Note - 11 : Equity Share capital

Share Capital	As at 31 March 2026		As at 31 March 2025	
	Number	Rs. In hundreds	Number	Rs. In hundreds
Authorised 100000000 Eq Shares of Re.1 each/-	50,00,00,000	50,00,000	10,00,00,000	10,00,00,000
Issued, Subscribed & fully Paid up 14,41,50,000 Equity Shares of Rs. 1 each fully paid up	14,41,50,000	14,41,500	4,80,50,000	4,80,500
Total	**14,41,50,000**	**14,41,500**	**4,80,50,000**	**4,80,500**

a. Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

Particulars	2025-26		2024-25	
	Equity Shares		Equity Shares	
	Number	Rs. In hundreds	Number	Rs. In hundreds
Shares outstanding at the beginning of the year	4,80,50,000	4,80,500	4,80,50,000	4,80,500
Add: Shares issued during the year	9,61,00,000	9,61,000	-	-
Add: on account of split	-	-	-	-
Less : Forfeited shares re-issued during the year	-	-	-	-
Less : Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	14,41,50,000	14,41,500	4,80,50,000	4,80,500

b. Details of shareholders holding more than 5%

Name	As at 31 March 2026		As at 31 March 2025	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding

The Rights, powers and preferences relating to each class of share capital and the qualifications, limitations and restrictions thereof are contained in the Memorandum and Articles of Association of the Company. The principle rights are as follows :

Equity Shares of Rs. 1/- each The Company has only one class of share capital namely Equity shares having a face value of Rs. 1/- per share.

a. In respect of every Equity Share (whether fully paid or partly paid),voting right shall be in the same proportion as the capital paid up on such Equity Share bears to the total paid up Equity capital of the Company

During the year ended 31st March 2026, the amount of per share dividend recognized as distributions to equity shareholders was Rs. Nil

b. In the event of liquidation, the shareholders of Equity Shares are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholdings.

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Fianancial Year - 2025-26

Note - 12 : Other Equity — **Rs. In Hundreds**

	As at 31st March, 2026	As at 31st March, 2025
Capital Reserve		
As Per last Balance Sheet	20,680	20,680
Add / (Less) : Profit/(Loss) for the year	-	-
Balance at end of the reporting period	**20,680**	**20,680**
Share Premium account		
Opening Balance	9,27,937	9,27,937
Add: Share Premium on shares issued	30,36,760	-
Less : Right issue expense	-40,016	-
Balance at end of the reporting period	**39,24,681**	**9,27,937**
Retained Earnings		
As Per last Balance Sheet	6,75,601	5,89,528
Less : Dividend paid during the year	-1,44,150	
Add / (Less) : Profit/(Loss) for the year	1,29,911	86,073
Balance at end of the reporting period	6,61,362	6,75,601
Equity instruments through other comprehensive income (FVTOCI Reserve)		
As Per last Balance Sheet	1,29,680	23,471
Add / (Less) : Movement in OCI (Net) during the year	(10,24,076)	1,06,210
Deferred Tax on Comprehensive Income	-	-
Balance at end of the reporting period	(8,94,396)	1,29,680
Aggregate Total	**37,12,327**	**17,53,898**

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Financial Year - 2025-26

Note - 13: Financial Liabilities

Rs. In Hundreds

Other Current Liabilities	As at 31st March 2026	As at 31st March 2025
Unsecured Loan		
Prakash Solanki - Loans	37,281	**60,846**
Al Risha Recruitment Pvt. Ltd.		-
	37,281	**60,846**
Total	**37,281**	**60,846**

Note - 14 : Trade Payables

Rs. In Hundreds

Other Current Liabilities	As at 31st March 2026	As at 31st March 2025
Sundry Creditors	33,502	66,618
		-
Total	**33,502**	**66,618**

Trade Payables aging schedule for the year 2025-2026

	Particulars	***Outstanding for following periods from due date of payment***				
		Less than 1 year	***1-2 years***	***2-3 years***	***More than 3 years***	***Total***
(i)	MSME			-	-	-
(ii)	Others				-	-
(iii)	Disputed dues – MSME					
(iv)	Disputed dues - Others					
		-	-	-	-	-

Trade Payables aging schedule for the year 2024-2025

	Particulars	***Outstanding for following periods from due date of payment***				
		Less than 1 year	***1-2 years***	***2-3 years***	***More than 3 years***	***Total***
(i)	MSME			-	-	-
(ii)	Others	29,400		37,218	-	66,618
(iii)	Disputed dues – MSME					
(iv)	Disputed dues - Others					
		29,400	-	37,218	-	66,618

Note - 15 : Provisions

Rs. In Hundreds

Other Current Liabilities	As at 31st March 2026	As at 31st March 2025
Other Current Liabilities	-	17,980
Total	**-**	**17,980**

Note - 16 : Current Tax Liabilities

Rs. In Hundreds

Other Current Liabilities	As at 31st March 2026	As at 31st March 2025
	-	-
Income tax AY 2026-27	-	6,290
GST		5,728
Profession Tax Payable (Employees)		211
TDS Payable	440	2,694
Total	**440**	**14,923**

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Financial Year - 2025-26

Note - 17 : Revenue from operations

Rs. In Hundreds

Revenue from operations	For the year ended 31 March 2026	For the year ended 31 March 2025
Sale of Gold and Diamond Studded jewellery	-	20,909
Consultancy fee	4,25,000	1,05,000
Total	**4,25,000**	**1,25,909**

Note - 18 : Other Income

Rs. In Hundreds

Other Income	For the year ended 31 March 2026	For the year ended 31 March 2025
Dividend on shares	62	-
Interest income	35,216	45,712
Interest on Bank FD	35,955	27,999
Interest on IT Refund	-	348
Balances Written off	23,312	40
Miscellaneous Income-Health Scanner Income	11	65
Short Term Gain on sale of Gold Investment	3,29,467	466
Total	**4,24,023**	**74,630**

Note - 19 : Changes in inventories of finished goods work-in- progress and

Rs. In Hundreds

Changes in Inventories of finished goods work-in-progress and Stock-in-Trade excluding Raw Material	For the year ended 31 March 2026	For the year ended 31 March 2025
Closing Stock		
Finished Goods-Manufactured	-	-
Finished Goods-Traded	51,457	49,613
Work in Progress	-	-
Stock in Trade excluding Raw Material	-	-
	51,457	49,613
Less: Opening Stock		
Finished Goods-Manufactured	-	
Finished Goods-Traded	51,457	64,119
Work in Progress	-	
Stock in Trade	-	-
	51,457	64,119
Net Changes	**-**	**14,506**

Note - 20 : Employee benefits expense

Rs. In Hundreds

Employee Benefits Expense	For the year ended 31 March 2026	For the year ended 31 March 2025
(a) Salaries and incentives	6,685	5,749
(b) Director Remuneration	11,236	10,699
(b) Staff Welfare expenses	885	287
Total	**18,806**	**16,735**

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Financial Year - 2025-26

Note - 21 : Finance Cost

Rs. In Hundreds

Finance Cost	For the year ended 31 March 2026	For the year ended 31 March 2025
(a) Bank Charges	131	2,594
(b) Interest on Loan A/c-Taken	2,581	6,777
(c) Interest on Bank OD	-	-
(d) Interest on Late Payment of TDS	1	45
Total	**2,713.18**	**9,416**

Note - 22 : Other Expenses

Rs. In Hundreds

OTHER EXPENSES	For the year ended 31 March 2026	For the year ended 31 March 2025
Other Expenses		
Auditor Remuneration	1,750	1,250
Advertisement	2,804	740
Brokerage-STT and Other	5,588	-
Sales Promotion Expenses	28	42
Conveyance Expenses	15	97
Electricity Expenses	502	300
Consultancy Expenses	3,000	-
Legal Fees	970	-
GST Late Fees	2	34
Loss on Shares Written Off	98	-
Listing Charges	10,750	3,250
Printing & Stationery	194	86
Professional Fees	20,531	29,316
Professional Fees (Director)	540	-
Interest on Professional Fees	24	50
Interest on GST	12	-
Office Maintenance	465	-
Right Entitlement	65	-
Registration Charges	103	-
ROC Fees	3,553	5,509
Subscription Charges	-	111
Rent for Office	7,650	5,350
Late Fees for professional tax	20	-
Demat Charges	71	-
Telephone Expenses	172	220
Travelling Expenses	244	382
Repairs and maintenance	25	64
Discount Given	-	1,025
Loss on sale of Fixed asset	-	48
Software and Website charges	13,034	192
General Expenses	431	892
Total	**72,640**	**48,958**

NOTES TO ACCOUNTS:

(Rs in Hundreds)

23. Earnings Per Share (Ind AS 33)

As per (Ind AS 33) "Earning Per Share'' issued by Institute of Chartered Accountant of India the Company gives following disclosure for the year.

Basic & Diluted Earnings Per Share

	Unit	31/03/2026	31/03/2025
a) Net Profit attributable to equity shareholders	Rs.	1,29,911	86,073
b) Weighted average number of equity shares	No.	9,43,88,630	4,80,50,000
c) Nominal Value Per Share	Rs.	0.01	0.01
d) Earning Per Share	Rs.	0.14	0.18

24. Contingent Liabilities (IndAS37) :

There are no contingent liabilities other than those disclosed in the notes on accounts as on 31/03/2026.

25. OTHER NOTES:

i) Foreign Exchange Transactions**:** During the year, the Company incurred foreign currency expenditure amounting to Rs.12,862.15 (in hundreds) towards the purchase of software. There were no foreign exchange earnings during the year.

ii) During the year, the Company was pursuing acquisition of Oasis Ceramics Private Limited pursuant to a Resolution Plan approved under the Insolvency and Bankruptcy Code, 2016.

As per the approved Resolution Plan, the Company was required to pay aggregate consideration of Rs.32 crore. Against the same, the Company had remitted Rs.55 lakh towards Earnest Money Deposit and Rs.2 Crore towards acquisition consideration. Owing to delays in remittance of the balance consideration within the stipulated timeline, the Company filed an application before the Hon'ble NCLT seeking extension of time, which remains pending as at the reporting date.

Consequent to such delay, the Resolution Professional invoked the bank guarantee amounting to Rs.3.21 lakh. Further, Committee of Creditors initiated proceedings in relation to alleged non-compliance with the approved Resolution Plan, including discussions regarding commencement of liquidation proceedings.

In view of the prevailing uncertainties and based on management's assessment regarding recoverability, the aggregate exposure of Rs. 5.76 crore has been recognized as an exceptional item in the Statement of Profit and Loss.

iii) During the year, the Company raised Rs.39.97 crore through a Rights Issue for purposes stated in the Letter of Offer, including proposed acquisition under IBC proceedings, general corporate purposes and issue expenses.

Pending utilization towards the stated objects, the Company deployed Rs. 37.47 crore in investments through recognized stock exchanges instead of the proposed objects stated in the Letter of Offer. Such deviation was subsequently approved by the shareholders at the Extra-Ordinary General Meeting held on 22 January 2026.

The balance amount of Rs. 2.5 crore was utilized towards the stated objects of the issue.

iv) During the year, the Company has divested its investment in Joint Venture namely Hemonc Pharma Private Limited. Further, the Board of Directors has passed a resolution for striking off the wholly owned subsidiary namely Microcure Biotech Private Limited, subject to necessary approvals and compliances under applicable law

26. Related Party Disclosure (Ind AS 24)

Disclosure requirements as per (Ind AS 24)" Related Party Disclosure" issued by the Institute of Chartered Accountants of India

I. List of Related Parties: Name of Related Parties and nature of relationships:

A. Key Managerial Personnel

- Mr. Narayan Singh Rathore – Managing Director appointed on 11.04.2025
- Mr. Narendra Kumar Shrimali – Director till date 17.11.2025
- Mr. Rajesh Pherwani - Director
- Miss Laveena Pokharna – CFO and Whole Time Director appointed on 11.04.2025
- Mr. Prashant Tali – Company Secretary till date 27.06.2025
- Mr. Kailash Chandra – Director
- Mr. Kaushal Jain – Director
- Mrs. Shashi Kala Dhabriya – Director appointed on 20.03.2026
- Mr. Rakesh Vishnoi - Company Secretary appointed on 13.08.2025

B. Subsidiary Entity

- Mircocure Biotech Private Limited (Till date 31.03.2026)

C. Associate Enterprises

- Ferry Automotive Private Limited

D. Joint Venture

- Hemonc Pharma Private Limited (Till date 28.03.2026)

E. Other Related Parties – NIL

II. Particulars of transactions during the year with Related Parties: (in '00)

Name of the Party	Nature of transaction	31/03/2026	31/03/2025
Prakash Solanki	Loan taken by Company Repayment of Loan Interest Paid	NIL 20,000.00 2,580.99	NIL 9,000.00 6,541.89
Ganpati Nyati (Director till November 2024)	Remuneration to Director	NIL	4000.00
Narendra Kumar Shrimali (Director till November 2025)	Remuneration to Director	1170.00	1800.00
Kaushal Jain	Professional fee to Director	NIL	NIL
Sonali Laddha(Director till November 2024)	Salary to Whole Time Director	NIL	2800.00
Prashant Tali (CS till June 2025)	Salary to Company Secretary	542.00	2178.00
Mircocure Biotech Private Limited	Investment in Subsidiary Company	NIL	NIL
Ferry Automotive Private Limited	Investment in associate Loan given to Associate Interest Received TDS Deducted	NIL NIL 18,769.56 (Nil)	NIL NIL 16,871.52 (1687.15)
Hemonc Pharma Private Limited	Investment in Joint Venture	NIL	NIL
Narayan Singh Rathore	Remuneration to Director	7825.00	1593.55
Rakesh Bishnoi	Salary to Company Secretary	1,297.00	Nil
Laveena Pokharna	Salary to whole time director and CFO	2,241.30	505.81

III. Particulars of Outstanding Balance at the end of the year with Related Parties. (in '00)

Name of the Party	Nature of transaction	31/03/2026	31/03/2025
Prakash Solanki	Loan outstanding Interest Payable	34,958.14 2,322.89	60,845.84 6548.19
Narendra Kumar Shrimali	Remuneration to Director	NIL	NIL
Prashant Tali	Salary to Company Secretary	NIL	NIL
Mircocure Biotech Private Limited	Investment in Subsidiary Company	NIL	1834.00
Ferry Automotive Private Limited	Investment in Associate Loan given to Associate	1,16,250.00 1,68,926.07	1,16,250.00 1,50,156.51
Hemonc Pharma Private Limited	Investment in Joint Venture	NIL	5000.00
Narayan Singh Rathore	Remuneration to Director	650.00	NIL
Laveena Pokharna	Salary to whole time director and CFO	200.00	NIL
Rakesh Bishnoi	Salary to Company Secretary	160.00	NIL

27.Managerial Remuneration: -

Salary and other benefits include remuneration paid to Director, as under: -

(in '00)

Nature of transaction	31/03/2026	31/03/2025
Narayan Singh Rathore	7,825.00	1593.55
Laveena Pokharna	2,241.30	505.81
Narendra Kumar Shrimali	1170.00	1800.00
Prashant Tali	542.00	2178.00
Rakesh Bishnoi	1297.00	NIL

28. Segment Reporting (IndAS -108)

The Company is responsible for Segment reporting as per IndAS -108 "Operating Segment" specified under section 133 of the Companies Act, 2013. As the Company is engaged in two segment viz. Jewellery of Gold and Diamond Studded and Marketing of Pharmaceutical goods in India. (Rs. in Hundreds)

	Particulars	Year to date figures for current period ended 31-03-2026	Year to date figures for previous period ended 31-03-2025
1	**Segment Revenue (Income)**		
	(net sale/income from each segment should be disclosed)		
1	Gold Diamond and Jewellery	0	20,909
2	Consultancy fee related to Pharmaceuticals	4,25,000	1,05,000
	Total Segment Revenue	4,25,000	1,25,909
	Less: Inter segment revenue		
	Revenue from operations	4,25,000	1,25,909
2	**Segment Result**		
	Profit (+) / Loss (-) before tax and interest from each segment		
1	Gold Diamond and Jewellery	0	-5,122
2	Consultancy fee related to Pharmaceuticals	3,32,770	47,129
	Total Profit(+)/ Loss(-) before tax	3,32,770	42,007
	i. Finance cost	-2,710	-6,777
	ii. Other unallocable expenditure net off Unallocable income (-)	4,24,026	74,630
	Profit before tax and exceptional items	7,54,086	1,09,860
	Exceptional Items	5,77,844	0
	Profit before Tax	1,76,242	1,09,860
3	**(Segment Asset - Segment Liabilities)**		
	Segment Asset		
1	Gold Diamond and Jewellery	51,457	1,06,660
2	Consultancy fee related to Pharmaceuticals	9,40,381	3,83,014
	Total Segment Asset	9,91,838	4,89,674
	Un-allocable Assets	42,33,212	19,05,091

	Net Segment Asset	52,25,050	23,94,765
4	**Segment Liabilities**		
	Segment Liabilities		
1	Gold Diamond and Jewellery	0	0
2	Consultancy fee related to Pharmaceuticals	0	0
	Total Segment Liabilities	0	0
	Un-allocable Liabilities	52,25,050	23,94,765
	Net Segment Liabilities	52,25,050	23,94,765

29. Deferred taxes on Income (IndAS 12):-

The company is entitled to create deferred tax asset in the books of A/cs with respect to timing difference of carried forward Capital Loss as well as depreciation.

30. In the absence of confirmation from some of the parties and pending reconciliation the debit and credit balances with regard to recoverable and payable have been taken as reflected in the books. In the opinion of the Directors, Loans and Advances and Current Assets, if realized in the ordinary course of business, have the value at which they are stated in the Balance Sheet.

31. **Auditors' Remuneration**

Particulars	**31/03/2026**	**31/03/2025**
As Auditor		
Audit Fees	1,750.00	1,250.00
Total	1,750.00	1,250.00

32. Financial Risk Management Objective & Policies

This section gives an overview of the significance of financial instruments for the Company and provides additional information on the balance sheet. Details of significant accounting policies, including the criteria for recognition, the basis of measurement and the basis on which income and expenses are recognised, in respect of each class of financial assets and financial liabilities are disclosed.

I. **Financial Instruments by Category**

Particulars	**Carrying Value**		**Fair Value**	
	31/03/2026	**31/03/2025**	**31/03/2026**	**31/03/2025**
FINANCIAL ASSETS				
At Amortized Cost				
Non-Current Loans & Advances	5,47,558.00	8,28,173.84	5,47,558.00	8,28,173.84
Others – Security Deposit	1,350.00	55,000.00	1,350.00	55,000.00
Trade Receivables	2,91,587.00	50,795.65	2,91,587.00	50,795.65
Current Loans & Advances	86,350.00	74,045.01	86,350.00	74,045.01
TOTAL	**9,26,845.00**	**10,08,014.50**	**9,26,845.00**	**10,08,014.50**
FINANCIAL LIABILITIES				
Short Term Borrowings	37,281	60,846	37,281	60,846
Trade Payables	33,502	66,618	33,502	66,618
TOTAL	**70,783**	**1,27,464**	**70,783**	**1,27,464**

The management has assessed that the fair value of current and non-current loan and advances, other non-current asset, trade receivables approximate their carrying amounts largely due to the short term maturities of these instruments.

The fair value of Investments are based on the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

1) The fair values of the quoted equity shares are based on price quotations at the reporting date.
2) Investment in Subsidiary and Associate Companies are carried at cost.
3) The fair values of the unquoted debentures, mutual fund and equity shares have been estimated using Net Asset Value (NAV) as at reporting date.

The valuation of unquoted equity shares requires management to make certain assumptions about the Model Inputs, including forecast of cash flows, discount rate, credit risk and volatility. The probabilities of the various estimates within range can be reasonably assessed and are used in management's estimate of fair value for these unquoted shares. Wherever, the probability is low, valuation has been done based on redemption assumptions.

Fair Value Hierarchy

The different levels have been defined below:
Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities
Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices)
Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs)

Quantitative disclosures fair value measurement hierarchy for assets

As at 31st March 2026 :		**Fair value measurement using**		
Particulars	**Total**	**Level 1**	**Level 2**	**Level 3**
Asset measured at fair value:				
Investment at fair value through OCI				
Investment in quoted equity shares	27,39,652.03	27,39,652.03	NIL	NIL
Investment in unquoted equity shares	1,16,250.00	NIL	1,16,250	NIL
Investment in Gold	NIL	NIL	NIL	NIL
Investment in Rupee Co-op bank	NIL	NIL	NIL	NIL

During the year Company invested in Unquoted Shares of Subsidiary, Associates and Joint Venture as well.

As at 31st March 2025 :	Fair value measurement using			
Particulars	**Total**	**Level 1**	**Level 2**	**Level 3**
Asset measured at fair value:				
Investment at fair value through OCI				
Investment in quoted equity shares	NIL	NIL	NIL	NIL
Investment in unquoted equity shares	1,23,084.00	NIL	1,23,084.00	NIL
Investment in Gold	4,36,272.87	4,36,272.87	NIL	NIL
Investment in Rupee Co-op bank	NIL	NIL	NIL	NIL

There have been no transfers between Level 1 and Level 2 during the period.

33. Ratio Analysis

The table for ratio analysis is enclosed below in **Annexure A**

34. Other Statutory Information

I. The company has not traded or invested in crypto currency or virtual currency during the financial year.

II. As per information available, the company has no transactions which are not recorded in the books of accounts and which are surrendered or disclosed as income during the year in the tax assessment or in search or survey or under any other relevant provisions of the Income Tax Act, 1961.

III. The company is not covered under the requirements of Section 135 of the Companies Act, 2013, with respect to the CSR activities.

IV. The company is holding all the immovable properties in its own name as investment.

V. The company do not hold any benami property and no proceedings has been initiated or pending against the company for holding any benami property under Benami Transactions (Prohibition) Act 1988 and rules made there under

VI. The company has not been declared as willful defaulter by any bank or financial Institution or any other lender during the year.

VII. The company do not had any transactions during the year with the companies which are struck off under section 248 of the companies Act 2013 or section 560 of the companies Act 1956.

VIII. The company does not have any charge which are required to be registered with ROC under the terms of the loans & liabilities.

IX. As per the information & details available on records and the disclosure given by the management, the company has complied with the number of layers prescribed under clause (87) of section 2 of the companies Act read with the Companies (Restriction on number of layers) Rules 2017.

35. The figures for the previous year have been regrouped / rearranged / reclassified wherever necessary.

As per our report of even date attached

For V R S K & Co. LLP	**For Deep Health AI India Limited**
(Formerly known as V R S K & Co.)	(Formerly known as Deep Diamond India Limited)
Chartered Accountants	
Firm reg No. 111426W/W100988	

(Suresh G. Kothari)	(Narayan Singh Rathore)	(Laveena Pokharna)
Partner	**Managing Director**	**Whole Time Director**
M.No.047625	(DIN - 10900646)	(DIN - 10977709)
UDIN: 26047625VVAWOL4406		
Place: Mumbai		
Date: May 29, 2026		

Rakesh Vishnoi
(Company Secretary)

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Financial Ratios :

Ratio	Current period	Previous period	% variance	Reason for variance
(a) Current ratio	19.34	3.03	537.79%	Increase in current assets compared to current liabilities during the year.
(b) Debt-equity ratio	0.01	0.03	-73.44%	Reduction in borrowings and increase in shareholders' funds during the year
(c) Debt service coverage ratio	4.68	0.93	403.75%	Improvement in earnings available for debt servicing during the year.
(d) Return on equity ratio	3.52%	4.03%	-12.64%	Increase in shareholders' equity was higher than the increase in net profit during the year.
(e) Inventory turnover ratio	0%	0%	NA	No inventory transactions during the year.
(f) Trade receivables turnover ratio	2.48	1.28	93.53%	Increase in credit sales and better recovery from debtors during the year.
(g) Trade payables turnover ratio	-	0.23	-100.00%	No significant credit purchases/payables during the current year.
(h) Net capital turnover ratio	32.54%	38.64%	-15.78%	Increase in operating and other expenses reduced the profit margin during the year.
(i) Net profit ratio*	30.57%	68.36%	-55.29%	Increase in operating and other expenses reduced the profit margin during the year.
(j) Return on capital employed	3.37%	4.61%	-26.93%	The increase in capital employed during the year was not proportionately matched by growth in earnings before interest and taxes, resulting in a decline in the ratio.
(k) Return on investment	-21.33%	11.85%	-280.01%	The ratio declined significantly due to lower returns and reduction in the market value of investments during the year as compared to the previous year.

INDEPENDENT AUDITORS' REPORT

TO THE MEMBERS OF
DEEP HEALTH AI INDIA LIMITED
(Formerly known as Deep Diamond India Limited)

Report on the Audit of Consolidated Financial Statements

Opinion

We have audited the accompanying Consolidated Financial Statements of **DEEP HEALTH AI INDIA LIMITED** (hereinafter referred to as the 'Parent Company") and Associate Company Ferry Automotive Private Limited (together referred to as "Group"), which comprise the Balance Sheet as at March 31, 2026, and the Statement of Profit and Loss including Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and notes to the Financial Statements, including a summary of significant accounting policies and other explanatory information (collectively referred to as 'Consolidated Financial Statements').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated Financial Statements give the information required by the Companies Act, 2013 (hereinafter referred to as "the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026 and its profit, total comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Consolidated Financial Statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Standalone Financial Statements of the current period. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Sr. No.	Key Audit Matter	Auditor's response
1.	**Accounting implications arising from acquisition under Insolvency Resolution Process** The Company has proposed to acquire Oasis Ceramics Pvt. Ltd. pursuant to the Resolution Plan approved by the Hon'ble National Company Law Tribunal ("NCLT") under the Insolvency and Bankruptcy Code, 2016. As per the approved Resolution Plan, the Company was required to pay total acquisition consideration of ₹32 crore. The Company has paid ₹55 lakh as Earnest Money Deposit (EMD) and ₹2 crore towards the consideration; however, the balance amount could not be remitted within the stipulated timeline. Accordingly, the Company filed an application before the Hon'ble NCLT seeking extension of time for payment of the balance consideration and related reliefs, which remains pending as at the reporting date. Meanwhile, the Resolution Professional invoked the bank guarantee amounting to ₹3.21 crore. Further, members of the Committee of Creditors initiated proceedings consequent to non-compliance with the payment timelines prescribed under the approved Resolution Plan. In the minutes of the meeting of the Committee of Creditors, a resolution was also passed to consider initiation of the liquidation process. Based on management's assessment of the prevailing circumstances, the Company recognised the amount paid and the bank guarantee invoked as an exceptional loss in the standalone financial results. This matter was considered significant to our audit due to the materiality of the amounts involved, ongoing legal and contractual uncertainties, and the significant management judgement involved in determining the related accounting treatment and disclosures. Refer 25.ii to the Standalone Financial Statements	**Principal Audit Procedures Performed included the following:** • We obtained an understanding of the approved Resolution Plan and evaluated management's process for accounting of acquisition-related transactions and contingencies. • We inspected relevant documents including the NCLT order, application filed before the Hon'ble NCLT, correspondence with the Resolution Professional and Committee of Creditors, and other related records. • We evaluated management's assessment regarding the likelihood and financial implications of liquidation proceedings of Oasis Ceramics Pvt. Ltd. and pending legal matters. • We verified payments made towards acquisition consideration, invocation of the bank guarantee and related accounting entries using supporting bank documents and records. • We assessed the appropriateness of the accounting treatment adopted for recognition of exceptional loss in accordance with the applicable accounting standards. • We reviewed the disclosures made in the standalone financial results to assess whether they adequately describe the nature of the transaction, uncertainties involved and consequential financial impact.

2.	**Utilization of Proceeds from Right Issue and Deviation from Objects Stated in the Letter of Offer.** During the year, the Company raised an amount of Rs. 39.97 crore through a Rights Issue. As disclosed in the Letter of Offer, the proceeds were proposed to be utilised, inter alia, towards acquisition of Oasis Ceramics Private Limited pursuant to the provisions of the Insolvency and Bankruptcy Code, 2016, for general corporate purposes and to meet the issue expense. Out of the total proceeds raised, the Company has utilised Rs.2.5 crore towards the objects stated in the Letter of Offer. The balance amount of Rs. 37.47 crore was utilised for purposes other than those specified in the Letter of Offer, namely investment in securities through recognised stock exchange. The aforesaid deviation in utilisation of issue proceeds was subsequently ratified by the shareholders at the Extra-Ordinary General Meeting held on 22nd January 2026. Considering the significance of the amount involved, regulatory compliances relating to utilisation of issue proceeds and adequacy of related disclosures in the financial statements, the matter was considered to be a Key Audit Matter. Refer 25.iii to the Standalone Financial Statements	**Principal Audit Procedures Performed included the following:** • Obtained and examined the Letter of Offer and related Board and shareholder resolutions pertaining to the Rights Issue; • Verified the utilisation of Rights Issue proceeds with supporting bank statements, books of account and underlying documents; • Examined the nature and purpose of utilisation of funds and assessed whether the same was in accordance with the objects stated in the Letter of Offer; • Verified the approval and ratification obtained from shareholders in the Extra-Ordinary General Meeting held on 22nd January 2026 in respect of the deviation in utilisation of proceeds; and • Assessed the adequacy and appropriateness of disclosures made in the financial statements in respect of utilisation and deviation of Rights Issue proceeds.

Other Information

The Parent Company's Board of Directors are responsible for the other information. The other information comprises the information included in the annual report, but does not include the Consolidated Financial Statements and our auditor's report thereon.

Our opinion on the Consolidated Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.
In connection with our audit of the Consolidated Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Consolidated Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report the fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Parent Company's Board of Directors is responsible for the preparation and presentation of these Consolidated Financial Statements in term of the requirements of the Companies Act, 2013 that give a true and fair view of the consolidated financial position, consolidated financial performance including Other Comprehensive Income, consolidated cash flows and consolidated Changes in Equity of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Statements by the Directors of the Parent Company, as aforesaid.

In preparing the Consolidated Financial Statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion, The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Group has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Statements, including the disclosures, and whether the Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Consolidated Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Consolidated Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

The Consolidated Financial Statements/information comprised in the Group's Consolidated Financial Statements are inclusive of Rs.17.16 lacs being the net Profit of its associate company being the Parent's share for the year ended 31st March, 2026. Financial statements of subsidiary and associate company have been audited by other auditors, whose reports have been furnished to us by the management of the Parent Company and our opinion on the consolidated financial statements, in so far as it relates to the said amounts and disclosures is based solely on the report of such other auditors.

The Parent Company has disposed of its investment in the joint venture, namely Hemonc Pharma Private Limited on 28.03.2026. Further, the Company has initiated strike off process for its subsidiary, namely Microcure Biotech Private. Limited under Companies Act,2013.

Our opinion on the Consolidated Financial Statements is not modified in respect of the above matters with respect to our reliance on the financial statements audited by other auditors.

Report on Other Legal and Regulatory Requirements

As required by Section 143(3) of the Act, we report, to the extent applicable, that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid Consolidated Financial Statements;

b) In our opinion, proper books of account as required by law to be maintained by the Group including relevant records relating to preparation of the aforesaid Consolidated Financial Statements, have been kept so far as it appears from our examination of those books and records of the Parent Company;

c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss including Other Comprehensive Income, the Consolidated Cash Flow Statement and the Consolidated Statement of Changes in Equity dealt with by this Report are in agreement with the relevant books of account and records maintained by the Group for the purpose of preparation of the Consolidated Financial Statements;

d) In our opinion, the aforesaid Consolidated Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2015 as amended.

e) On the basis of written representations received from the directors of the Group Companies as on March 31, 2026, and taken on record by the respective Board of Directors, none of the directors of the Group Companies is disqualified as on March 31, 2026, from being appointed as a director in terms of Section 164 (2) of the Act;

f) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the Parent Company has not paid and provided remuneration to its directors during the year.

g) With respect to the adequacy of the internal financial controls over financial reporting and the operating effectiveness of such controls relevant to the Parent Company's preparation of the Consolidated Financial Statements, we refer to Annexure-B of our report of even date on the Standalone Financial Statements of the Parent Company; and

h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us, we report that:

i) There were no pending litigations which would impact the consolidated financial position of the Group.

ii) The Group did not have any material foreseeable losses on long-term contracts including derivative contracts.

iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Parent Company and its Associate Companies.

iv) (a) As per the information and explanation given to us by the management, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Parent Company to or in any other person or entity, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Parent Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) As per the information and explanation given to us by the management, no funds have been received by the Parent Company from any person or entity, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

(c) On the basis of above representations, nothing has come to our notice that has caused us to believe that the above representations contained any material mis-statement.

v) The Company has declared and paid dividend during the year in compliance with the provisions of Section 123 of the companies Act,2013 to the extent applicable.

vi) Based on our examination, which included test checks, and other generally accepted audit procedures performed by us, we report that the company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit, we did not come across any instance of audit trail feature being tampered with and the audit trail has been preserved by the Company as per the statutory requirements for record retention.

For and on behalf of
V R S K & CO. LLP
(Formerly known as V R S K & Co)
Chartered Accountants
Firm Regn No. 111426W/W100988

(Suresh G. Kothari)
Partner
Membership No. 047625
UDIN : 26047625WHKKHS5439

Place: Mumbai
Dated: May 29, 2026

Corporate information

Deep Health AI Limited (the Company) is domiciled in India and is incorporated under the provisions of the Companies Act, 1956 applicable in India. Its shares are listed on Bombay Stock Exchange in India. The Company is engaged in the business Rough & Polished Diamonds, sale, and trading of diamond studded jewellery & Gold Jewellery. From financial year 2022-23 the company has also started business of providing consultancy service to Pharmaceutical Industry.

During the year, the Company shifted its registered office from 309, 3rd Floor, V Star Plaza, Plot No. 16, Chandavarkar Road, Opp. Saraswat Bank, Borivali West, Opposite Raj Mahal Hotel, Mumbai, Maharashtra – 400092 to 506–509, Fifth Floor, Apeksha, Plot No. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan – 313001.

The Company has also changed its name from Deep Diamond India Limited to Deep Health AI Limited, in accordance with the applicable provisions of the Companies Act, 2013 and subject to the requisite approvals.

1. Statement of compliance:

The Consolidated financial statements of Deep Health AI Limited (the "Company") and its subsidiary, associates and joint ventures (together "the group") have been prepared in accordance with the provisions of the Companies Act, 2013 and the Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) issued by Ministry of Corporate Affairs in exercise of the powers conferred by section 133 read with sub-section (1) of section 210A of the Companies Act, 2013. In addition, the guidance notes/announcements issued by the Institute of Chartered Accountants of India (ICAI) are also applied along with compliance with other statutory promulgations require a different treatment.

2. Basis of Preparation of Financial Statements

These consolidated financial statements of the Company havebeen prepared in accordance with IndAS prescribed under section 133 of the Companies Act, 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015, the companies (Indian Accounting Standards) Amendment Rules, 2016 and the Companies (Indian Accounting Standards) Amendment Rules, 2017.

The Consolidated Financial Statements have been prepared on a going concern basis using historical cost convention and on an accrual method of accounting, except for certain financial assets and liabilities, which have been measured at fair value as described below:

3. Fair Value Measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date.Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderlytransaction between market participants at the measurement date. The fair value measurement is based onthe presumption that the transaction to sell the asset or transfer the liability takes place either:

(i) In the principal market for the asset or liability, **or**

(ii) In the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

Fair value for measurement and /or disclosure purpose in these financial statements is determined on such basis, except for share based payment transactions that are within the scope of Ind As 102, leasing transactions that are within the scope of Ind As 17, and measurements that have some similarities to fairvalue, such as net realisable value in Ind As 2 or value in use in Ind As 36.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities
Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
Level 3 — Valuation techniques for which the lowest level input that is significant to the fair valuemeasurement is unobservable

Management determines the policies and procedures for both recurring fair value measurement, such as derivative instruments and unquoted financial assets measured at fair value, and for non-recurring measurement, such as assets held for distribution in discontinued operations.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on thebasis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

4. Principles of Consolidation:

The Consolidated Financial Statements incorporate the financial statements of the Holding Company and its subsidiaries (collectively referred as "the Group").

a. Subsidiaries are entities controlled by the Holding Company. The Holding Company controls an entity when it is exposed or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are consolidated from the date of their acquisition, being the date on which the Holding Company obtains control and continue to be consolidated until the date that such control ceases.

The Consolidated Financial Statements are prepared using uniform accounting policies consistently for material like transactions and other events in similar circumstances and are presented to the extent possible, in the same manner as the Holding Company's Standalone Financial Statements except otherwise stated. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies.

The Consolidated Financial Statements have been prepared by combining the financial statements of the Holding Company and its subsidiaries on a line-by-line basis by adding together the book values of like items of assets, liabilities, equity, income, expenses and cash flow after eliminating in full intra-group assets, liabilities, equity, income, expenses and cash flow relating to intra-group transactions and unrealized profits. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Such unrealized profit/losses are fully attributed to the Holding Company.

Profit or loss and each component of other comprehensive income are attributed to the owners of the Holding Company and to the non-controlling interests. Total comprehensive income is attributed to the owners of the Holding Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

Changes in the Group's ownership interests in subsidiaries that do not result in the Group losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the Group's interests and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognised directly in equity and attributed to the owners of the Holding Company.

When the Group loses control of a subsidiary, a gain or loss is recognised in the consolidated statement of profit and loss and is calculated as the difference between

(i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and

(ii) the previous carrying amount of the assets (including goodwill) and liabilities of the subsidiary and any non-controlling interests. All amounts previously recognised in other comprehensive income in relation to that subsidiary are accounted for as if the Group had directly disposed of the related assets or liabilities of the subsidiary (i.e. reclassified to the consolidated statement of profit and loss or transferred to another category of equity as specified/permitted by applicable Ind AS). The fair value of any investment retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under Ind AS 109, or, when applicable, the cost on initial recognition of an investment in an associate or a joint venture.

b. An Associate is an entity over which the Group has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but is not control or joint control over those policies. This is generally the case where the Group holds between 20% and 50% of the voting rights. Investments in associates are accounted for using the equity method of accounting, after initially being recognised at cost.

The results and assets and liabilities of associates are incorporated in these consolidated financial statements using equity method of accounting. Under the equity method, an investment in associate is initially recognised in the consolidated balance sheet at cost and adjusted thereafter to recognise the Group's share of profit or loss and other comprehensive income of the associate. Distributions received from an associate reduce the carrying amount of the investment. When the Group's share of losses of an associate exceeds the Group's interest in that associate, the Group discontinues recognising its share of further losses. Additional losses are recognised only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the associate.

Unrealised gains on transactions between the Group and its associates are eliminated to the extent of the Group's interest in these entities. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of equity accounted investees have been changed where necessary to ensure consistency with the policies adopted by the Group.

The carrying amount of investment in associates is reduced to recognize impairment, if any, when there is objective evidence of impairment.

5. The Consoidated financials includes the following Companies in accordance with the provisions of Companies Act 2013 and IndAS:

Name of Associate	**As at 31st March, 2026**		**As at 31st March, 2025**	
	Proportion of Ownership Interest (%)	Proportion of Voting Power (%)	Proportion of Ownership Interest (%)	Proportion of Voting Power (%)
Mircocure Biotech Private Limited	0.00%	0.00%	100.00%	100.00%
Ferry Automotive Private Limited	33.33%	33.33%	33.33%	33.33%
Hemonc Pharma Private Limited	0.00%	0.00%	50.00%	50.00%

6. Use of estimates and judgments:

The preparation of consolidated financial statements inconformity with Ind AS requires that the management of the Company estimates and assumptions that affect the reported amounts of income and expenses of the period, the reported balances of assets and liabilities and the disclosures relating to contingent liabilities as of the date of the financial statements. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates include expected credit loss on loan books, fair value measurement etc.

Difference, if any, between the actual results and estimates is recognised in the period in which the results are known.

Significant Accounting Policies

(i) Property, Plant and Equipment

The initial cost of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, attributable borrowing cost and any other directly attributable costs of bringing an asset to working condition and location for its intended use. It also includes the present value of the expected cost for the decommissioning and removing of an asset and restoring the site after its use, if the recognition criteria for a provision are met.

Expenditure incurred after the property, plant and equipment have been put into operation, such as repairs and maintenance, are normally charged to the statements of profit and loss in the period in which the costs are incurred. Major inspection and overhaul expenditure is capitalized if the recognition criteria are met.

When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in the statement of profit and loss as incurred.

Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognized net within other income/other expenses in statement of profit and loss.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss, when the asset is derecognised.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

(ii) Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. The Company's income from operation is accounted for on accrual basis. Revenue from sales of Gold and Diamonds is recognized on delivery of the products, when all significant contractual obligations have been satisfied, the property in the goods is transferred for a price significant risks & rewards of ownership are transferred to the customers and no effective ownership is retained. Interest is recognized using the time-proportion method, based on rates implicit in the transaction. Dividend income is recognised when the Company right to receive dividend is established by the reporting date and no significant uncertainty as to collectability exists

(iii) Taxation

Current Tax

A provision for current income tax is made on the taxable income using the applicable tax rates and tax laws.

Deferred Tax

Deferred tax arising on account of timing differences and which are capable of reversal in one or more subsequent periods is recognized using the tax rates and tax laws that have been enacted or substantively enacted. Deferred tax assets are not recognized unless there is a virtual certainty with respect to the reversal of the same in future.

Deferred Tax on Comprehensive Income

Deferred tax arising on account of difference between fair value and cost of Financial Assets. which are capable of reversal in one or more subsequent periods is recognized using the tax rates and tax laws that have been enacted or substantively enacted. Deferred tax assets are not recognized unless there is a virtual certainty with respect to the reversal of the same in future.

(iv) Impairment of Assets

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating units (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or Company's assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered as impaired and is written down to its recoverable amount

Impairment losses are recognised in the statement of profit and loss.

(v) Provisions and Contingencies

The company creates a provision when there is present obligation as a result of a past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of obligation. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that probably will not require an outflow of resources or where a reliable estimate of the obligation cannot be made.

(vi) Employee Benefits

The retirement benefits, Gratuity and Leave encashment benefits will be debited as and when paid.

(vii) Borrowing Costs

Borrowing Costs that are attributable to the acquisition or construction of qualifying assets are capitalised as part of the cost of such assets. A qualifying asset is one that necessarily takes a substantial period of time to get ready for its intended use or sale. All other borrowing costs are charged to revenue. Borrowing costs consists of interest and other costs that an entity incurs in connection with the borrowing of funds.

(viii) Foreign Currency Transactions

a) Transactions in Foreign Currency are accounted at the exchange rate prevailing on the date of Transactions. Exchange fluctuations between the transaction date and the settlement date in respect of Revenue Transactions are recognized in Profit & Loss Account.

b) All export proceeds not realised at the yearend are restated at the rate prevailing at the year end. The exchange difference arising there from has been recognised as income / expenses in the Current Year's Profit & Loss A/c along with underlying transaction.

c) The premium or discount arising at the inception of forward exchange contract is amortised as expense or income over the life of the contract. Exchange differences on such contracts are recognised in the statement of profit and loss in the year in which the exchange rates change. Any profit or loss arising on cancellation or renewal of forward exchange contracts is recognised as income or as expense for the year. None of the forward exchange contracts are taken for trading or speculation purpose.

(ix) Cash flow Statement

Cash flows are reported using the indirect method, whereby the net profit before tax is adjusted for the effects of transactions of a non-cash nature, any defects or accruals of past or future operating cash receipts and payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the company are segregated.

(x) Cash and Cash Equivalent

Cash and Cash Equivalents for the purpose of cash flow statement comprise cash in hand and cash at bank including fixed deposit with original maturity period of three months and short term highly liquid investments with an original maturity of three months or less.

(xi) Inventories

Inventories are valued at the lower of cost and net realisable value except scrap and by products which are valued at net realisable value.

Costs incurred in bringing the inventory to its present location and conditions are accounted for as follows:

- Raw materials: cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is determined on weighted average basis.
- Finished goods and work in progress: cost includes cost of direct materials and labour and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs. Cost is determined on weighted average basis.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

Obsolete inventories are identified and written down to net realisable value. Slow moving and defective inventories are identified and provided to net realisable value.

(xii) Earnings Per Share(EPS)

Basic and diluted EPS is computed by dividing the net profit attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year.

DEEP HEALTH AI INDIA LIMITED

CIN:-L24100RJ1994PLC112895

Consolidated Balance Sheet as at 31st March 2026

Rs. In Hundreds

Particulars	Note No.	As at 31st March, 2026	As at 31st March, 2025
(1) ASSETS			
(A) Non-current assets			
(i) Property Plant & Equipment	Note - 2	1,034	1,489
(ii) Financial Assets			
(a) Investments	Note - 3	32,82,001	10,00,818
(b) Loans & Advances	Note - 4	5,47,558	8,49,470
(c) Others	Note - 5	-	55,000
(B) Current assets			
(i) Inventories	Note - 6	51,457	51,457
(ii) Financial Assets			
(a) Trade Receivables	Note - 7	2,91,587	50,796
(b) Cash & Cash Equivalents	Note - 8	8,33,847	3,32,390
(c) Loans & Advances	Note - 9	86,350	52,749
(iii) Current Tax Assets (Net)	Note - 10	1,14,056	258
Total Assets		**52,07,891**	**23,94,425**
(2) EQUITY AND LIABILITIES			
(A) Equity			
(i) Equity Share capital	Note - 11	14,41,500	4,80,500
(ii) Other Equity	Note - 12	36,95,168	17,53,257
(B) LIABILITIES			
(i) Non-Current liabilities			
(ii) Current liabilities			
(a) Financial Liabilities			
i) Borrowings	Note - 13	37,281	60,846
ii) Trade Payables	Note - 14	33,502	66,618
(b) Other Current Liabilities	Note - 15	-	18,280
(c) Current Tax Liabilities (Net)	Note - 16	440	14,923
Total Equity and Liabilities		**52,07,891**	**23,94,425**

See accompanying notes to the financial statements

Significant Accounting Policies Note - 1

Other Notes on accounts from Nos. 24 to 36 are an integral part of the Financial Statements

This is the Balance Sheet referred to in our Report of even date.

For V R S K & CO. LLP
(Formerly known as V R S K & Co)
Chartered Accountants
Firm No.: 111426W/W100988

For DEEP HEALTH AI INDIA LIMITED
(Formerly known as Deep Diamond India Ltd)

Narayan Singh Rathore
Managing Director
(DIN - 10900646)

Laveena Pokharna
Whole Time Director
(DIN - 10977709)

Suresh G. Kothari
Partner
Membership No. 047625
UDIN: 26047625WHKKHS5439
Date : May 29,2026
Place : Mumbai

Rakesh Vishnoi
Company Secretary

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Consolidated Statement of Profit and loss for the year ended 31st March , 2026

	Particulars	Note No.	For the year ended 31st March, 2026	For the year ended 31st March, 2025
			Rs. In Hundreds	Rs. In Hundreds
I.	Revenue from operations	Note - 17	4,25,000	1,25,909
II.	Other income	Note - 18	4,24,023	74,630
III.	**Total Income (I + II)**		**8,49,023**	**2,00,538**
IV.	Expenses:			
	1. Cost of material consumed		-	-
	2. Purchase of Stock -in-Trade		-	-
	3. Changes in inventories of finished goods work-in-		-	-
	progress and Stock -in-Trade	Note -19	-	14,506
	4. Employee benefits expense	Note - 20	18,806	16,735
	5. Finance costs	Note - 21	2,713	9,424
	6. Depreciation and Amortization	Note - 2	814	1,113
	7. Other expenses	Note - 22	72,640	49,156
				-
	Total expenses (IV)		**94,973**	**90,935**
V.	**Profit/(loss) before exceptional items and Tax**		7,54,050	1,09,604
VI.	**Exceptional Items**			
	Loss on Business Acquisition/Undertaking		**5,77,167**	
VII.	**Profit before tax (III-IV)**		1,76,883	1,09,604
	Share of Profit /(Loss) in Associates		(17,159)	1,908
	Share of Profit /(Loss) in Joint Venture			(75)
	Net Profit		1,59,724	1,11,437
VIII.	Tax expense: Provision for Taxation			
	1. Current tax			
	i. Current year		46,331	27,755
	ii. Earlier years			(3,969)
	2. Deferred tax		-	-
	Profit (Loss) for the period /Profit After Tax (V - VI)		1,13,393	87,651
IX.	**Other Comprehensive Income**			
	1. Other Comprehensive Income not to be reclassified to profit and loss in subsequent periods		-	
	2. Net Gain/(Loss) on FVTOCI Investments		(10,24,076)	1,06,210
	3. Deferred Tax Asset on Comprehensive Income		-	-
X.	**Total Income for the period (VI - VII)**		**(9,10,684)**	**1,93,861**
	(Profit/ loss + other comprehensive income)			
XI.	**Earnings per equity share :**			
	1. Basic (in Rupees)	Note 23	0.12	0.18
	2. Diluted (in Rupees)		0.12	0.18

See accompanying notes to the financial statements
Significant Accounting Policies Note - 1
Other Notes on accounts from Nos. 24 to 36 are an integral part of the Financial Statements

For V R S K & CO. LLP
(Formerly known as V R S K & Co)
Chartered Accountants
Firm No.: 111426W/W100988

For DEEP HEALTH AI INDIA LIMITED
(Formerly known as Deep Diamond India Limited)

SD/-
Narayan Singh Rathore
Managing Director
(DIN - 10900646)

SD/-
Laveena Pokharna
Whole Time Director
(DIN - 10977709)

SD/-
Suresh G. Kothari
Partner
Membership No. 047625
UDIN: 26047625WHKKHS5439
Date : May 29,2026
Place : Mumbai

SD/-
Rakesh Vishnoi
Company Secretary

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Consolidated Cash Flow Statement for the year ended March 31, 2026

Rs. In Hundreds

	Particulars	As at 31st March, 2026	As at 31st March, 2025
A.	**Cash flow from operating activities:**		
	Profit/(loss) before tax	**1,59,724**	**1,11,437**
	Adjustments for:		
	Share of profit in group companies	17,159	(1,908)
	Share of Expenses from Group Companies	(1,797)	75
	Depreciation	814	1,113
	Finance Cost	2,713	9,424
	Short term Capital Gain	(3,29,467)	-
	Profit on sale of fixed assets(net)	-	48
	Dividend income	(62)	
	Interest income	(71,171)	(74,059)
	Operating profit before working capital changes	**(2,22,087)**	**46,130**
	Adjustments for:		
	Trade and Other Receivables	(2,40,791)	94,712
	Inventories	-	14,506
	Loans and Advances	3,23,311	(6,431)
	Other Current Tax Liabilities	(13,644)	10,859
	Trade Payable & Provisions	(51,396)	(8,972)
	Cash (used in)/generated from operations	(2,04,608)	**1,50,804**
	Income Tax Paid/Refund (Net)	(1,60,969)	-16,748
	Net cash (used in)/from operating activities	**(3,65,577)**	**1,34,057**
B.	**Cash flow from investing activities:**		
	Purchases & Sale of fixed Assets	(360)	(98)
	Sale of Investment	12,44,037	-
	Purchase of Investment	(42,35,192)	(97,216)
	Interest Income	71,171	74,059
	Dividend Income	62	-
	Cash (used in)/from investing activities	**(29,20,281)**	**(23,255)**
C.	**Cash flow from financing activities:**		
	Proceeds from fresh issue of share capital	39,97,760	-
	Repayment of short term borrowings	(23,565)	-
	Right issue expense	(40,016)	-
	Dividend paid during the year	(1,44,150)	(1,05,609)
	Finance Cost	(2,713)	(9,424)
	Net cash (used in)/ from financing activities	**37,87,316**	**(1,15,033)**
	Net (decrease)/increase in cash and cash equivalents (A + B + C)	5,01,457	(4,231)
	Cash and cash equivalents at beginning of the year	**3,32,390**	**3,36,621**
	Cash and cash equivalents at end of the year	**8,33,847**	**3,32,390**

Previous year's figures have been reworked, regrouped and rearranged wherever necessary.

As per our Report of even date

For V R S K & CO. LLP
(Formerly known as V R S K & Co)
Chartered Accountants
Firm No.: 111426W/W100988

SD/-
Suresh G. Kothari
Partner
Membership No. 047625
UDIN: 26047625WHKKHS5439
Date : May 29,2026
Place : Mumbai

For DEEP HEALTH AI INDIA LIMITED
(Formerly known as Deep Diamond India Limited)

SD/-
Narayan Singh Rathore
Managing Director
(DIN - 10900646)

SD/-
Laveena Pokharna
Whole Time Director
(DIN - 10977709)

SD/-
Rakesh Vishnoi
Company Secretary

DEEP HEALTH AI INDIA LIMITED

CIN: - L24100RJ1994PLC112895

Notes to the Consolidated Financial Statements for the Year Ended 31st March, 2026

Corporate information

Deep Health AI Limited (the Company) is domiciled in India and is incorporated under the provisions of the Companies Act, 1956 applicable in India. Its shares are listed on Bombay Stock Exchange in India. The Company is engaged in the business Rough & Polished Diamonds, sale, and trading of diamond studded jewellery & Gold Jewellery. From financial year 2022-23 the company has also started business of providing consultancy service to Pharmaceutical Industry.

During the year, the Company shifted its registered office from 309, 3rd Floor, V Star Plaza, Plot No. 16, Chandavarkar Road, Opp. Saraswat Bank, Borivali West, Opposite Raj Mahal Hotel, Mumbai, Maharashtra – 400092 to 506–509, Fifth Floor, Apeksha, Plot No. 256, Main Road, Hiran Magri, Sector 11, Udaipur, Rajasthan – 313001.

The Company has also changed its name from Deep Diamond India Limited to Deep Health AI Limited, in accordance with the applicable provisions of the Companies Act, 2013 and subject to the requisite approvals.

1. Statement of compliance:

The Consolidated financial statements of Deep Health AI Limited (the "Company") and its subsidiary, associates and joint ventures (together "the group") have been prepared in accordance with the provisions of the Companies Act, 2013 and the Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) issued by Ministry of Corporate Affairs in exercise of the powers conferred by section 133 read with sub-section (1) of section 210A of the Companies Act, 2013. In addition, the guidance notes/announcements issued by the Institute of Chartered Accountants of India (ICAI) are also applied along with compliance with other statutory promulgations require a different treatment.

2. Basis of Preparation of Financial Statements

These consolidated financial statements of the Company havebeen prepared in accordance with IndAS prescribed under section 133 of the Companies Act, 2013 read together with the Companies (Indian Accounting Standards) Rules, 2015, the companies (Indian Accounting Standards) Amendment Rules, 2016 and the Companies (Indian Accounting Standards) Amendment Rules, 2017.

The Consolidated Financial Statements have been prepared on a going concern basis using historical cost convention and on an accrual method of accounting, except for certain financial assets and liabilities, which have been measured at fair value as described below:

3. Fair Value Measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date.Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderlytransaction between market participants at the measurement date. The fair value measurement is based onthe presumption that the transaction to sell the asset or transfer the liability takes place either:

(i) In the principal market for the asset or liability, **or**
(ii) In the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

Fair value for measurement and /or disclosure purpose in these financial statements is determined on such basis, except for share based payment transactions that are within the scope of Ind As 102, leasing transactions that are within the scope of Ind As 17, and measurements that have some similarities to fairvalue, such as net realisable value in Ind As 2 or value in use in Ind As 36.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities
Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
Level 3 — Valuation techniques for which the lowest level input that is significant to the fair valuemeasurement is unobservable

Management determines the policies and procedures for both recurring fair value measurement, such as derivative instruments and unquoted financial assets measured at fair value, and for non-recurring measurement, such as assets held for distribution in discontinued operations.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on thebasis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

4. <u>Principles of Consolidation:</u>

The Consolidated Financial Statements incorporate the financial statements of the Holding Company and its subsidiaries (collectively referred as "the Group").

a. Subsidiaries are entities controlled by the Holding Company. The Holding Company controls an entity when it is exposed or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are consolidated from the date of their acquisition, being the date on which the Holding Company obtains control and continue to be consolidated until the date that such control ceases.

The Consolidated Financial Statements are prepared using uniform accounting policies consistently for material like transactions and other events in similar circumstances and are presented to the extent possible, in the same manner as the Holding Company's Standalone Financial Statements except otherwise stated. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the Group's accounting policies.

The Consolidated Financial Statements have been prepared by combining the financial statements of the Holding Company and its subsidiaries on a line-by-line basis by adding together the book values of like items of assets, liabilities, equity, income, expenses and cash flow after eliminating in full intra-group assets, liabilities, equity, income, expenses and cash flow relating to intra-group transactions and unrealized profits. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Such unrealized profit/losses are fully attributed to the Holding Company.

Profit or loss and each component of other comprehensive income are attributed to the owners of the Holding Company and to the non-controlling interests. Total comprehensive income is attributed to the owners of the Holding Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

Changes in the Group's ownership interests in subsidiaries that do not result in the Group losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the Group's interests and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognised directly in equity and attributed to the owners of the Holding Company.

When the Group loses control of a subsidiary, a gain or loss is recognised in the consolidated statement of profit and loss and is calculated as the difference between

(i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and
(ii) the previous carrying amount of the assets (including goodwill) and liabilities of the subsidiary and any non-controlling interests. All amounts previously recognised in other comprehensive income in relation to that subsidiary are accounted for as if the Group had directly disposed of the related assets or liabilities of the subsidiary (i.e. reclassified to the consolidated statement of profit and loss or transferred to another category of equity as specified/permitted by applicable Ind AS). The fair value of any investment retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under Ind AS 109, or, when applicable, the cost on initial recognition of an investment in an associate or a joint venture.

b. An Associate is an entity over which the Group has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but is not control or joint control over those policies. This is generally the case where the Group holds between 20% and 50% of the voting rights. Investments in associates are accounted for using the equity method of accounting, after initially being recognised at cost.

The results and assets and liabilities of associates are incorporated in these consolidated financial statements using equity method of accounting. Under the equity method, an investment in associate is initially recognised in the consolidated balance sheet at cost and adjusted thereafter to recognise the Group's share of profit or loss and other comprehensive income of the associate. Distributions received from an associate reduce the carrying amount of the investment. When the Group's share of losses of an associate exceeds the Group's interest in that associate, the Group discontinues recognising its share of further losses. Additional losses are recognised only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the associate.

Unrealised gains on transactions between the Group and its associates are eliminated to the extent of the Group's interest in these entities. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of equity accounted investees have been changed where necessary to ensure consistency with the policies adopted by the Group.

The carrying amount of investment in associates is reduced to recognize impairment, if any, when there is objective evidence of impairment.

5. The Consoidated financials includes the following Companies in accordance with the provisions of Companies Act 2013 and IndAS:

Name of Associate	**As at 31st March, 2026**		**As at 31st March, 2025**	
	Proportion of Ownership Interest (%)	Proportion of Voting Power (%)	Proportion of Ownership Interest (%)	Proportion of Voting Power (%)
Mircocure Biotech Private Limited	0.00%	0.00%	100.00%	100.00%
Ferry Automotive Private Limited	33.33%	33.33%	33.33%	33.33%
Hemonc Pharma Private Limited	0.00%	0.00%	50.00%	50.00%

6. Use of estimates and judgments:

The preparation of consolidated financial statements inconformity with Ind AS requires that the management of the Company estimates and assumptions that affect the reported amounts of income and expenses of the period, the reported balances of assets and liabilities and the disclosures relating to contingent liabilities as of the date of the financial statements. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates include expected credit loss on loan books, fair value measurement etc.

Difference, if any, between the actual results and estimates is recognised in the period in which the results are known.

Significant Accounting Policies

(i) Property, Plant and Equipment

The initial cost of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, attributable borrowing cost and any other directly attributable costs of bringing an asset to working condition and location for its intended use. It also includes the present value of the expected cost for the decommissioning and removing of an asset and restoring the site after its use, if the recognition criteria for a provision are met.

Expenditure incurred after the property, plant and equipment have been put into operation, such as repairs and maintenance, are normally charged to the statements of profit and loss in the period in which the costs are incurred. Major inspection and overhaul expenditure is capitalized if the recognition criteria are met.

When significant parts of plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. Likewise, when a major inspection is performed, its cost is recognised in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognised in the statement of profit and loss as incurred.

Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognized net within other income/other expenses in statement of profit and loss.

An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss, when the asset is derecognised.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

(ii) Revenue Recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, regardless of when the payment is being made. The Company's income from operation is accounted for on accrual basis. Revenue from sales of Gold and Diamonds is recognized on delivery of the products, when all significant contractual obligations have been satisfied, the property in the goods is transferred for a price significant risks & rewards of ownership are transferred to the customers and no effective ownership is retained. Interest is recognized using the time-proportion method, based on rates implicit in the transaction. Dividend income is recognised when the Company right to receive dividend is established by the reporting date and no significant uncertainty as to collectability exists

(iii) Taxation

Current Tax

A provision for current income tax is made on the taxable income using the applicable tax rates and tax laws.

Deferred Tax

Deferred tax arising on account of timing differences and which are capable of reversal in one or more subsequent periods is recognized using the tax rates and tax laws that have been enacted or substantively enacted. Deferred tax assets are not recognized unless there is a virtual certainty with respect to the reversal of the same in future.

Deferred Tax on Comprehensive Income

Deferred tax arising on account of difference between fair value and cost of Financial Assets. which are capable of reversal in one or more subsequent periods is recognized using the tax rates and tax laws that have been enacted or substantively enacted. Deferred tax assets are not recognized unless there is a virtual certainty with respect to the reversal of the same in future.

(iv) Impairment of Assets

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating units (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or Company's assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered as impaired and is written down to its recoverable amount

Impairment losses are recognised in the statement of profit and loss.

(v) Provisions and Contingencies

The company creates a provision when there is present obligation as a result of a past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of obligation. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that probably will not require an outflow of resources or where a reliable estimate of the obligation cannot be made.

(vi) Employee Benefits

The retirement benefits, Gratuity and Leave encashment benefits will be debited as and when paid.

(vii) Borrowing Costs

Borrowing Costs that are attributable to the acquisition or construction of qualifying assets are capitalised as part of the cost of such assets. A qualifying asset is one that necessarily takes a substantial period of time to get ready for its intended use or sale. All other borrowing costs are charged to revenue. Borrowing costs consists of interest and other costs that an entity incurs in connection with the borrowing of funds.

(viii) Foreign Currency Transactions

a) Transactions in Foreign Currency are accounted at the exchange rate prevailing on the date of Transactions. Exchange fluctuations between the transaction date and the settlement date in respect of Revenue Transactions are recognized in Profit & Loss Account.

b) All export proceeds not realised at the yearend are restated at the rate prevailing at the year end. The exchange difference arising there from has been recognised as income / expenses in the Current Year's Profit & Loss A/c along with underlying transaction.

c) The premium or discount arising at the inception of forward exchange contract is amortised as expense or income over the life of the contract. Exchange differences on such contracts are recognised in the statement of profit and loss in the year in which the exchange rates change. Any profit or loss arising on cancellation or renewal of forward exchange contracts is recognised as income or as expense for the year. None of the forward exchange contracts are taken for trading or speculation purpose.

(ix) Cash flow Statement

Cash flows are reported using the indirect method, whereby the net profit before tax is adjusted for the effects of transactions of a non-cash nature, any defects or accruals of past or future operating cash receipts and payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the company are segregated.

(x) Cash and Cash Equivalent

Cash and Cash Equivalents for the purpose of cash flow statement comprise cash in hand and cash at bank including fixed deposit with original maturity period of three months and short term highly liquid investments with an original maturity of three months or less.

(xi) Inventories

Inventories are valued at the lower of cost and net realisable value except scrap and by products which are valued at net realisable value.

Costs incurred in bringing the inventory to its present location and conditions are accounted for as follows:

- Raw materials: cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition. Cost is determined on weighted average basis.
- Finished goods and work in progress: cost includes cost of direct materials and labour and a proportion of manufacturing overheads based on the normal operating capacity, but excluding borrowing costs. Cost is determined on weighted average basis.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

Obsolete inventories are identified and written down to net realisable value. Slow moving and defective inventories are identified and provided to net realisable value.

(xii) Earnings Per Share(EPS)

Basic and diluted EPS is computed by dividing the net profit attributable to equity shareholders for the year by the weighted average number of equity shares outstanding during the year.

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2026

a. Equity Share Capital

(i). Current reporting period — **Rs. In Hundreds**

Balance at the beginning of the current reporting period	Changes in equity share capital during the current year	Balance at the end of the current reporting period
4,80,500.00	9,61,000	14,41,500.00

(ii). Previous reporting period — **Rs. In Hundreds**

Balance at the beginning of the previous reporting period	Changes in equity share capital during the previous year	Balance at the end of the previous reporting period
4,80,500.00	-	4,80,500.00

b. Other Equity — **Rs. In Hundreds**

Particular	Reserves and Surplus				Total
	Capital Reserve	Retained earnings	Securities Premium	Other Comprehensive Income	
Balance at the beginning of the previous reporting period	20,459	5,87,530	9,27,937	23,471	**15,59,397**
Profit /(Loss) for the year	-	87,651	-	-	**87,651**
Other comprehensive income	-	-	-	1,06,210	**1,06,210**
Total comprehensive income	-	87,651	-	1,06,210	**1,93,860**
Other adjustments	-		-	-	-
Balance at the beginning of the current reporting period	20,459	6,75,181	9,27,937	1,29,680	**17,53,257**
Profit /(Loss) for the year	-	1,13,393	30,36,760	-	**31,50,153**
Other comprehensive income	-	-	-	(10,24,076)	**(10,24,076)**
Total comprehensive income	-	1,13,393	30,36,760	(10,24,076)	**21,26,076**
Dividends	-	(1,44,150)	-	-	**(1,44,150)**
Right Issue Expense	-	-	(40,016)	-	**(40,016)**
Balance at the end of the current reporting period	**20,459**	**6,44,423**	**39,24,681**	**(8,94,396)**	**36,95,168**

As per our Report of even date
For V R S K & CO. LLP
(Formerly known as V R S K & Co)
Chartered Accountants
Firm No.: 111426W/W100988

For DEEP HEALTH AI INDIA LIMITED
(Formerly known as Deep Diamond India Limited)

Narayan Singh Rathore
Managing Director
(DIN - 10900646)

Laveena Pokharna
Whole Time Director
(DIN - 10977709)

Suresh G. Kothari
Partner
Membership No. 047625
UDIN: 26047625WHKKHS5439
Date : May 29,2026
Place : Mumbai

Rakesh Vishnoi
Company Secretary

DEEP HEALTH AI INDIA LIMITED

CIN:-L24100RJ1994PLC112895

Financial Year - 2025-26

Note - 2 : Property Plant & Equipment

Rs. In Hundreds

Fixed Assets	Gross Block				Accumulated Depreciation				Net Block	
	Balance as at 31st March 2025	**Additions**	**Disposals/Retirement**	**Balance as at 31st March 2026**	**Balance as at 31st March 2025**	**Depreciation charge for the year**	**Accumulated Depreciation on assets sold/retired**	**Balance as at 31st March 2026**	**Balance as at 31st March 2026**	**Balance as at 31st March 2025**
Tangible Assets										
Air conditioner	1,031			1,031	1,031		-	1,031	-	-
Furniture & Fittings	1,769		-	1,769	895	336	-	1,231	538	874
Computers	2,366	106	-	2,472	2,162	189	-	2,351	121	204
Office equipment	4,310	254		4,564	4,208	63	-	4,271	292	102
Laptops	1,662	-		1,662	1,353	226		1,579	83	309
Total	11,138	360	-	11,498	9,649	814	-	10,463	1,034	1,489
Previous Year	10,929	13,304	8,315	10,979	8,464	1,063	-	9,528	1,452	2,465

DEEP HEALTH AI INDIA LIMITED

CIN:-L24100RJ1994PLC112895

Financial Year - 2025-26

Note 3 : INVESTMENTS | **Rs. In Hundreds**

Particulars	Face Value	Number	As at 31st March 2026	Number	As at 31st March 2025
Non Current Investments					
A) Investment in Immovable Properties					
Investment in Flats / Bunglow			4,43,258		4,43,258
			4,43,258		**4,43,258**
B) Unquoted Equiy shares					
I) Investment in Associates					
Ferry Automotives Pvt. Ltd.	10	5,000	1,16,250	5,000	1,14,602
@ Rs 2325/- each fully paid up					
Add: Profit /(Loss) for the year			-17,159		1,908
			99,091		**1,16,511**
II) Investment in Subsidiary					
Microcure Biotech Pvt. Ltd.	10	20,000	-	20,000	
@ Rs 9.17 each fully paid up					
Add: Profit /(Loss) for the year					
			-		**-**
III) Investment in Joint Venture					
Hemonc Pharma Pvt. Ltd.	10	50,000	-	50,000	4,850
@ Rs 10/- each fully paid up					
Add: Profit /(Loss) for the year			-		-75
			-		**4,775**
III) Investment in Listed Equity Shares					
Equity Shares			36,34,090		-
Aggregate value of quoted investments			**36,34,090**		**-**
Aggregate value of unquoted investments			**5,42,349**		**5,64,545**
Fair Market Value of Quoted Shares			27,39,652		-
Other Investment					
Investment in Gold			-		4,36,273
			-		**4,36,273**
TOTAL			**32,82,001**		**10,00,818**

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Financial Year - 2025-26

Note - 4 : Loans & Advances - Non Current Asset

Rs. In Hundreds

Loans and advances	As at 31st March, 2026	As at 31st March,2025
Other Loans and Advances	21,290	21,296
Unsecured, considered good		
- Inter corporate Loans *	5,26,268	8,28,174
Total	**5,47,558**	**8,49,470**

(* Intercorporate Loans given are refundable on demand, are interest bearing, are not discounted, therefore valued at their transaction value)

Note - 5 : Other - Non-Current Assets

Rs. In Hundreds

Other Non-Current Assets	As at 31st March, 2026	As at 31st March,2025
Earnest Money Deposit	-	55,000
Total	**-**	**55,000**

*The deposits being refundable, however the refundable time period not being defined hence there is no need for discounting.

Note - 6 : Inventories

Rs. In Hundreds

Inventories	As at 31st March, 2026	As at 31st March,2025
a. Raw Materials	**1,844**	**1,844**
b. Stock in Process	-	-
c. Finished Goods	49,613	49,613
Total	**51,457**	**51,457**

Note - 7 : Trade Receivables

Rs. In Hundreds

Trade Receivables	As at 31st March, 2026	As at 31st March,2025
Unsecured, considered good		
Over Six Months *	-	-
Others *	2,91,587	50,796
Total	**2,91,587**	**50,796**

***1. No lien/charge against trade receivables**
***2. No trade receivables are due from directors or other officers of the Company either severally or jointly with any other person. Nor any trade receivables are due from firms or private companies respectively in which any director is a partner, a director or a member.**

Trade receivables ageing Schedule - for the year 2025-26

	Particulars	*Outstanding for following periods from due date of payment*					
		Less than 6 months	*6 months -1 year*	*1-2 Years*	*2-3 years*	*More than 3 years*	*Total*
(i)	Undisputed Trade receivables – considered good	1,86,087	1,05,500				2,91,587
(ii)	Undisputed Trade Receivables – which have significant increase in credit risk						
(iii)	Undisputed Trade Receivables – credit impaired						
(iv)	Disputed Trade Receivables–considered good						
(v)	Disputed Trade Receivables – which have significant increase in credit risk						
(vi)	Disputed Trade Receivables – credit impaired						
	TOTAL	1,86,087	1,05,500				2,91,587

Trade receivables ageing Schedule - for the year 2024-25

	Particulars	*Outstanding for following periods from due date of payment*					
		Less than 6 months	*6 months -1 year*	*1-2 Years*	*2-3 years*	*More than 3 years*	*Total*
(i)	Undisputed Trade receivables – considered good	50,796	-				50,796
(ii)	Undisputed Trade Receivables – which have significant increase in credit risk						
(iii)	Undisputed Trade Receivables – credit impaired						
(iv)	Disputed Trade Receivables–considered good						
(v)	Disputed Trade Receivables – which have significant increase in credit risk						
(vi)	Disputed Trade Receivables – credit impaired						
	TOTAL	50,796	-				50,796

Note - 8 : Cash & Cash Equivalents

Rs. In Hundreds

Cash and cash equivalents	As at 31st March, 2026	As at 31st March, 2025
a. Balances with banks*		
In Current Accounts		
Balances with bank	**-**	**1,420**
ICICI Bank Ltd.641505000331	8,30,983	1,926
Fixed Deposit with ICICI Bank Ltd.	-	3,25,000
b. Cash on Hand	2,865	4,044
(As per Books & Certified)		
	8,33,847	3,32,390

Note - 9 : Loans & Advances - Current Asset

Rs. In Hundreds

Short-term loans and advances	As at 31st March, 2026	As at 31st March, 2025
Unsecured, considered good		
Advances recoverable in cash or in kind or for value to be received	85,000	25,000
Security Deposits - Rental Deposit	1,350	2,550
Interest Accrued on FDR	-	25,199
CIRP Expenses	-	-
Total	**86,350**	**52,749**

(* Intercorporate Loans given are for short term, refundable on demand, are interest bearing, are not discounted, therefore valued at their transaction value)

Note - 10 : Current Tax Assets (Net)

Rs. In Hundreds

Current Tax Assets (Net)	As at 31st March, 2026	As at 31st March, 2025
Income tax Refundable	55,897	-
GST	5,451	-
TDS Receivables Net	52,450	
Deferred Tax Asset	258	258
	1,14,056	**258**

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Financial Year - 2025-26

Note - 11 : Equity Share capital

Share Capital	As at 31 March 2026		As at 31 March 2025	
	Number	Rs. In hundreds	Number	Rs. In hundreds
Authorised 100000000 Eq Shares of Re.1 each/-	50,00,00,000	10,00,000	10,00,00,000	10,00,000
Issued, Subscribed & fully Paid up 14,41,50,000 Equity Shares of Rs. 1 each fully paid up	14,41,50,000	14,41,500	4,80,50,000	4,80,500
Total	**14,41,50,000**	**14,41,500**	**4,80,50,000**	**4,80,500**

a. Reconciliation of the shares outstanding at the beginning and at the end of the reporting period

Particulars	2025-26		2024-25	
	Equity Shares		Equity Shares	
	Number	Rs. In hundreds	Number	Rs. In hundreds
Shares outstanding at the beginning of the year	4,80,50,000	4,80,500	4,80,50,000	4,80,500
Add: Shares issued during the year	9,61,00,000	9,61,000	-	-
Add: on account of split	-	-	-	-
Less : Forfeited shares re-issued during the year	-	-	-	-
Less : Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	14,41,50,000	14,41,500	4,80,50,000	4,80,500

b. Details of shareholders holding more than 5%

Name	As at 31 March 2026		As at 31 March 2025	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding

The Rights, powers and preferences relating to each class of share capital and the qualifications, limitations and restrictions thereof are contained in the Memorandum and Articles of Association of the Company. The principle rights are as follows :

Equity Shares of Rs. 1/- each The Company has only one class of share capital namely Equity shares having a face value of Rs. 1/- per share.

a. In respect of every Equity Share (whether fully paid or partly paid),voting right shall be in the same proportion as the capital paid up on such Equity Share bears to the total paid up Equity capital of the Company

During the year ended 31st March 2026, the amount of per share dividend recognized as distributions to equity shareholders was Rs. Nil

b. In the event of liquidation, the shareholders of Equity Shares are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholdings.

DEEP HEALTH AI INDIA LIMITED

CIN:-L24100RJ1994PLC112895

Fianancial Year - 2025-26

Note - 12 : Other Equity

Rs. In Hundreds

	As at 31st March, 2026	As at 31st March, 2025
Capital Reserve		
As Per last Balance Sheet	20,459	20,459
Add / (Less) : Profit/(Loss) for the	-	-
Balance at end of the reporting period	**20,459**	**20,459**
Share Premium account		
Opening Balance	9,27,937	9,27,937
Add: Share Premium on shares issued	30,36,760	-
Less : Utilised	-40,016	-
Balance at end of the reporting period	**39,24,681**	**9,27,937**
Retained Earnings		
As Per last Balance Sheet	6,75,181	5,87,530
Less : Dividend paid during the	-1,44,150	
Add / (Less) : Profit/(Loss) for the year	1,13,393	87,651
Balance at end of the reporting period	6,44,424	6,75,181
Equity instruments through other comprehensive income (FVTOCI Reserve)		
As Per last Balance Sheet	1,29,680	23,471
Add / (Less) : Movement in OCI (Net) during the year	(10,24,076)	1,06,210
Deferred Tax on Comprehensive Income	-	-
Balance at end of the reporting period	(8,94,396)	1,29,680
Aggregate Total	**36,95,168**	**17,53,257**

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Financial Year - 2025-26

Note - 13: Financial Liabilities

Rs. In Hundreds

Other Current Liabilities	As at 31st March 2026	As at 31st March 2025
Unsecured Loan		
Prakash Solanki - Loans	37,281	**60,846**
Al Risha Recruitment Pvt. Ltd.		-
	37,281	**60,846**
Total	**37,281**	**60,846**

Note - 14 : Trade Payables

Rs. In Hundreds

Other Current Liabilities	As at 31st March 2026	As at 31st March 2025
Sundry Creditors	33,502	66,618
		-
Total	**33,502**	**66,618**

Trade Payables aging schedule for the year 2025-2026

Particulars	***Outstanding for following periods from due date of payment***				
	Less than 1 year	***1-2 years***	***2-3 years***	***More than 3 years***	***Total***
MSME			-	-	-
Others				-	-
Disputed dues – MSME					
Disputed dues - Others					
	-	-	-	-	-

Trade Payables aging schedule for the year 2024-2025

Particulars	***Outstanding for following periods from due date of payment***				
	Less than 1 year	***1-2 years***	***2-3 years***	***More than 3 years***	***Total***
MSME			-	-	-
Others	29,400		37,218	-	66,618
Disputed dues – MSME					
Disputed dues - Others					
	29,400	-	37,218	-	66,618

Note - 15 : Provisions

Rs. In Hundreds

Other Current Liabilities	As at 31st March 2026	As at 31st March 2025
Other Current Liabilities	-	18,280
Total	**-**	**18,280**

Note - 16 : Current Tax Liabilities

Rs. In Hundreds

Other Current Liabilities	As at 31st March 2026	As at 31st March 2025
	-	-
Income tax AY 2026-27	-	6,290
GST		5,728
Profession Tax Payable (Employees)		211
TDS Payable	440	2,694
Total	**440**	**14,923**

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Financial Year - 2025-26

Note - 17 : Revenue from operations

Rs in Hundreds

Revenue from operations	For the year ended 31 March 2026	For the year ended 31 March 2025
Sale of Gold and Diamond Studded jewellery	-	20,909
Consultancy fee	4,25,000	1,05,000
Total	**4,25,000**	**1,25,909**

Note - 18 : Other Income

Rs in Hundreds

Other Income	For the year ended 31 March 2026	For the year ended 31 March 2025
Dividend on shares	62	-
Interest income	35,216	45,712
Interest on Bank FD	35,955	27,999
Interest on IT Refund	-	348
Balances Written off	23,312	40
Miscellaneous Income-Health Scanner Income	11	65
Short Term Gain on sale of Gold Investment	3,29,467	466
Total	**4,24,023**	**74,630**

Note - 19 : Changes in inventories of finished goods

Rs in Hundreds

Changes in Inventories of finished goods work-in-progress and Stock-in-Trade excluding Raw Material	For the year ended 31 March 2026	For the year ended 31 March 2025
Closing Stock		
Finished Goods-Manufactured	-	-
Finished Goods-Traded	51,457	49,613
Work in Progress	-	-
Stock in Trade excluding Raw Material	-	-
	51,457	49,613
Less: Opening Stock		
Finished Goods-Manufactured	-	
Finished Goods-Traded	51,457	64,119
Work in Progress	-	
Stock in Trade	-	-
	51,457	64,119
Net Changes	**-**	**14,506**

Note - 20 : Employee benefits expense

Rs in Hundreds

Employee Benefits Expense	For the year ended 31 March 2026	For the year ended 31 March 2025
(a) Salaries and incentives	6,685	5,749
(b) Director Remuneration	11,236	10,699
(b) Staff Welfare expenses	885	287
Total	**18,806**	**16,735**

DEEP HEALTH AI INDIA LIMITED
CIN:-L24100RJ1994PLC112895
Financial Year - 2025-26

Note - 21 : Finance Cost

Rs in Hundreds

Finance Cost	For the year ended 31 March 2026	For the year ended 31 March 2025
(a) Bank Charges	131	2,602
(b) Interest on Loan A/c-Taken	2,581	6,777
(C) Interest on Late Payment of TDS	1	45
Total	**2,713**	**9,424**

Note - 22 : Other Expenses

Rs in Hundreds

OTHER EXPENSES	For the year ended 31 March 2026	For the year ended 31 March 2025
Other Expenses		
Auditor Remuneration	1,750	1,350
Advertisement	2,804	740
Brokerage-STT and Other	5,588	-
Sales Promotion Expenses	28	42
Conveyance Expenses	15	97
Electricity Expenses	502	300
Consultancy Expenses	3,000	-
Legal Fees	970	-
GST Late Fees	2	34
Loss on Shares Written Off	98	-
Listing Charges	10,750	3,250
Printing & Stationery	194	86
Professional Fees	20,531	29,316
Professional Fees (Director)	540	-
Interest on Professional Fees	24	50
Interest on GST	12	-
Office Maintenance	465	-
Right Entitlement	65	-
Registration Charges	103	-
ROC Fees	3,553	5,607
Subscription Charges	-	111
Rent for Office	7,650	5,350
Late Fees for professional tax	20	-
Demat Charges	71	-
Telephone Expenses	172	220
Travelling Expenses	244	382
Repairs and maintenance	25	64
Discount Given	-	1,025
Loss on sale of Fixed asset	-	48
Software and Website charges	13,034	192
General Expenses	431	892
Total	**72,640**	**49,156**

(Rs. in Hundreds)

23. Earnings Per Share (Ind AS 33)

As per (Ind AS 33) "Earning Per Share'' issued by Institute of Chartered Accountant of India the Company gives following disclosure for the year.

Basic & Diluted Earnings Per Share

	Unit	31/03/2026	31/03/2025
a) Net Profit attributable to equity shareholders	Rs.	1,13,393	87,651
b) Weighted average number of equity shares	No.	9,43,88,630	4,80,50,000
c) Nominal Value Per Share	Rs.	0.01	0.01
d) Earning Per Share	Rs.	0.12	0.18

24. Contingent Liabilities (IndAS37)

Contingent Liabilities Not Provided For :-31/03/2026

a) Estimated amount of contracts remaining to be executed on capital account - NIL

b) Claims against company not acknowledged as debts NIL

25. OTHER NOTES :

i) No proceedings have been initiated or pending against the Company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 and rules made thereunder, as at 31st March 2026 and 31st March 2025.

ii) During the year, the Company was pursuing acquisition of Oasis Ceramics Private Limited pursuant to a Resolution Plan approved under the Insolvency and Bankruptcy Code, 2016.

As per the approved Resolution Plan, the Company was required to pay aggregate consideration of Rs.32 crore. Against the same, the Company had remitted Rs.55 lakh towards Earnest Money Deposit and Rs.2 Crore towards acquisition consideration. Owing to delays in remittance of the balance consideration within the stipulated timeline, the Company filed an application before the Hon'ble NCLT seeking extension of time, which remains pending as at the reporting date.

Consequent to such delay, the Resolution Professional invoked the bank guarantee amounting to Rs.3.21 lakh. Further, Committee of Creditors initiated proceedings in relation to alleged non-compliance with the approved Resolution Plan, including discussions regarding commencement of liquidation proceedings.

In view of the prevailing uncertainties and based on management's assessment regarding recoverability, the aggregate exposure of Rs. 5.76 crore has been recognized as an exceptional item in the Statement of Profit and Loss.

iii) During the year, the Company raised Rs.39.97 crore through a Rights Issue for purposes stated in the Letter of Offer, including proposed acquisition under IBC proceedings, general corporate purposes and issue expenses.

Pending utilization towards the stated objects, the Company deployed Rs. 37.47 crore in investments through recognized stock exchanges instead of the proposed objects stated in the Letter of Offer. Such deviation was subsequently approved by the shareholders at the Extra-Ordinary General Meeting held on 22 January 2026.

The balance amount of Rs. 2.5 crore was utilized towards the stated objects of the issue.

iv) During the year, the Company has divested its investment in Joint Venture namely Hemonc Pharma Private Limited. Further, the Board of Directors has passed a resolution for striking off the wholly owned subsidiary namely Microcure Biotech Private Limited, subject to necessary approvals and compliances under applicable law.

26. **Foreign Exchange Transactions:** During the year, the Company incurred foreign currency expenditure amounting to Rs.12,862.15 (in hundreds) towards the purchase of software. There were no foreign exchange earnings during the year.

27. **Details of dues to Micro and Small Enterprises as defined under the MSMED Act, 2006:** Based on the intimation received by the Company, none of the suppliers have confirmed to be registered under "The Micro, Small and Medium Enterprises Development ('MSMED') Act, 2006". Accordingly, no disclosures relating to amounts unpaid as at the year-end together with interest paid /payable are required to be furnished.

28. **Related Party Disclosure (Ind AS 24)**

Disclosure requirements as per (Ind AS 24)" Related Party Disclosure" issued by the Institute of Chartered Accountants of India

I. List of Related Parties: Name of Related Parties and nature of relationships:

A. Key Managerial Personnel

- Mr. Narayan Singh Rathore - Managing Director appointed on 11.04.2025
- Mr. Narendra Kumar Shrimali - Director of DDIL (till date 17.11.2025) and Director of Subsidiary Co.
- Mr. Rajesh Pherwani - Director
- Miss Laveena Pokharna - CFO and Whole Time Director appointed on 11.04.2025
- Mr. Prashant Tali - Company Secretary till date 27.06.2025
- Mr. Kailash Chandra - Director
- Mr. Kaushal Jain – Director
- Mrs. Shashi Kala Dhabriya – Director appointed on 20.03.2026
- Mr. Rakesh Vishnoi - Company Secretary appointed on 13.08.2025
- Deval Sandeep Merchant - Director of Associate Co.
- Faraaz Irfan Chapra - Director of Associate Co.
- Ganpat Lal Nyati - Additional Director of Subsidiary Co.
- Narendra Parshuram Shelar - Director of Joint Venture
- Surabhi Viraj Shelar - Additional Director of Joint Venture

B. Subsidiary Entity

- Mircocure Biotech Private Limited (Till date 31.03.2026)

C. Associate Company

- Ferry Automotive Private Limited

D. Joint Venture

- Hemonc Pharma Private Limited (Till date 28.03.2026)

II. Particulars of transactions during the year with Related Parties :

Name of the Party	Nature of transaction	31/03/2026	31/03/2025
Prakash Solanki	Loan taken by Company Repayment of Loan Interest Paid	NIL 20,000.00 2,580.99	NIL 9,000.00 6,541.89
Ganpati Nyati (Director till November 2024)	Remuneration to Director	NIL	4000.00
Narendra Kumar Shrimali (Director till November 2025)	Remuneration to Director	1170.00	1800.00
Kaushal Jain	Professional fee to Director	NIL	NIL
Sonali Laddha(Director till November 2024)	Salary to Whole Time Director	NIL	2800.00
Prashant Tali (CS till June 2025)	Salary to Company Secretary	542.00	2178.00
Mircocure Biotech Private Limited	Investment in Subsidiary Company	NIL	NIL
Ferry Automotive Private Limited	Investment in associate Loan given to Associate Interest Received TDS Deducted	NIL NIL 18769.56 NIL	NIL NIL 16,871.52 (1687.15)
Hemonc Pharma Private Limited	Investment in Joint Venture	NIL	NIL
Narayan Singh Rathore	Salary to Director	7825.00	1593.55
Rakesh Vishnoi	Salary to Company Secretary	1,297.00	Nil
Laveena Pokharna	Salary to whole time director and CFO	2241.30	505.81

III. Particulars of Outstanding Balance at the end of the year with Related Parties.

Name of the Party	Nature of transaction	31/03/2026	31/03/2025
Prakash Solanki	Loan outstanding Interest Payable	34,958.14 2,322.89	60,845.84 6548.19
Narendra Kumar Shrimali	Remuneration to Director	NIL	NIL
Sonali Laddha	Salary to Whole Time Director	NIL	NIL
Prashant Tali	Salary to Company Secretary	NIL	NIL
Mircocure Biotech Private Limited	Investment in Subsidiary Company	NIL	1834.00
Ferry Automotive Private Limited	Investment in Associate Loan given to Associate	1,16,250.00 1,68,926.07	1,16,250.00 NIL
Hemonc Pharma Private Limited	Investment in Joint Venture	NIL	5000.00

Narayan Singh Rathore	Remuneration to Director	650.00	NIL
Laveena Pokharna	Salary to whole time director and CFO	200.00	NIL
Rakesh Vishnoi	Salary to Company Secretary	160.00	NIL

29. Managerial Remuneration :- (including Salary and other benefits paid to Directors)

(in '00)

Nature of transaction	31/03/2026	31/03/2025
Narayan Singh Rathore	7,825.00	1593.55
Laveena Pokharna	2,241.30	505.81
Narendra Kumar Shrimali	1170.00	1800.00
Prashant Tali	542.00	2178.00
Rakesh Vishnoi	1297.00	NIL

30. Gratuity and other post employment benefit plans

No provision for gratuity has been made since gratuity liability is accounted for on payment basis.

31. Segment Reporting (IndAS -108)

The Company is responsible for Segment reporting as per IndAS -108 "Operating Segment" specified under section 133 of the Companies Act, 2013. As the Company is engaged in two segment viz. Jewellery of Gold and Diamond Studded and Marketing of Pharmaceutical goods in India. However, there were no business activities in the Subsidiary, Associate and joint Venture Companies.

(Rs. in Hundreds)

Particulars		Year to date figures for current period ended 31-03-2026	Year to date figures for previous period ended 31-03-2025
1	**Segment Revenue (Income)**		
	(net sale/income from each segment should be disclosed)		
1	Gold Diamond and Jewellery	0	20,909
2	Consultancy fee related to Pharmaceuticals	4,25,000	1,05,000
	Total Segment Revenue	4,25,000	1,25,909
	Less: Inter segment revenue		
	Revenue from operations	4,25,000	1,25,909
2	**Segment Result**		
	Profit (+) / Loss (-) before tax and interest from each segment		

1	Gold Diamond and Jewellery	0	-5,122
2	Consultancy fee related to Pharmaceuticals	3,31,620	47,129
	Total Profit(+)/ Loss(-) before tax	3,31,620	42,007
	i. Finance cost	-2,710	6,777
	ii. Other unallocable expenditure net off Unallocable income (-)	4,06,861	76,207
	Profit before tax and exceptional items	7,35,771	1,11,437
	Exceptional Items	5,76,687	0
	Profit before Tax	1,59,724	1,11,437
3	**(Segment Asset - Segment Liabilities)**		
	Segment Asset		
1	Gold Diamond and Jewellery	51,457	1,06,660
2	Consultancy fee related to Pharmaceuticals	9,40,381	3,83,014
	Total Segment Asset	9,91,838	4,89,674
	Un-allocable Assets	42,16,053	19,04,751
	Net Segment Asset	52,07,891	23,94,425
4	**Segment Liabilities**		
	Segment Liabilities		
1	Gold Diamond and Jewellery	0	0
2	Consultancy fee related to Pharmaceuticals	0	0
	Total Segment Liabilities	0	0
	Un-allocable Liabilities	52,07,891	23,94,425
	Net Segment Liabilities	52,07,891	23,94,425

32. Deferred taxes on Income (IndAS 12):-

The company is entitled to create deferred tax asset in the books of A/cs with respect to timing difference of carried forward Capital Loss as well as depreciation.

33. In the absence of confirmation from some of the parties and pending reconciliation the debit and credit balances with regard to recoverable and payable have been taken as reflected in the books. In the opinion of the Directors, Loans and Advances and Current Assets, if realized in the ordinary course of business, have the value at which they are stated in the Balance Sheet.

34. Auditors' Remuneration

Particulars	31/03/2026	31/03/2025
<u>**As Auditor**</u>		
Audit Fees	1,750.00	1250.00
Total	1750.00	1,250.00

35. Financial Risk Management Objective & Policies

This section gives an overview of the significance of financial instruments for the Company and provides additional information on the balance sheet. Details of significant accounting policies, including the criteria for recognition, the basis of measurement and the basis on which income and expenses are recognised, in respect of each class of financial assets and financial liabilities are disclosed.

I. **Financial Instruments by Category**

Particulars	Carrying Value		Fair Value	
	31/03/2026	**31/03/2025**	**31/03/2026**	**31/03/2025**
FINANCIAL ASSETS				
At Amortized Cost				
Non-Current Loans & Advances	5,47,558.00	8,28,173.84	5,47,558.00	8,28,173.84
Others – Security Deposit	1,350.00	55,000.00	1,350.00	55,000.00
Trade Receivables	2,91,587.00	50,795.65	2,91,587.00	50,795.65
Current Loans & Advances	86,350.00	74,045.01	86,350.00	74,045.01
TOTAL	**9,26,845.00**	**10,08,014.50**	**9,26,845.00**	**10,08,014.50**
FINANCIAL LIABILITIES				
Short Term Borrowings	37,281	60,846	37,281	60,846
Trade Payables	33,502	66,618	33,502	66,618
TOTAL	**70,783**	**1,27,464**	**70,783**	**1,27,464**

The management has assessed that the fair value of current and non-current loan and advances, other non-current asset, trade receivables approximate their carrying amounts largely due to the short term maturities of these instruments.

The fair value of Investments are based on the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

1) The fair values of the quoted equity shares are based on price quotations at the reporting date.

2) Investment in Subsidiary and Associate Companies are carried at cost.

3) The fair values of the unquoted debentures, mutual fund and equity shares have been estimated using Net Asset Value (NAV) as at reporting date.

The valuation of unquoted equity shares requires management to make certain assumptions about the Model Inputs, including forecast of cash flows, discount rate, credit risk and volatility. The probabilities of the various estimates within range can be reasonably assessed and are used in management's estimate of fair value for these unquoted shares. Wherever, the probability is low, valuation has been done based on redemption assumptions.

The significant unobservable inputs used in the fair value measurement categorized within Level 3 of the fair value hierarchy together with a quantitative sensitivity analysis as at 31st March, 2026 and 31st March, 2025 are as shown below:

Fair Value Hierarchy

The different levels have been defined below:

Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities

Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices)

Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs)

Quantitative disclosures fair value measurement hierarchy for assets

During the year Company invested in Unquoted Shares of Subsidiary, Associates and Joint Venture as well.

(Rs. In Hundreds)

As at 31st March 2026 :		**Fair value measurement using**		
Particulars	**Total**	**Level 1**	**Level 2**	**Level 3**
Asset measured at fair value:				

Investment at fair value through OCI				
Investment in quoted equity shares	27,39,652.03	2739652.03	NIL	NIL
Investment in unquoted equity shares	99,091	NIL	99,091	NIL
Investment in Gold	0	0	NIL	NIL
Investment inRupeeCo-op bank	NIL	NIL	NIL	NIL

As at 31st March 2025 :		**Fair value measurement using**		
Particulars	**Total**	**Level 1**	**Level 2**	**Level 3**
Asset measured at fair value:				
Investment at fair value through OCI				
Investment in quoted equity shares	NIL	NIL	NIL	NIL
Investment in unquoted equity shares	1,23,084.00	NIL	1,23,084.00	NIL
Investment in Gold	4,36,272.87	4,36,272.87	NIL	NIL
Investment inRupee Co-op bank	NIL	NIL	NIL	NIL

There have been no transfers between Level 1 and Level 2 during the period.

36. Other Statutory Information

I. The Group has not traded or invested in crypto currency or virtual currency during the financial year.

II. As per information available, the Group has no transactions which are not recorded in the books of accounts and which are surrendered or disclosed as income during the year in the tax assessment or in search or survey or under any other relevant provisions of the Income Tax Act, 1961.

III. The Group is not covered under the requirements of Section 135 of the Companies Act, 2013, with respect to the CSR activities.

IV. The Group is holding all the immovable properties in its own name as investment.

V. The Group do not hold any benami property and no proceedings has been initiated or pending against the company for holding any benami property under Benami Transactions (Prohibition) Act 1988 and rules made there under

VI. The Group has not been declared as willful defaulter by any bank or financial Institution or any other lender during the year.

VII. The Group do not had any transactions during the year with the companies which are struck off under section 248 of the companies Act 2013 or section 560 of the companies Act 1956.

VIII. The Group does not have any charge which are required to be registered with ROC under the terms of the loans & liabilities.

IX. As per the information & details available on records and the disclosure given by the management, the group has complied with the number of layers prescribed under clause (87) of section 2 of the companies Act read with the Companies (Restriction on number of layers) Rules 2017.

As per our report of even date attached
For V R S K & Co. LLP
(Formerly known as V R S K & Co.)
Chartered Accountants
Firm reg No. 111426W/W100988

For Deep Health AI India Limited
(Formerly known as Deep Diamond India Limited)

(SureshG. Kothari)
Partner
M.No.047625
UDIN: 26047625WHKKHS5439
Place: Mumbai
Date: May 29, 2026

(Narayan Singh Rathore)
Managing Director
(DIN - 10900646)

(Laveena Pokharna)
Whole Time Director
(DIN - 10977709)

Rakesh Vishnoi
(Company Secretary)

NOTES TO FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2026

Financial Ratios :

Ratio	Current period	Previous period	% variance	Reason for variance
(a) Current ratio	19.34	3.04	537.12%	Increase in current assets compared to current liabilities during the year.
(b) Debt-equity ratio	0.01	0.03	-73.36%	Reduction in borrowings and increase in shareholders' funds during the year
(c) Debt service coverage ratio	4.10	0.95	333.93%	Improvement in earnings available for debt servicing during the year.
(d) Return on equity ratio (Note-1)	3.08%	4.10%	-24.96%	Increase in shareholders' equity was higher than the increase in net profit during the year.
(e) Inventory turnover ratio (Note-2)	0%	0%	NA	No inventory transactions during the year.
(f) Trade receivables turnover ratio (Note-3)	2.48	1.28	93.53%	Increase in credit sales and better recovery from debtors during the year.
(g) Trade payables turnover ratio (Note-4)	-	0.00	-100.00%	No significant credit purchases/payables during the current year.
(h) Net capital turnover ratio (Note-5)	32.54%	38.51%	-15.49%	Increase in operating and other expenses reduced the profit margin during the year.
(i) Net profit ratio*	26.68%	69.62%	-61.67%	Increase in operating and other expenses reduced the profit margin during the year.
(j) Return on capital employed (Note-6)	3.34%	4.18%	-20.05%	The increase in capital employed during the year was not proportionately matched by growth in earnings before interest and taxes, resulting in a decline in the ratio.
(k) Return on investment (Note-7)	-21.42%	11.85%	-280.75%	The ratio declined significantly due to lower returns and reduction in the market value of investments during the year as compared to the previous year.